US11274107B2 - NMDA receptor modulators and uses thereof - Google Patents
NMDA receptor modulators and uses thereof Download PDFInfo
- Publication number
- US11274107B2 US11274107B2 US16/471,880 US201716471880A US11274107B2 US 11274107 B2 US11274107 B2 US 11274107B2 US 201716471880 A US201716471880 A US 201716471880A US 11274107 B2 US11274107 B2 US 11274107B2
- Authority
- US
- United States
- Prior art keywords
- alkyl
- butyl
- tert
- mmol
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *.CC.[1*]c1c([2*])([2*])N2C(=O)C(C)=C(C)N=C2S1 Chemical compound *.CC.[1*]c1c([2*])([2*])N2C(=O)C(C)=C(C)N=C2S1 0.000 description 46
- OJLJCCFFAUHAFT-UHFFFAOYSA-N CC1CSC2=NC(C3=CN=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=NC(C3=CN=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N2C1 OJLJCCFFAUHAFT-UHFFFAOYSA-N 0.000 description 5
- SLCFBEWROYHXAH-UHFFFAOYSA-N N#CC1=C(C2=CC=C(Br)N=C2)N=C2SCCCN2C1=O Chemical compound N#CC1=C(C2=CC=C(Br)N=C2)N=C2SCCCN2C1=O SLCFBEWROYHXAH-UHFFFAOYSA-N 0.000 description 5
- AGJDDNMOSILCJV-UHFFFAOYSA-N C=CC1=C(C2=CC=C(C(C)(C)C)C=C2)N=C2CCCCN2C1=O Chemical compound C=CC1=C(C2=CC=C(C(C)(C)C)C=C2)N=C2CCCCN2C1=O AGJDDNMOSILCJV-UHFFFAOYSA-N 0.000 description 4
- YUCSSTQCXMMTQX-UHFFFAOYSA-N CC(C)(C)C1=C(F)C=C(C2=C(\C#N)C(=O)N3CCCS\C3=C\2)C=N1 Chemical compound CC(C)(C)C1=C(F)C=C(C2=C(\C#N)C(=O)N3CCCS\C3=C\2)C=N1 YUCSSTQCXMMTQX-UHFFFAOYSA-N 0.000 description 4
- KWJZXPZGGCOHOA-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(Br)C(=O)N3CCCSC3=N2)C=N1 Chemical compound CC(C)(C)C1=CC=C(C2=C(Br)C(=O)N3CCCSC3=N2)C=N1 KWJZXPZGGCOHOA-UHFFFAOYSA-N 0.000 description 4
- SYTZYRGBEZFMNF-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C=CC=CC3=N2)C=C1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C=CC=CC3=N2)C=C1 SYTZYRGBEZFMNF-UHFFFAOYSA-N 0.000 description 4
- DLXNFSAALXGKNI-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1 DLXNFSAALXGKNI-UHFFFAOYSA-N 0.000 description 4
- FDNVSGFBHYDYDW-UHFFFAOYSA-N CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3C=CSC3=N2)C=C1 Chemical compound CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3C=CSC3=N2)C=C1 FDNVSGFBHYDYDW-UHFFFAOYSA-N 0.000 description 4
- YPOOUTSVXREELV-UHFFFAOYSA-N CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CC(CO)CSC3=N2)C=N1 Chemical compound CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CC(CO)CSC3=N2)C=N1 YPOOUTSVXREELV-UHFFFAOYSA-N 0.000 description 4
- WHOHMHKGILWWBF-UHFFFAOYSA-N CC1(C2=CC=C(C3=C(C#N)C(=O)N4CCCSC4=N3)C=N2)CC1(F)F Chemical compound CC1(C2=CC=C(C3=C(C#N)C(=O)N4CCCSC4=N3)C=N2)CC1(F)F WHOHMHKGILWWBF-UHFFFAOYSA-N 0.000 description 4
- UQGVVDRXDHOBLW-UHFFFAOYSA-N CC1(F)CN(C2=CC=C(C3=C(C#N)C(=O)N4CCCSC4=N3)C=N2)C1 Chemical compound CC1(F)CN(C2=CC=C(C3=C(C#N)C(=O)N4CCCSC4=N3)C=N2)C1 UQGVVDRXDHOBLW-UHFFFAOYSA-N 0.000 description 4
- UYDWWXPJKCTINL-UHFFFAOYSA-N CC1CSC2=CC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=CC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1 UYDWWXPJKCTINL-UHFFFAOYSA-N 0.000 description 4
- NRVKDBYTVIXQGL-UHFFFAOYSA-N CC1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 NRVKDBYTVIXQGL-UHFFFAOYSA-N 0.000 description 4
- JJLROJSJDQZPCE-UHFFFAOYSA-N CCOC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(C)CSC3=N2)C=N1 Chemical compound CCOC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(C)CSC3=N2)C=N1 JJLROJSJDQZPCE-UHFFFAOYSA-N 0.000 description 4
- LORWPICBGDADAC-JTQLQIEISA-N C[C@@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound C[C@@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 LORWPICBGDADAC-JTQLQIEISA-N 0.000 description 4
- BCYWSUBDQHYNKO-LLVKDONJSA-N C[C@H]1CSC2=CC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound C[C@H]1CSC2=CC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 BCYWSUBDQHYNKO-LLVKDONJSA-N 0.000 description 4
- OAWMREFEKUHRDI-LLVKDONJSA-N C[C@H]1CSC2=CC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound C[C@H]1CSC2=CC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 OAWMREFEKUHRDI-LLVKDONJSA-N 0.000 description 4
- NRVKDBYTVIXQGL-SNVBAGLBSA-N C[C@H]1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound C[C@H]1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 NRVKDBYTVIXQGL-SNVBAGLBSA-N 0.000 description 4
- CCCYRULRUJPNHB-UHFFFAOYSA-N N#CC1=C(C2=CC=C(C3(C(F)(F)F)CC3)C=C2)N=C2SCCCN2C1=O Chemical compound N#CC1=C(C2=CC=C(C3(C(F)(F)F)CC3)C=C2)N=C2SCCCN2C1=O CCCYRULRUJPNHB-UHFFFAOYSA-N 0.000 description 4
- UEILGIDFCMFDJW-UHFFFAOYSA-N N#CC1=C(C2=CN=C(C3CC3)N=C2)N=C2SCCCN2C1=O Chemical compound N#CC1=C(C2=CN=C(C3CC3)N=C2)N=C2SCCCN2C1=O UEILGIDFCMFDJW-UHFFFAOYSA-N 0.000 description 4
- FJELEFPNNDSCSN-FXBPSFAMSA-N C/N=C1/C(C#N)=C(C2=CC=C(C(C)(C)C)C=C2)N=C2SCCCN21 Chemical compound C/N=C1/C(C#N)=C(C2=CC=C(C(C)(C)C)C=C2)N=C2SCCCN21 FJELEFPNNDSCSN-FXBPSFAMSA-N 0.000 description 3
- JULHYSKTRIFWQN-UHFFFAOYSA-N CC(=O)NCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC(=O)NCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 JULHYSKTRIFWQN-UHFFFAOYSA-N 0.000 description 3
- HDQOJCBFNYMNBK-UHFFFAOYSA-N CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3CC(CO)CSC3=N2)C=N1 Chemical compound CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3CC(CO)CSC3=N2)C=N1 HDQOJCBFNYMNBK-UHFFFAOYSA-N 0.000 description 3
- HDQOJCBFNYMNBK-SNVBAGLBSA-N CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3C[C@H](CO)CSC3=N2)C=N1 Chemical compound CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3C[C@H](CO)CSC3=N2)C=N1 HDQOJCBFNYMNBK-SNVBAGLBSA-N 0.000 description 3
- UWYVDTADABYAFY-UHFFFAOYSA-N CC(C)(C)C1=C(O)C=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1 Chemical compound CC(C)(C)C1=C(O)C=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1 UWYVDTADABYAFY-UHFFFAOYSA-N 0.000 description 3
- YHSNQTJLFKFANU-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(CN)CSC3=N2)C=N1.[H]Cl Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(CN)CSC3=N2)C=N1.[H]Cl YHSNQTJLFKFANU-UHFFFAOYSA-N 0.000 description 3
- FRQQYMWSJHHCRK-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(CO)CSC3=N2)C=N1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(CO)CSC3=N2)C=N1 FRQQYMWSJHHCRK-UHFFFAOYSA-N 0.000 description 3
- GTZLJGKPPDIKKE-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(O)CSC3=N2)C=C1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(O)CSC3=N2)C=C1 GTZLJGKPPDIKKE-UHFFFAOYSA-N 0.000 description 3
- ORBAPQIQESMVBH-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC4(CC4)CSC3=N2)C=C1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC4(CC4)CSC3=N2)C=C1 ORBAPQIQESMVBH-UHFFFAOYSA-N 0.000 description 3
- PAAHRRTUTWCZKE-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC=CCSC3=N2)C=N1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC=CCSC3=N2)C=N1 PAAHRRTUTWCZKE-UHFFFAOYSA-N 0.000 description 3
- UYDVIDQDNISMRG-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=C2)C=C1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=C2)C=C1 UYDVIDQDNISMRG-UHFFFAOYSA-N 0.000 description 3
- MIBDFWSULBCKKB-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=C1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=C1 MIBDFWSULBCKKB-UHFFFAOYSA-N 0.000 description 3
- SABPHUMSBJKOFS-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)N=C1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)N=C1 SABPHUMSBJKOFS-UHFFFAOYSA-N 0.000 description 3
- TVVIHENGGNIBLQ-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)S1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)S1 TVVIHENGGNIBLQ-UHFFFAOYSA-N 0.000 description 3
- NULOWYYMVUGRCL-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCSC3=N2)C=N1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCSC3=N2)C=N1 NULOWYYMVUGRCL-UHFFFAOYSA-N 0.000 description 3
- DEGSDCKGKKRHNC-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CN(C4=CC=CC=C4)CSC3=N2)C=C1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CN(C4=CC=CC=C4)CSC3=N2)C=C1 DEGSDCKGKKRHNC-UHFFFAOYSA-N 0.000 description 3
- DFBBGYPLQHZVNO-UHFFFAOYSA-N CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CC(F)(F)CSC3=N2)C=C1 Chemical compound CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CC(F)(F)CSC3=N2)C=C1 DFBBGYPLQHZVNO-UHFFFAOYSA-N 0.000 description 3
- ZFJWINNHMJLAAG-UHFFFAOYSA-N CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CC(F)CSC3=N2)C=C1 Chemical compound CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CC(F)CSC3=N2)C=C1 ZFJWINNHMJLAAG-UHFFFAOYSA-N 0.000 description 3
- LXLBKRCWLLEECT-UHFFFAOYSA-N CC(C)(C)c(nc1)ccc1C(N=C1SCCCN11)=C(C)C1=O Chemical compound CC(C)(C)c(nc1)ccc1C(N=C1SCCCN11)=C(C)C1=O LXLBKRCWLLEECT-UHFFFAOYSA-N 0.000 description 3
- XYWNGJVYKXCUDX-UHFFFAOYSA-N CC(C)C1=CC=C(C2=C(C#N)C(=O)N3CCSC3=N2)C=C1 Chemical compound CC(C)C1=CC=C(C2=C(C#N)C(=O)N3CCSC3=N2)C=C1 XYWNGJVYKXCUDX-UHFFFAOYSA-N 0.000 description 3
- KIXCQYRBRABKPI-UHFFFAOYSA-N CC(CF)(CF)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1 Chemical compound CC(CF)(CF)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1 KIXCQYRBRABKPI-UHFFFAOYSA-N 0.000 description 3
- MRGSDGQEOKVFSE-UHFFFAOYSA-N CC1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=C1 Chemical compound CC1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=C1 MRGSDGQEOKVFSE-UHFFFAOYSA-N 0.000 description 3
- CAONFHZLGFZJON-UHFFFAOYSA-N CC1=CN2C(=O)C(C#N)=C(C3=CN=C(C(C)(C)C)C=C3)N=C2C=C1 Chemical compound CC1=CN2C(=O)C(C#N)=C(C3=CN=C(C(C)(C)C)C=C3)N=C2C=C1 CAONFHZLGFZJON-UHFFFAOYSA-N 0.000 description 3
- QVEJMDSCOJICAT-UHFFFAOYSA-N CC1CCN2C(=O)C(C#N)=C(C3=CC=C(C(C)(C)C)N=C3)N=C2S1 Chemical compound CC1CCN2C(=O)C(C#N)=C(C3=CC=C(C(C)(C)C)N=C3)N=C2S1 QVEJMDSCOJICAT-UHFFFAOYSA-N 0.000 description 3
- PPWZURDFLXEXAT-UHFFFAOYSA-N CC1CCSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N21 Chemical compound CC1CCSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N21 PPWZURDFLXEXAT-UHFFFAOYSA-N 0.000 description 3
- BCYWSUBDQHYNKO-UHFFFAOYSA-N CC1CSC2=CC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=CC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 BCYWSUBDQHYNKO-UHFFFAOYSA-N 0.000 description 3
- MLJHMKYXWWRDRC-UHFFFAOYSA-N CC1CSC2=CC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=CC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 MLJHMKYXWWRDRC-UHFFFAOYSA-N 0.000 description 3
- OAWMREFEKUHRDI-UHFFFAOYSA-N CC1CSC2=CC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=CC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 OAWMREFEKUHRDI-UHFFFAOYSA-N 0.000 description 3
- ZPZCMQNGJMRVPC-UHFFFAOYSA-N CC1CSC2=NC(C3=CC(Br)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=NC(C3=CC(Br)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 ZPZCMQNGJMRVPC-UHFFFAOYSA-N 0.000 description 3
- YPBDCUJTRKGNMX-UHFFFAOYSA-N CC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1 Chemical compound CC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1 YPBDCUJTRKGNMX-UHFFFAOYSA-N 0.000 description 3
- VRJSWMLYWAWLET-UHFFFAOYSA-N CC1CSC2=NC(C3=CC=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=NC(C3=CC=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N2C1 VRJSWMLYWAWLET-UHFFFAOYSA-N 0.000 description 3
- KJZRVVNVYOGBDD-UHFFFAOYSA-N CC1CSC2=NC(C3=CC=C(C4(C(F)(F)F)CC4)C=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=NC(C3=CC=C(C4(C(F)(F)F)CC4)C=C3)=C(C#N)C(=O)N2C1 KJZRVVNVYOGBDD-UHFFFAOYSA-N 0.000 description 3
- FSXREGKUAVTVIF-UHFFFAOYSA-N CC1CSC2=NC(C3=CC=C(C4(C)CC4(F)F)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=NC(C3=CC=C(C4(C)CC4(F)F)N=C3)=C(C#N)C(=O)N2C1 FSXREGKUAVTVIF-UHFFFAOYSA-N 0.000 description 3
- OUILFAXFDWQZLW-UHFFFAOYSA-N CC1CSC2=NC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=NC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1 OUILFAXFDWQZLW-UHFFFAOYSA-N 0.000 description 3
- BVMNZVVFCLHZFC-UHFFFAOYSA-N CC1CSC2=NC(C3=CC=C(C45CC(C4)C5)N=C3C34CC(C3)C4)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=NC(C3=CC=C(C45CC(C4)C5)N=C3C34CC(C3)C4)=C(C#N)C(=O)N2C1 BVMNZVVFCLHZFC-UHFFFAOYSA-N 0.000 description 3
- ULELZBJPQRHMOO-UHFFFAOYSA-N CC1CSC2=NC(C3=CC=C(N(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=NC(C3=CC=C(N(C)C)N=C3)=C(C#N)C(=O)N2C1 ULELZBJPQRHMOO-UHFFFAOYSA-N 0.000 description 3
- BSVVMPXMGGAKMX-UHFFFAOYSA-N CC1CSC2=NC(C3=CC=C(N4CC(C)(C)C4)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=NC(C3=CC=C(N4CC(C)(C)C4)N=C3)=C(C#N)C(=O)N2C1 BSVVMPXMGGAKMX-UHFFFAOYSA-N 0.000 description 3
- VKHCCWNZQVABMC-UHFFFAOYSA-N CC1CSC2=NC(C3=CC=C(N4CC(F)(F)C4)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=NC(C3=CC=C(N4CC(F)(F)C4)N=C3)=C(C#N)C(=O)N2C1 VKHCCWNZQVABMC-UHFFFAOYSA-N 0.000 description 3
- SVJDQYWGIQUYRD-UHFFFAOYSA-N CC1CSC2=NC(C3=CC=CN=C3C34CC(C3)C4)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=NC(C3=CC=CN=C3C34CC(C3)C4)=C(C#N)C(=O)N2C1 SVJDQYWGIQUYRD-UHFFFAOYSA-N 0.000 description 3
- ZSLADFFOFDPYEN-UHFFFAOYSA-N CC1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1 Chemical compound CC1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1 ZSLADFFOFDPYEN-UHFFFAOYSA-N 0.000 description 3
- JUYWKOBSNLPDML-UHFFFAOYSA-N CCC1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CCC1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 JUYWKOBSNLPDML-UHFFFAOYSA-N 0.000 description 3
- LMRRBGQMHGICGO-UHFFFAOYSA-N CCOC(=O)NCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CCOC(=O)NCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 LMRRBGQMHGICGO-UHFFFAOYSA-N 0.000 description 3
- KBVSTVLURBERQE-UHFFFAOYSA-N CN(C)C(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1 Chemical compound CN(C)C(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1 KBVSTVLURBERQE-UHFFFAOYSA-N 0.000 description 3
- WEBGWDJLPIPDKW-UHFFFAOYSA-N CN1CCCN2C(=O)C(C#N)=C(C3=CN=C(C(C)(C)C)C=C3)N=C12 Chemical compound CN1CCCN2C(=O)C(C#N)=C(C3=CN=C(C(C)(C)C)C=C3)N=C12 WEBGWDJLPIPDKW-UHFFFAOYSA-N 0.000 description 3
- YYWPBPOHQXUURH-UHFFFAOYSA-N CN1CSC2=NC(C3=CC=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N2C1 Chemical compound CN1CSC2=NC(C3=CC=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N2C1 YYWPBPOHQXUURH-UHFFFAOYSA-N 0.000 description 3
- RJCVATGUURKQQL-UHFFFAOYSA-N CN1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CN1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 RJCVATGUURKQQL-UHFFFAOYSA-N 0.000 description 3
- PNUBPXXKGKGNRN-UHFFFAOYSA-N COC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1 Chemical compound COC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1 PNUBPXXKGKGNRN-UHFFFAOYSA-N 0.000 description 3
- FOVQMRIUIZABRZ-UHFFFAOYSA-N COC1=C(C(C)(C)C)N=CC(C2=C(C#N)C(=O)N3CCCSC3=N2)=C1 Chemical compound COC1=C(C(C)(C)C)N=CC(C2=C(C#N)C(=O)N3CCCSC3=N2)=C1 FOVQMRIUIZABRZ-UHFFFAOYSA-N 0.000 description 3
- DPIQABWOTXKNJU-UHFFFAOYSA-N COC1=CC(C(C)(C)C)=CC=C1C1=C(C#N)C(=O)N2CCCSC2=N1 Chemical compound COC1=CC(C(C)(C)C)=CC=C1C1=C(C#N)C(=O)N2CCCSC2=N1 DPIQABWOTXKNJU-UHFFFAOYSA-N 0.000 description 3
- SIGPGQMPLRJJFL-UHFFFAOYSA-N COCC1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound COCC1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 SIGPGQMPLRJJFL-UHFFFAOYSA-N 0.000 description 3
- OCKJRQNQHWLHKB-GFCCVEGCSA-N COCOC[C@@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound COCOC[C@@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 OCKJRQNQHWLHKB-GFCCVEGCSA-N 0.000 description 3
- JRJNKMHJIKZBQY-LLVKDONJSA-N COC[C@@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound COC[C@@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 JRJNKMHJIKZBQY-LLVKDONJSA-N 0.000 description 3
- DEQLPLFKLDILRW-UHFFFAOYSA-N CS(=O)C1=C(C2=CC=C(C(C)(C)C)C=C2)N=C2CCCCN2C1=O Chemical compound CS(=O)C1=C(C2=CC=C(C(C)(C)C)C=C2)N=C2CCCCN2C1=O DEQLPLFKLDILRW-UHFFFAOYSA-N 0.000 description 3
- LKZBUUNIRLNGOQ-UHFFFAOYSA-N CSC1=C(C(C)(C)C)N=CC(C2=C(C#N)C(=O)N3CC(C)CSC3=N2)=C1 Chemical compound CSC1=C(C(C)(C)C)N=CC(C2=C(C#N)C(=O)N3CC(C)CSC3=N2)=C1 LKZBUUNIRLNGOQ-UHFFFAOYSA-N 0.000 description 3
- DLIXWLQXQXSFAQ-UHFFFAOYSA-N CSC1=C(C(C)(C)C)N=CC(C2=C(C#N)C(=O)N3CCCSC3=N2)=C1 Chemical compound CSC1=C(C(C)(C)C)N=CC(C2=C(C#N)C(=O)N3CCCSC3=N2)=C1 DLIXWLQXQXSFAQ-UHFFFAOYSA-N 0.000 description 3
- PKBYHHWMSNQZIE-UHFFFAOYSA-N CSC1=CC=C(C2=C(C#N)C(=O)N3CCSC3=N2)C=C1 Chemical compound CSC1=CC=C(C2=C(C#N)C(=O)N3CCSC3=N2)C=C1 PKBYHHWMSNQZIE-UHFFFAOYSA-N 0.000 description 3
- UYDWWXPJKCTINL-GFCCVEGCSA-N C[C@H]1CSC2=CC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1 Chemical compound C[C@H]1CSC2=CC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1 UYDWWXPJKCTINL-GFCCVEGCSA-N 0.000 description 3
- YPBDCUJTRKGNMX-SNVBAGLBSA-N C[C@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1 Chemical compound C[C@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1 YPBDCUJTRKGNMX-SNVBAGLBSA-N 0.000 description 3
- NQTIWQSNDRRNTH-LLVKDONJSA-N C[C@H]1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1 Chemical compound C[C@H]1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1 NQTIWQSNDRRNTH-LLVKDONJSA-N 0.000 description 3
- ZSLADFFOFDPYEN-SNVBAGLBSA-N C[C@H]1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1 Chemical compound C[C@H]1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1 ZSLADFFOFDPYEN-SNVBAGLBSA-N 0.000 description 3
- KOZNHJDUZFPOOL-UHFFFAOYSA-N N#CC1=C(C2=CC=C(Br)C=C2F)N=C2SCCCN2C1=O Chemical compound N#CC1=C(C2=CC=C(Br)C=C2F)N=C2SCCCN2C1=O KOZNHJDUZFPOOL-UHFFFAOYSA-N 0.000 description 3
- AVOJSGWOQJWVME-UHFFFAOYSA-N N#CC1=C(C2=CC=C(C3=CN=CC=C3)C=C2F)N=C2SCCCN2C1=O Chemical compound N#CC1=C(C2=CC=C(C3=CN=CC=C3)C=C2F)N=C2SCCCN2C1=O AVOJSGWOQJWVME-UHFFFAOYSA-N 0.000 description 3
- ADAFSQMDIVJMNB-UHFFFAOYSA-N N#CC1=C(C2=CC=C(C3=NC=CC=C3)C=C2F)N=C2SCCCN2C1=O Chemical compound N#CC1=C(C2=CC=C(C3=NC=CC=C3)C=C2F)N=C2SCCCN2C1=O ADAFSQMDIVJMNB-UHFFFAOYSA-N 0.000 description 3
- RCCHXFSSJMWMFI-UHFFFAOYSA-N N#CC1=C(C2=CC=C(C3CC3)C=C2)N=C2SCCCN2C1=O Chemical compound N#CC1=C(C2=CC=C(C3CC3)C=C2)N=C2SCCCN2C1=O RCCHXFSSJMWMFI-UHFFFAOYSA-N 0.000 description 3
- RNKRUOZWPAGZSO-UHFFFAOYSA-N N#CC1=C(C2=CC=C(Cl)C=C2)N=C2SCCN2C1=O Chemical compound N#CC1=C(C2=CC=C(Cl)C=C2)N=C2SCCN2C1=O RNKRUOZWPAGZSO-UHFFFAOYSA-N 0.000 description 3
- LKAZXAJWCHNYMP-UHFFFAOYSA-N N#CC1=C(C2=CC=C(N3CC(F)(F)C3)N=C2)N=C2SCCCN2C1=O Chemical compound N#CC1=C(C2=CC=C(N3CC(F)(F)C3)N=C2)N=C2SCCCN2C1=O LKAZXAJWCHNYMP-UHFFFAOYSA-N 0.000 description 3
- SUBMRCPBCUYOHQ-UHFFFAOYSA-N N#CC1=C(C2=CN=C(C(F)(F)F)C=C2)N=C2SCCCN2C1=O Chemical compound N#CC1=C(C2=CN=C(C(F)(F)F)C=C2)N=C2SCCCN2C1=O SUBMRCPBCUYOHQ-UHFFFAOYSA-N 0.000 description 3
- ULWROLQLRBGBLF-UHFFFAOYSA-N N#CC1=C(C2=NC(C3CC3)=NC=C2)N=C2SCCCN2C1=O Chemical compound N#CC1=C(C2=NC(C3CC3)=NC=C2)N=C2SCCCN2C1=O ULWROLQLRBGBLF-UHFFFAOYSA-N 0.000 description 3
- MRPNYENONFTWFO-UHFFFAOYSA-N C=C1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound C=C1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 MRPNYENONFTWFO-UHFFFAOYSA-N 0.000 description 2
- WNZYPBSPGIPZCR-UHFFFAOYSA-N C=CC1=C(C2=CN=C(C(C)(C)C)C=C2)N=C2SCCCN2C1=O Chemical compound C=CC1=C(C2=CN=C(C(C)(C)C)C=C2)N=C2SCCCN2C1=O WNZYPBSPGIPZCR-UHFFFAOYSA-N 0.000 description 2
- ZFUZBTNPVIGXTL-UHFFFAOYSA-N CC(=O)C1=CC(F)=CN=C1 Chemical compound CC(=O)C1=CC(F)=CN=C1 ZFUZBTNPVIGXTL-UHFFFAOYSA-N 0.000 description 2
- MPJQQCMTOSLRJC-UHFFFAOYSA-N CC(=O)C1=CC=C(C(C)(C)C)N=C1 Chemical compound CC(=O)C1=CC=C(C(C)(C)C)N=C1 MPJQQCMTOSLRJC-UHFFFAOYSA-N 0.000 description 2
- JULHYSKTRIFWQN-LBPRGKRZSA-N CC(=O)NC[C@@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC(=O)NC[C@@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 JULHYSKTRIFWQN-LBPRGKRZSA-N 0.000 description 2
- JULHYSKTRIFWQN-GFCCVEGCSA-N CC(=O)NC[C@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC(=O)NC[C@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 JULHYSKTRIFWQN-GFCCVEGCSA-N 0.000 description 2
- XAMKGQSKALBQLG-UHFFFAOYSA-N CC(C)(C#N)C1=CC=C(C#N)C=N1 Chemical compound CC(C)(C#N)C1=CC=C(C#N)C=N1 XAMKGQSKALBQLG-UHFFFAOYSA-N 0.000 description 2
- CYOOYKIWGNLZKW-UHFFFAOYSA-N CC(C)(C#N)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1 Chemical compound CC(C)(C#N)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1 CYOOYKIWGNLZKW-UHFFFAOYSA-N 0.000 description 2
- YJNREWMAQHJNDE-UHFFFAOYSA-N CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=N)N3CCCSC3=N2)C=N1 Chemical compound CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=N)N3CCCSC3=N2)C=N1 YJNREWMAQHJNDE-UHFFFAOYSA-N 0.000 description 2
- AMOALYALNOQLRP-UHFFFAOYSA-N CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3CC(C(=O)N4CCOCC4)CSC3=N2)C=N1 Chemical compound CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3CC(C(=O)N4CCOCC4)CSC3=N2)C=N1 AMOALYALNOQLRP-UHFFFAOYSA-N 0.000 description 2
- QREUIYMQLLHXLW-UHFFFAOYSA-N CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1 Chemical compound CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1 QREUIYMQLLHXLW-UHFFFAOYSA-N 0.000 description 2
- HDQOJCBFNYMNBK-JTQLQIEISA-N CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3C[C@@H](CO)CSC3=N2)C=N1 Chemical compound CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3C[C@@H](CO)CSC3=N2)C=N1 HDQOJCBFNYMNBK-JTQLQIEISA-N 0.000 description 2
- MJAQHTUDHHVOKW-UHFFFAOYSA-N CC(C)(C)C1=C(F)C=C(C=O)C=N1 Chemical compound CC(C)(C)C1=C(F)C=C(C=O)C=N1 MJAQHTUDHHVOKW-UHFFFAOYSA-N 0.000 description 2
- SLSVPFZTSWHQLF-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(Br)C(=O)N3CCCCC3=N2)C=C1 Chemical compound CC(C)(C)C1=CC=C(C2=C(Br)C(=O)N3CCCCC3=N2)C=C1 SLSVPFZTSWHQLF-UHFFFAOYSA-N 0.000 description 2
- QOSZMKYCAZEOCL-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(Br)C(=O)N3CCCSC3=N2)C=C1 Chemical compound CC(C)(C)C1=CC=C(C2=C(Br)C(=O)N3CCCSC3=N2)C=C1 QOSZMKYCAZEOCL-UHFFFAOYSA-N 0.000 description 2
- ACZOTOWJESRFJC-QQXSKIMKSA-N CC(C)(C)C1=CC=C(C2=C(C#N)/C(=N/C(=O)C(F)(F)F)N3CCCSC3=N2)C=C1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)/C(=N/C(=O)C(F)(F)F)N3CCCSC3=N2)C=C1 ACZOTOWJESRFJC-QQXSKIMKSA-N 0.000 description 2
- RDFSJHYKHOLAEA-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=N)N3CCCSC3=N2)C=C1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=N)N3CCCSC3=N2)C=C1 RDFSJHYKHOLAEA-UHFFFAOYSA-N 0.000 description 2
- FHXDAISZGXREGH-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=N)N3CCCSC3=N2)C=N1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=N)N3CCCSC3=N2)C=N1 FHXDAISZGXREGH-UHFFFAOYSA-N 0.000 description 2
- TYXSOFPQQQZRNY-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C(=N2)SCCC3C2=CC=CC=C2)C=C1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C(=N2)SCCC3C2=CC=CC=C2)C=C1 TYXSOFPQQQZRNY-UHFFFAOYSA-N 0.000 description 2
- QNDCAQLVRRFFPT-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C=CC=CC3=N2)C=N1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C=CC=CC3=N2)C=N1 QNDCAQLVRRFFPT-UHFFFAOYSA-N 0.000 description 2
- MALCIUFEHCLLFY-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(CF)CSC3=N2)C=N1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(CF)CSC3=N2)C=N1 MALCIUFEHCLLFY-UHFFFAOYSA-N 0.000 description 2
- BRIIWMYRKWHDKC-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC4(COC4)CSC3=N2)C=C1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC4(COC4)CSC3=N2)C=C1 BRIIWMYRKWHDKC-UHFFFAOYSA-N 0.000 description 2
- XRAOFUHQYFCKQS-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCCC3=N2)C=C1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCCC3=N2)C=C1 XRAOFUHQYFCKQS-UHFFFAOYSA-N 0.000 description 2
- WATMNUYIDDEUKB-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=C2)C=N1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=C2)C=N1 WATMNUYIDDEUKB-UHFFFAOYSA-N 0.000 description 2
- MQEPVWKVIBIVDU-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCSC3=N2)C=C1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCSC3=N2)C=C1 MQEPVWKVIBIVDU-UHFFFAOYSA-N 0.000 description 2
- MALCIUFEHCLLFY-LLVKDONJSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C[C@@H](CF)CSC3=N2)C=N1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C[C@@H](CF)CSC3=N2)C=N1 MALCIUFEHCLLFY-LLVKDONJSA-N 0.000 description 2
- FRQQYMWSJHHCRK-LLVKDONJSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C[C@H](CO)CSC3=N2)C=N1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C[C@H](CO)CSC3=N2)C=N1 FRQQYMWSJHHCRK-LLVKDONJSA-N 0.000 description 2
- HBFYJLPDFFFVNC-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=CC(=O)N3C=CC=CC3=N2)C=C1 Chemical compound CC(C)(C)C1=CC=C(C2=CC(=O)N3C=CC=CC3=N2)C=C1 HBFYJLPDFFFVNC-UHFFFAOYSA-N 0.000 description 2
- QOZRGMFRRCQYGU-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C=O)C=N1 Chemical compound CC(C)(C)C1=CC=C(C=O)C=N1 QOZRGMFRRCQYGU-UHFFFAOYSA-N 0.000 description 2
- QBCWSAPYKRVEIH-UHFFFAOYSA-N CC(C)(C)C1=NC=C(Br)C(C(=O)O)=N1 Chemical compound CC(C)(C)C1=NC=C(Br)C(C(=O)O)=N1 QBCWSAPYKRVEIH-UHFFFAOYSA-N 0.000 description 2
- UKTKFRAHPJCFGI-UHFFFAOYSA-N CC(C)(C)C1=NC=C(C2=C(Br)C(=O)N3CCCCC3=N2)C=C1 Chemical compound CC(C)(C)C1=NC=C(C2=C(Br)C(=O)N3CCCCC3=N2)C=C1 UKTKFRAHPJCFGI-UHFFFAOYSA-N 0.000 description 2
- OLAMGRAIMPEFPV-UHFFFAOYSA-N CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3C=CC=CC3=N2)C=N1 Chemical compound CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3C=CC=CC3=N2)C=N1 OLAMGRAIMPEFPV-UHFFFAOYSA-N 0.000 description 2
- IASKVNHCHGRECZ-UHFFFAOYSA-N CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CC(C(F)(F)F)CSC3=N2)C=N1 Chemical compound CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CC(C(F)(F)F)CSC3=N2)C=N1 IASKVNHCHGRECZ-UHFFFAOYSA-N 0.000 description 2
- KQXRKSQKOKGMRU-UHFFFAOYSA-N CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CC(CF)CSC3=N2)C=N1 Chemical compound CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CC(CF)CSC3=N2)C=N1 KQXRKSQKOKGMRU-UHFFFAOYSA-N 0.000 description 2
- DDJNNJYUJORZRX-UHFFFAOYSA-N CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CC(F)CSC3=N2)C=N1 Chemical compound CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CC(F)CSC3=N2)C=N1 DDJNNJYUJORZRX-UHFFFAOYSA-N 0.000 description 2
- XIRMYFARMJQGMX-UHFFFAOYSA-N CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CCCOC3=N2)C=C1 Chemical compound CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CCCOC3=N2)C=C1 XIRMYFARMJQGMX-UHFFFAOYSA-N 0.000 description 2
- AYCDTDRRJPNGHJ-UHFFFAOYSA-N CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1 Chemical compound CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1 AYCDTDRRJPNGHJ-UHFFFAOYSA-N 0.000 description 2
- MUDMLADIPQHGPR-UHFFFAOYSA-N CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CCSC3=N2)C=N1 Chemical compound CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CCSC3=N2)C=N1 MUDMLADIPQHGPR-UHFFFAOYSA-N 0.000 description 2
- YPOOUTSVXREELV-JTQLQIEISA-N CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3C[C@@H](CO)CSC3=N2)C=N1 Chemical compound CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3C[C@@H](CO)CSC3=N2)C=N1 YPOOUTSVXREELV-JTQLQIEISA-N 0.000 description 2
- KQXRKSQKOKGMRU-JTQLQIEISA-N CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3C[C@H](CF)CSC3=N2)C=N1 Chemical compound CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3C[C@H](CF)CSC3=N2)C=N1 KQXRKSQKOKGMRU-JTQLQIEISA-N 0.000 description 2
- YPOOUTSVXREELV-SNVBAGLBSA-N CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3C[C@H](CO)CSC3=N2)C=N1 Chemical compound CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3C[C@H](CO)CSC3=N2)C=N1 YPOOUTSVXREELV-SNVBAGLBSA-N 0.000 description 2
- QOKOJLFEKDKWOB-UHFFFAOYSA-N CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)NC(SCC(F)(F)CO)=N2)C=C1 Chemical compound CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)NC(SCC(F)(F)CO)=N2)C=C1 QOKOJLFEKDKWOB-UHFFFAOYSA-N 0.000 description 2
- LSSGCDSHSZWRMM-UHFFFAOYSA-N CC(C)(C)C1=NC=CC(C2=C(C#N)C(=O)N3CCCSC3=N2)=C1 Chemical compound CC(C)(C)C1=NC=CC(C2=C(C#N)C(=O)N3CCCSC3=N2)=C1 LSSGCDSHSZWRMM-UHFFFAOYSA-N 0.000 description 2
- QPMDOLCZOIIYGI-UHFFFAOYSA-N CC(C)(C)OC(=O)NCC1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC(C)(C)OC(=O)NCC1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 QPMDOLCZOIIYGI-UHFFFAOYSA-N 0.000 description 2
- IRAWYKKPMOFPHP-UHFFFAOYSA-N CC(C)(C)OC1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=C1 Chemical compound CC(C)(C)OC1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=C1 IRAWYKKPMOFPHP-UHFFFAOYSA-N 0.000 description 2
- DZSQKJUGMIPGSY-UHFFFAOYSA-N CC(C)(C)SC1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=C1 Chemical compound CC(C)(C)SC1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=C1 DZSQKJUGMIPGSY-UHFFFAOYSA-N 0.000 description 2
- VEHCSQGLEHTROH-UHFFFAOYSA-N CC(C)(C)c(c(F)c1)ncc1C(N=C(N(C1)C2=O)SCC1C(N(C)C)=O)=C2C#N Chemical compound CC(C)(C)c(c(F)c1)ncc1C(N=C(N(C1)C2=O)SCC1C(N(C)C)=O)=C2C#N VEHCSQGLEHTROH-UHFFFAOYSA-N 0.000 description 2
- UKGIKKYPZSEEQF-UHFFFAOYSA-N CC(C)(C)c(c(F)c1)ncc1C(N=C1SCC(CN2CCCC2)CN1C1=O)=C1C#N Chemical compound CC(C)(C)c(c(F)c1)ncc1C(N=C1SCC(CN2CCCC2)CN1C1=O)=C1C#N UKGIKKYPZSEEQF-UHFFFAOYSA-N 0.000 description 2
- IIJVFFBOWAKJOE-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1C(NC(NC1=O)=S)=C1C#N Chemical compound CC(C)(C)c(cc1)ccc1C(NC(NC1=O)=S)=C1C#N IIJVFFBOWAKJOE-UHFFFAOYSA-N 0.000 description 2
- IBFNQCLHXGKERL-UHFFFAOYSA-N CC(C)(CF)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1 Chemical compound CC(C)(CF)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1 IBFNQCLHXGKERL-UHFFFAOYSA-N 0.000 description 2
- IGTCGXNVJBFFIN-UHFFFAOYSA-N CC(C)(O)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1 Chemical compound CC(C)(O)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1 IGTCGXNVJBFFIN-UHFFFAOYSA-N 0.000 description 2
- BKLFJBWSACRTPG-UHFFFAOYSA-N CC(C)C1=CC=C(C2=CC=C(C3=C(C#N)C(=O)N4CCCSC4=N3)C(F)=C2)C=C1 Chemical compound CC(C)C1=CC=C(C2=CC=C(C3=C(C#N)C(=O)N4CCCSC4=N3)C(F)=C2)C=C1 BKLFJBWSACRTPG-UHFFFAOYSA-N 0.000 description 2
- VHNAWEHQAXBRPX-UHFFFAOYSA-N CC(C)C1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC(C)C1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 VHNAWEHQAXBRPX-UHFFFAOYSA-N 0.000 description 2
- VAFNBXCSVDPSQS-UHFFFAOYSA-N CC(CCO)SC1=NC(C2=CC=C(C(C)(C)C)N=C2)=C(C#N)C(=O)N1 Chemical compound CC(CCO)SC1=NC(C2=CC=C(C(C)(C)C)N=C2)=C(C#N)C(=O)N1 VAFNBXCSVDPSQS-UHFFFAOYSA-N 0.000 description 2
- PVIRMMFQUIKDTI-UHFFFAOYSA-N CC(c(cc1)ncc1C(N=C1SCCCN1C1=O)=C1C#N)=C Chemical compound CC(c(cc1)ncc1C(N=C1SCCCN1C1=O)=C1C#N)=C PVIRMMFQUIKDTI-UHFFFAOYSA-N 0.000 description 2
- NVOFZICBWJNOQB-UHFFFAOYSA-N CC1(C2=C(F)C=C(C3=C(C#N)C(=O)N4CCCSC4=C3)C=N2)CC1 Chemical compound CC1(C2=C(F)C=C(C3=C(C#N)C(=O)N4CCCSC4=C3)C=N2)CC1 NVOFZICBWJNOQB-UHFFFAOYSA-N 0.000 description 2
- LMNKLMFWCHMYAM-UHFFFAOYSA-N CC1(C2=CC=C(C3=C(C#N)C(=O)N4CCCSC4=N3)C=N2)CC1 Chemical compound CC1(C2=CC=C(C3=C(C#N)C(=O)N4CCCSC4=N3)C=N2)CC1 LMNKLMFWCHMYAM-UHFFFAOYSA-N 0.000 description 2
- XMNRYMWINNVQBD-UHFFFAOYSA-N CC1(C2=CC=C(C3=C(C#N)C(=O)N4CCCSC4=N3)C=N2)COC1 Chemical compound CC1(C2=CC=C(C3=C(C#N)C(=O)N4CCCSC4=N3)C=N2)COC1 XMNRYMWINNVQBD-UHFFFAOYSA-N 0.000 description 2
- PTAOLDXVWUZEJU-UHFFFAOYSA-N CC1(C2=NC=C(C3OCCO3)C=C2)CC1(F)F Chemical compound CC1(C2=NC=C(C3OCCO3)C=C2)CC1(F)F PTAOLDXVWUZEJU-UHFFFAOYSA-N 0.000 description 2
- DMPXFPWPPNAVEF-UHFFFAOYSA-N CC1=C(C2=CC=C(C(C)(C)C)C=C2)N=C2SCCCN2C1=O Chemical compound CC1=C(C2=CC=C(C(C)(C)C)C=C2)N=C2SCCCN2C1=O DMPXFPWPPNAVEF-UHFFFAOYSA-N 0.000 description 2
- MBVHTLGRQINZGV-UHFFFAOYSA-N CC1=CC=C(C2=CC=C(C3=C(C#N)C(=O)N4CCCSC4=N3)C(F)=C2)C=C1 Chemical compound CC1=CC=C(C2=CC=C(C3=C(C#N)C(=O)N4CCCSC4=N3)C(F)=C2)C=C1 MBVHTLGRQINZGV-UHFFFAOYSA-N 0.000 description 2
- BLVKNQSFRWONHN-UHFFFAOYSA-N CC1=CN2C(=O)C(C#N)=C(C3=CN=C(C(C)(C)C)N=C3)N=C2C=C1 Chemical compound CC1=CN2C(=O)C(C#N)=C(C3=CN=C(C(C)(C)C)N=C3)N=C2C=C1 BLVKNQSFRWONHN-UHFFFAOYSA-N 0.000 description 2
- OJBAUPNDTPWOKK-UHFFFAOYSA-N CC1=CSC2=NC(C3=CN=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N12 Chemical compound CC1=CSC2=NC(C3=CN=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N12 OJBAUPNDTPWOKK-UHFFFAOYSA-N 0.000 description 2
- PJWBDCKMVXSGTH-UHFFFAOYSA-N CC1=NC(C(C)(C)C)=CC=C1C1=C(C#N)C(=O)N2CCCSC2=N1 Chemical compound CC1=NC(C(C)(C)C)=CC=C1C1=C(C#N)C(=O)N2CCCSC2=N1 PJWBDCKMVXSGTH-UHFFFAOYSA-N 0.000 description 2
- CUWBGSPWXDTDHO-UHFFFAOYSA-N CC1CCSC2=NC(C3=CC=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N21 Chemical compound CC1CCSC2=NC(C3=CC=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N21 CUWBGSPWXDTDHO-UHFFFAOYSA-N 0.000 description 2
- DZYFNVSSMAJSTF-UHFFFAOYSA-N CC1CSC2=CC(C3=CC(F)=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=CC(C3=CC(F)=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1 DZYFNVSSMAJSTF-UHFFFAOYSA-N 0.000 description 2
- LORWPICBGDADAC-UHFFFAOYSA-N CC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 LORWPICBGDADAC-UHFFFAOYSA-N 0.000 description 2
- LLHJDQJVUWXAOK-UHFFFAOYSA-N CC1CSC2=NC(C3=CC(O)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=NC(C3=CC(O)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 LLHJDQJVUWXAOK-UHFFFAOYSA-N 0.000 description 2
- RTSNGHAZPSVEIE-UHFFFAOYSA-N CC1CSC2=NC(C3=CC=C(C(C)(C)C#N)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=NC(C3=CC=C(C(C)(C)C#N)N=C3)=C(C#N)C(=O)N2C1 RTSNGHAZPSVEIE-UHFFFAOYSA-N 0.000 description 2
- ZYUHWHFVQJAFTB-UHFFFAOYSA-N CC1CSC2=NC(C3=CC=C(C(C)(C)CF)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=NC(C3=CC=C(C(C)(C)CF)N=C3)=C(C#N)C(=O)N2C1 ZYUHWHFVQJAFTB-UHFFFAOYSA-N 0.000 description 2
- GNPUVENIFLZTTC-UHFFFAOYSA-N CC1CSC2=NC(C3=CC=C(C4(C)COC4)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=NC(C3=CC=C(C4(C)COC4)N=C3)=C(C#N)C(=O)N2C1 GNPUVENIFLZTTC-UHFFFAOYSA-N 0.000 description 2
- UTDPIBUYRMXVND-UHFFFAOYSA-N CC1CSC2=NC(C3=CC=C(C45CC(C4)C5)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=NC(C3=CC=C(C45CC(C4)C5)N=C3)=C(C#N)C(=O)N2C1 UTDPIBUYRMXVND-UHFFFAOYSA-N 0.000 description 2
- WLHYZIMJGLSMOX-UHFFFAOYSA-N CC1CSC2=NC(C3=CC=C(N4CC(C)(F)C4)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=NC(C3=CC=C(N4CC(C)(F)C4)N=C3)=C(C#N)C(=O)N2C1 WLHYZIMJGLSMOX-UHFFFAOYSA-N 0.000 description 2
- NQTIWQSNDRRNTH-UHFFFAOYSA-N CC1CSC2=NC(C3=CN=C(C(C)(C)C)C=C3)=C(C#N)C(=N)N2C1 Chemical compound CC1CSC2=NC(C3=CN=C(C(C)(C)C)C=C3)=C(C#N)C(=N)N2C1 NQTIWQSNDRRNTH-UHFFFAOYSA-N 0.000 description 2
- VSCJIFLDCHOPRH-UHFFFAOYSA-N CCC(=O)C1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CCC(=O)C1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 VSCJIFLDCHOPRH-UHFFFAOYSA-N 0.000 description 2
- VUQNULUNLVIQPH-UHFFFAOYSA-N CCN1CSC2=NC(C3=CC=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N2C1 Chemical compound CCN1CSC2=NC(C3=CC=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N2C1 VUQNULUNLVIQPH-UHFFFAOYSA-N 0.000 description 2
- RXCCSNCJVUZJFV-UHFFFAOYSA-N CCN1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CCN1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 RXCCSNCJVUZJFV-UHFFFAOYSA-N 0.000 description 2
- GCYQTIXKFXMJSX-UHFFFAOYSA-N CCN1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CCN1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 GCYQTIXKFXMJSX-UHFFFAOYSA-N 0.000 description 2
- KOJKKWLEEISXHZ-NTCAYCPXSA-N CCOC(=O)/C(C#N)=C(\C)C1=CC=C(C(C)(C)C)C=C1 Chemical compound CCOC(=O)/C(C#N)=C(\C)C1=CC=C(C(C)(C)C)C=C1 KOJKKWLEEISXHZ-NTCAYCPXSA-N 0.000 description 2
- ZKSCDBLSTZPUNK-UHFFFAOYSA-N CCOC(=O)C1=CC=C(C2=C(C#N)C(=O)N3CC(C)CSC3=N2)C=N1 Chemical compound CCOC(=O)C1=CC=C(C2=C(C#N)C(=O)N3CC(C)CSC3=N2)C=N1 ZKSCDBLSTZPUNK-UHFFFAOYSA-N 0.000 description 2
- PQFWXLKVUIEDGI-UHFFFAOYSA-N CCOC(=O)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1 Chemical compound CCOC(=O)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1 PQFWXLKVUIEDGI-UHFFFAOYSA-N 0.000 description 2
- WYAAYTJXBZXDNQ-UHFFFAOYSA-N CCOC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1 Chemical compound CCOC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1 WYAAYTJXBZXDNQ-UHFFFAOYSA-N 0.000 description 2
- RRHWXTGBRBYZRG-UHFFFAOYSA-N CN(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1 Chemical compound CN(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1 RRHWXTGBRBYZRG-UHFFFAOYSA-N 0.000 description 2
- ULWITHNZEKEAQA-UHFFFAOYSA-N CN(C)CC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CN(C)CC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 ULWITHNZEKEAQA-UHFFFAOYSA-N 0.000 description 2
- OXHREQNXBPQULO-UHFFFAOYSA-N CN1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CN1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 OXHREQNXBPQULO-UHFFFAOYSA-N 0.000 description 2
- GWQNOVNPXNKWPH-UHFFFAOYSA-N COC(=O)C1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound COC(=O)C1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 GWQNOVNPXNKWPH-UHFFFAOYSA-N 0.000 description 2
- WBWOQLOBASTSJA-UHFFFAOYSA-N COC(=O)C1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound COC(=O)C1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 WBWOQLOBASTSJA-UHFFFAOYSA-N 0.000 description 2
- RNYZGSOZLRSAMW-UHFFFAOYSA-N COC(C)(C)C1=CC=C(C=O)C=N1 Chemical compound COC(C)(C)C1=CC=C(C=O)C=N1 RNYZGSOZLRSAMW-UHFFFAOYSA-N 0.000 description 2
- FUEWHWRONPGGFJ-UHFFFAOYSA-N COC1=C(C(C)(C)C)N=CC(C2=C(C#N)C(=O)N3CC(C)CSC3=N2)=C1 Chemical compound COC1=C(C(C)(C)C)N=CC(C2=C(C#N)C(=O)N3CC(C)CSC3=N2)=C1 FUEWHWRONPGGFJ-UHFFFAOYSA-N 0.000 description 2
- JMOIJWCJCVPFBX-UHFFFAOYSA-N COC1=C(OC)C(C2=C(C#N)C(=O)N3CCCSC3=N2)=CC=C1 Chemical compound COC1=C(OC)C(C2=C(C#N)C(=O)N3CCCSC3=N2)=CC=C1 JMOIJWCJCVPFBX-UHFFFAOYSA-N 0.000 description 2
- HNGMWTIAFLWITI-UHFFFAOYSA-N COC1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C(OC)=C1 Chemical compound COC1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C(OC)=C1 HNGMWTIAFLWITI-UHFFFAOYSA-N 0.000 description 2
- FVZBRAXUNKYZPJ-UHFFFAOYSA-N COC1=CC=C(C2=C(C#N)C(=O)N3CCSC3=N2)C(OC)=C1 Chemical compound COC1=CC=C(C2=C(C#N)C(=O)N3CCSC3=N2)C(OC)=C1 FVZBRAXUNKYZPJ-UHFFFAOYSA-N 0.000 description 2
- ATVRNAQEGXPWII-UHFFFAOYSA-N COC1=CC=CC=C1C1=C(C#N)C(=O)N2CCCSC2=N1 Chemical compound COC1=CC=CC=C1C1=C(C#N)C(=O)N2CCCSC2=N1 ATVRNAQEGXPWII-UHFFFAOYSA-N 0.000 description 2
- SWCLJLXVHJBRBL-SDNWHVSQSA-N COCC(=O)/C(C#N)=C(/O)C1=CC=C(C(C)(C)C)N=C1 Chemical compound COCC(=O)/C(C#N)=C(/O)C1=CC=C(C(C)(C)C)N=C1 SWCLJLXVHJBRBL-SDNWHVSQSA-N 0.000 description 2
- JRJNKMHJIKZBQY-UHFFFAOYSA-N COCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound COCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 JRJNKMHJIKZBQY-UHFFFAOYSA-N 0.000 description 2
- LOVZXNUHZYOVRG-UHFFFAOYSA-N COCC1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound COCC1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 LOVZXNUHZYOVRG-UHFFFAOYSA-N 0.000 description 2
- OCKJRQNQHWLHKB-UHFFFAOYSA-N COCOCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound COCOCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 OCKJRQNQHWLHKB-UHFFFAOYSA-N 0.000 description 2
- JRJNKMHJIKZBQY-NSHDSACASA-N COC[C@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound COC[C@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 JRJNKMHJIKZBQY-NSHDSACASA-N 0.000 description 2
- BENXCKAJXPSMEY-UHFFFAOYSA-N CSC1=C(C2=CC=C(C(C)(C)C)C=C2)N=C2CCCCN2C1=O Chemical compound CSC1=C(C2=CC=C(C(C)(C)C)C=C2)N=C2CCCCN2C1=O BENXCKAJXPSMEY-UHFFFAOYSA-N 0.000 description 2
- YKRSTILBPAISOX-UHFFFAOYSA-N CSC1=C(C2=CN=C(C(C)(C)C)C=C2)N=C2CCCCN2C1=O Chemical compound CSC1=C(C2=CN=C(C(C)(C)C)C=C2)N=C2CCCCN2C1=O YKRSTILBPAISOX-UHFFFAOYSA-N 0.000 description 2
- GJAXVXDBAJPAMA-UHFFFAOYSA-N CSC1=CC(C2OCCO2)=CN=C1C(C)(C)C Chemical compound CSC1=CC(C2OCCO2)=CN=C1C(C)(C)C GJAXVXDBAJPAMA-UHFFFAOYSA-N 0.000 description 2
- BCYWSUBDQHYNKO-NSHDSACASA-N C[C@@H]1CSC2=CC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound C[C@@H]1CSC2=CC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 BCYWSUBDQHYNKO-NSHDSACASA-N 0.000 description 2
- UYDWWXPJKCTINL-LBPRGKRZSA-N C[C@@H]1CSC2=CC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1 Chemical compound C[C@@H]1CSC2=CC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1 UYDWWXPJKCTINL-LBPRGKRZSA-N 0.000 description 2
- OAWMREFEKUHRDI-NSHDSACASA-N C[C@@H]1CSC2=CC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound C[C@@H]1CSC2=CC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 OAWMREFEKUHRDI-NSHDSACASA-N 0.000 description 2
- PQVRADVEAICSFC-LBPRGKRZSA-N C[C@@H]1CSC2=NC(C3=CC=C(C(C)(C)N(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound C[C@@H]1CSC2=NC(C3=CC=C(C(C)(C)N(C)C)N=C3)=C(C#N)C(=O)N2C1 PQVRADVEAICSFC-LBPRGKRZSA-N 0.000 description 2
- OUILFAXFDWQZLW-NSHDSACASA-N C[C@@H]1CSC2=NC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1 Chemical compound C[C@@H]1CSC2=NC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1 OUILFAXFDWQZLW-NSHDSACASA-N 0.000 description 2
- MLJHMKYXWWRDRC-GFCCVEGCSA-N C[C@H]1CSC2=CC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound C[C@H]1CSC2=CC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 MLJHMKYXWWRDRC-GFCCVEGCSA-N 0.000 description 2
- LORWPICBGDADAC-SNVBAGLBSA-N C[C@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound C[C@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 LORWPICBGDADAC-SNVBAGLBSA-N 0.000 description 2
- PQVRADVEAICSFC-GFCCVEGCSA-N C[C@H]1CSC2=NC(C3=CC=C(C(C)(C)N(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound C[C@H]1CSC2=NC(C3=CC=C(C(C)(C)N(C)C)N=C3)=C(C#N)C(=O)N2C1 PQVRADVEAICSFC-GFCCVEGCSA-N 0.000 description 2
- OUILFAXFDWQZLW-LLVKDONJSA-N C[C@H]1CSC2=NC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1 Chemical compound C[C@H]1CSC2=NC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1 OUILFAXFDWQZLW-LLVKDONJSA-N 0.000 description 2
- OJLJCCFFAUHAFT-LLVKDONJSA-N C[C@H]1CSC2=NC(C3=CN=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N2C1 Chemical compound C[C@H]1CSC2=NC(C3=CN=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N2C1 OJLJCCFFAUHAFT-LLVKDONJSA-N 0.000 description 2
- DRSSVDURFDRKKM-UHFFFAOYSA-N N#CC1=C(C2=CC=C(C3=CC=CC=C3)C=C2F)N=C2SCCCN2C1=O Chemical compound N#CC1=C(C2=CC=C(C3=CC=CC=C3)C=C2F)N=C2SCCCN2C1=O DRSSVDURFDRKKM-UHFFFAOYSA-N 0.000 description 2
- ILTWQBGHHVTNNF-UHFFFAOYSA-N N#CC1=C(C2=CN=C(C3CC3)C=C2)N=C2SCCCN2C1=O Chemical compound N#CC1=C(C2=CN=C(C3CC3)C=C2)N=C2SCCCN2C1=O ILTWQBGHHVTNNF-UHFFFAOYSA-N 0.000 description 2
- QOWOSLFJHTVONJ-UHFFFAOYSA-N [H]C(=O)C1=CC=C(C(=O)OC)N=C1 Chemical compound [H]C(=O)C1=CC=C(C(=O)OC)N=C1 QOWOSLFJHTVONJ-UHFFFAOYSA-N 0.000 description 2
- CDGUAFUZEJERHM-UHFFFAOYSA-N *.C=C1C(C)=C(C)C=C2cc(C)cc(C)N12.CC Chemical compound *.C=C1C(C)=C(C)C=C2cc(C)cc(C)N12.CC CDGUAFUZEJERHM-UHFFFAOYSA-N 0.000 description 1
- DVAFTWWAOHDXRT-UHFFFAOYSA-N *.CC.CC1=C(C)C(=O)N2C(=C1)SC(C)C(C)C2C Chemical compound *.CC.CC1=C(C)C(=O)N2C(=C1)SC(C)C(C)C2C DVAFTWWAOHDXRT-UHFFFAOYSA-N 0.000 description 1
- RCTSOFOSPMRXLC-UHFFFAOYSA-N *.CC.CC1=C(C)C(=O)N2C(=N1)CC(C)C(C)C2C Chemical compound *.CC.CC1=C(C)C(=O)N2C(=N1)CC(C)C(C)C2C RCTSOFOSPMRXLC-UHFFFAOYSA-N 0.000 description 1
- PTZFZVKHTKFLQL-UHFFFAOYSA-N *.CC.CC1=C(C)C(=O)N2C(=N1)OC(C)C(C)C2C Chemical compound *.CC.CC1=C(C)C(=O)N2C(=N1)OC(C)C(C)C2C PTZFZVKHTKFLQL-UHFFFAOYSA-N 0.000 description 1
- FEHHSPSWCQDOIO-UHFFFAOYSA-N *.CC.CC1=C(C)C(=O)N2C(=N1)SC(C)C(C)C2C Chemical compound *.CC.CC1=C(C)C(=O)N2C(=N1)SC(C)C(C)C2C FEHHSPSWCQDOIO-UHFFFAOYSA-N 0.000 description 1
- NAQZATGSFROHQD-LLVKDONJSA-N *.C[C@H]1CSC2=CC(C3=CC(O)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound *.C[C@H]1CSC2=CC(C3=CC(O)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 NAQZATGSFROHQD-LLVKDONJSA-N 0.000 description 1
- PWOOJABLTGHGHF-UHFFFAOYSA-N BrBr.BrCCCBr.CC(=O)C1=CC=C(C(C)(C)C)C=C1.CC(C)(C)C1=CC=C(C2=C(Br)C(=O)N3CCCSC3=N2)C=C1.CC(C)(C)C1=CC=C(C2=CC(=O)N3CCCSC3=N2)C=C1.CC(C)(C)C1=CC=C(C2=CC(=O)NC(=S)C2)C=C1.CCOC(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1.CCOC(C)=O.NC(N)=S Chemical compound BrBr.BrCCCBr.CC(=O)C1=CC=C(C(C)(C)C)C=C1.CC(C)(C)C1=CC=C(C2=C(Br)C(=O)N3CCCSC3=N2)C=C1.CC(C)(C)C1=CC=C(C2=CC(=O)N3CCCSC3=N2)C=C1.CC(C)(C)C1=CC=C(C2=CC(=O)NC(=S)C2)C=C1.CCOC(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1.CCOC(C)=O.NC(N)=S PWOOJABLTGHGHF-UHFFFAOYSA-N 0.000 description 1
- NUPKXNXWTDLZRI-UHFFFAOYSA-N BrBr.BrCCCBr.CC(=O)C1=CC=C(C(C)(C)C)N=C1.CC(=O)C1=CC=CN=C1.CC(C)(C)C(=O)O.CC(C)(C)C1=CC=C(C2=C(Br)C(=O)N3CCCSC3=N2)C=N1.CC(C)(C)C1=CC=C(C2=CC(=O)N3CCCSC3=N2)C=N1.CC(C)(C)C1=CC=C(C2=CC(=O)NC(=S)C2)C=N1.CCOC(=O)CC(=O)C1=CC=C(C(C)(C)C)N=C1.CCOC(=O)OCC.NC(N)=S Chemical compound BrBr.BrCCCBr.CC(=O)C1=CC=C(C(C)(C)C)N=C1.CC(=O)C1=CC=CN=C1.CC(C)(C)C(=O)O.CC(C)(C)C1=CC=C(C2=C(Br)C(=O)N3CCCSC3=N2)C=N1.CC(C)(C)C1=CC=C(C2=CC(=O)N3CCCSC3=N2)C=N1.CC(C)(C)C1=CC=C(C2=CC(=O)NC(=S)C2)C=N1.CCOC(=O)CC(=O)C1=CC=C(C(C)(C)C)N=C1.CCOC(=O)OCC.NC(N)=S NUPKXNXWTDLZRI-UHFFFAOYSA-N 0.000 description 1
- ZZMXQVRNAQSHQA-LLLODVRFSA-N BrCCBr.CC(C)(C)C(=N)N.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1.CC(C)(C)C1=NC=C(Br)C(C(=O)O)=N1.CC(C)(C)C1=NC=C(Br)C=N1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CCSC3=N2)C=N1.CC(C)(C)C1=NC=C(C=O)C=N1.CCOC(=O)CC#N.Cl.NC(N)=S.O=C/C(Br)=C(/Br)C(=O)O Chemical compound BrCCBr.CC(C)(C)C(=N)N.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1.CC(C)(C)C1=NC=C(Br)C(C(=O)O)=N1.CC(C)(C)C1=NC=C(Br)C=N1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CCSC3=N2)C=N1.CC(C)(C)C1=NC=C(C=O)C=N1.CCOC(=O)CC#N.Cl.NC(N)=S.O=C/C(Br)=C(/Br)C(=O)O ZZMXQVRNAQSHQA-LLLODVRFSA-N 0.000 description 1
- DCFHMYOCHFWTFU-UHFFFAOYSA-N BrCCBr.CC(C)(C)C(=O)O.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCSC3=N2)C=N1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1.CC(C)(C)C1=CC=C(C=O)C=N1.CCOC(=O)CC#N.OCC1=CC=CN=C1 Chemical compound BrCCBr.CC(C)(C)C(=O)O.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCSC3=N2)C=N1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1.CC(C)(C)C1=CC=C(C=O)C=N1.CCOC(=O)CC#N.OCC1=CC=CN=C1 DCFHMYOCHFWTFU-UHFFFAOYSA-N 0.000 description 1
- WBMXTBDLOOPAQM-UHFFFAOYSA-N BrCCCBr.C=C(C)B(F)(F)F.C=C(C)C1=NC=C(C2OCCO2)C=C1.CC1(C2=CC=C(C3=C(C#N)C(=O)NC(=S)C3)C=N2)CC1(F)F.CC1(C2=NC=C(C3OCCO3)C=C2)CC1(F)F.CC1(C2=NC=C(C=O)C=C2)CC1(F)F.CCOC(=O)CC#N.C[Si](C)(C)C(F)(F)F.NC(N)=S.OCCO.[H]C(=O)C1=CN=C(Br)C=C1.[H]C(=O)C1=CN=C(C(=C)C)C=C1.[K+] Chemical compound BrCCCBr.C=C(C)B(F)(F)F.C=C(C)C1=NC=C(C2OCCO2)C=C1.CC1(C2=CC=C(C3=C(C#N)C(=O)NC(=S)C3)C=N2)CC1(F)F.CC1(C2=NC=C(C3OCCO3)C=C2)CC1(F)F.CC1(C2=NC=C(C=O)C=C2)CC1(F)F.CCOC(=O)CC#N.C[Si](C)(C)C(F)(F)F.NC(N)=S.OCCO.[H]C(=O)C1=CN=C(Br)C=C1.[H]C(=O)C1=CN=C(C(=C)C)C=C1.[K+] WBMXTBDLOOPAQM-UHFFFAOYSA-N 0.000 description 1
- UQQTYSDPLOLTCO-UHFFFAOYSA-M BrCCCBr.C=O.CC(C)(N)C1=CC=C(Br)C=N1.CCOC(=O)CC#N.CN(C)C(C)(C)C1=CC=C(Br)C=N1.CN(C)C(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.CN(C)C(C)(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1.CN(C)C(C)(C)C1=CC=C(C=O)C=N1.C[Mg]Br.N#CC1=CC=C(Br)C=N1.[Li]CCCC Chemical compound BrCCCBr.C=O.CC(C)(N)C1=CC=C(Br)C=N1.CCOC(=O)CC#N.CN(C)C(C)(C)C1=CC=C(Br)C=N1.CN(C)C(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.CN(C)C(C)(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1.CN(C)C(C)(C)C1=CC=C(C=O)C=N1.C[Mg]Br.N#CC1=CC=C(Br)C=N1.[Li]CCCC UQQTYSDPLOLTCO-UHFFFAOYSA-M 0.000 description 1
- ZVGBTXULWVHAPQ-UHFFFAOYSA-N BrCCCBr.CC(C)(C#N)C1=CC=C(C#N)C=N1.CC(C)(C#N)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.CC(C)(C#N)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1.CC(C)C#N.CCOC(=O)CC#N.N#CC1=CC=C(F)N=C1.NC(N)=S.[H]C(=O)C1=CC=C(C(C)(C)C#N)N=C1 Chemical compound BrCCCBr.CC(C)(C#N)C1=CC=C(C#N)C=N1.CC(C)(C#N)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.CC(C)(C#N)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1.CC(C)C#N.CCOC(=O)CC#N.N#CC1=CC=C(F)N=C1.NC(N)=S.[H]C(=O)C1=CC=C(C(C)(C)C#N)N=C1 ZVGBTXULWVHAPQ-UHFFFAOYSA-N 0.000 description 1
- IWIVYCADDNWWPG-UHFFFAOYSA-N BrCCCBr.CC(C)(C)C(=O)O.CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1.CC(C)(C)C1=C(F)C=C(C=O)C=N1.O=CC1=CC(F)=CN=C1.[C-]#[N+]CC(=O)OCC Chemical compound BrCCCBr.CC(C)(C)C(=O)O.CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1.CC(C)(C)C1=C(F)C=C(C=O)C=N1.O=CC1=CC(F)=CN=C1.[C-]#[N+]CC(=O)OCC IWIVYCADDNWWPG-UHFFFAOYSA-N 0.000 description 1
- NZMMJLHTVQODAD-UHFFFAOYSA-M BrCCCBr.CC(C)(O)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.CCOC(=O)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.CCOC(=O)C1=CC=C(C2=C(C#N)C(=O)NC(=S)N2)C=N1.CCOC(=O)CC#N.C[Mg]Br.[C-]#[O+].[H]C(=O)C1=CC=C(Br)N=C1.[H]C(=O)C1=CC=C(C(=O)OC)N=C1 Chemical compound BrCCCBr.CC(C)(O)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.CCOC(=O)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.CCOC(=O)C1=CC=C(C2=C(C#N)C(=O)NC(=S)N2)C=N1.CCOC(=O)CC#N.C[Mg]Br.[C-]#[O+].[H]C(=O)C1=CC=C(Br)N=C1.[H]C(=O)C1=CC=C(C(=O)OC)N=C1 NZMMJLHTVQODAD-UHFFFAOYSA-M 0.000 description 1
- CSKPDENDVNFGJI-UHFFFAOYSA-N BrCCCBr.CCOC(=O)CC#N.CN(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.CN(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1.NC(N)=S.[C-]#[N+]C1=CC=C(N(C)C)N=C1.[C-]#[N+]C1=CC=C(N)N=C1.[H]C(=O)C1=CC=C(N(C)C)N=C1 Chemical compound BrCCCBr.CCOC(=O)CC#N.CN(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.CN(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1.NC(N)=S.[C-]#[N+]C1=CC=C(N(C)C)N=C1.[C-]#[N+]C1=CC=C(N)N=C1.[H]C(=O)C1=CC=C(N(C)C)N=C1 CSKPDENDVNFGJI-UHFFFAOYSA-N 0.000 description 1
- MTZBZFNCBQWYJS-UHFFFAOYSA-N BrP(Br)Br.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1.CC(C)Br.CC(C)C(CBr)CBr.CC(C)C(CO)CO.CC(C)C1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CCOC(=O)C(C(C)=O)C(C)C.CCOC(=O)CC(C)=O Chemical compound BrP(Br)Br.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1.CC(C)Br.CC(C)C(CBr)CBr.CC(C)C(CO)CO.CC(C)C1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CCOC(=O)C(C(C)=O)C(C)C.CCOC(=O)CC(C)=O MTZBZFNCBQWYJS-UHFFFAOYSA-N 0.000 description 1
- JZVNTZIKRKEWHI-UHFFFAOYSA-N C#CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(C)CSC3=N2)C=N1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.CC(C)C1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CC1=CC=C(C2=C(C#N)C(=O)N3CC(C)CSC3=N2)C=N1.CC1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.CCC1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound C#CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(C)CSC3=N2)C=N1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.CC(C)C1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CC1=CC=C(C2=C(C#N)C(=O)N3CC(C)CSC3=N2)C=N1.CC1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.CCC1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 JZVNTZIKRKEWHI-UHFFFAOYSA-N 0.000 description 1
- RVNNGHNLAYBNBF-JYHVOGICSA-N C#CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.C[C@@H]1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1.C[C@@H]1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@H]1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1.C[C@H]1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound C#CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.C[C@@H]1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1.C[C@@H]1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@H]1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1.C[C@H]1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 RVNNGHNLAYBNBF-JYHVOGICSA-N 0.000 description 1
- LRDWZDCFSFDAQW-UHFFFAOYSA-N C#CCBr.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)NC(=S)C2)C=C1.CC1=CSC2=NC(C3=CN=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N12 Chemical compound C#CCBr.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)NC(=S)C2)C=C1.CC1=CSC2=NC(C3=CN=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N12 LRDWZDCFSFDAQW-UHFFFAOYSA-N 0.000 description 1
- ZDKRKABGXLZMPT-VCHYOVAHSA-N C/N=C/C1=C(c(ccc(OC)c2)c2OC)N=C2SCCCN2C1=O Chemical compound C/N=C/C1=C(c(ccc(OC)c2)c2OC)N=C2SCCCN2C1=O ZDKRKABGXLZMPT-VCHYOVAHSA-N 0.000 description 1
- PXKCSFLBHIYIMZ-AOCNVXANSA-M C/N=C1/C(C#N)=C(C2=CC=C(C(C)(C)C)C=C2)N=C2SCCCN21.CC(C)(C)C1=CC=C(C(/N=C2/CCCCS2)=C(C#N)C#N)C=C1.CC(C)(C)C1=CC=C(C(N)=C(C#N)C#N)C=C1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=N)N3CCCSC3=N2)C=C1.CI.CSC1=N(C(=O)OC(C)(C)C)CCCS1.[C-]#[N+]/C(C#N)=C(\Cl)C1=CC=C(C(C)(C)C)C=C1.[I-] Chemical compound C/N=C1/C(C#N)=C(C2=CC=C(C(C)(C)C)C=C2)N=C2SCCCN21.CC(C)(C)C1=CC=C(C(/N=C2/CCCCS2)=C(C#N)C#N)C=C1.CC(C)(C)C1=CC=C(C(N)=C(C#N)C#N)C=C1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=N)N3CCCSC3=N2)C=C1.CI.CSC1=N(C(=O)OC(C)(C)C)CCCS1.[C-]#[N+]/C(C#N)=C(\Cl)C1=CC=C(C(C)(C)C)C=C1.[I-] PXKCSFLBHIYIMZ-AOCNVXANSA-M 0.000 description 1
- SMLCDPRAFSOLTD-UHFFFAOYSA-N C1CCNC1.CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3CC(CN4CCCC4)CSC3=N2)C=N1.CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3CC(COS(C)(=O)=O)CSC3=N2)C=N1 Chemical compound C1CCNC1.CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3CC(CN4CCCC4)CSC3=N2)C=N1.CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3CC(COS(C)(=O)=O)CSC3=N2)C=N1 SMLCDPRAFSOLTD-UHFFFAOYSA-N 0.000 description 1
- ZFMRTJXYVFXUOR-UHFFFAOYSA-N C=C(C)B(F)(F)F.C=C(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.N#CC1=C(C2=CC=C(Br)N=C2)N=C2SCCCN2C1=O.[K+] Chemical compound C=C(C)B(F)(F)F.C=C(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.N#CC1=C(C2=CC=C(Br)N=C2)N=C2SCCCN2C1=O.[K+] ZFMRTJXYVFXUOR-UHFFFAOYSA-N 0.000 description 1
- VLLVRKJMUVVJMC-UHFFFAOYSA-N C=C(C)C.CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3CC(CO)CSC3=N2)C=N1.CC(C)(C)OCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound C=C(C)C.CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3CC(CO)CSC3=N2)C=N1.CC(C)(C)OCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 VLLVRKJMUVVJMC-UHFFFAOYSA-N 0.000 description 1
- SJQAFATZHFVEFM-FFZCDNNQSA-N C=C(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3CC(CO)CSC3=N2)C=N1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CC(CF)CSC3=N2)C=N1.CC1CCN2C(=O)C(C#N)=C(C3=CC=C(C(C)(C)C)N=C3)N=C2S1.C[C@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound C=C(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3CC(CO)CSC3=N2)C=N1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CC(CF)CSC3=N2)C=N1.CC1CCN2C(=O)C(C#N)=C(C3=CC=C(C(C)(C)C)N=C3)N=C2S1.C[C@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 SJQAFATZHFVEFM-FFZCDNNQSA-N 0.000 description 1
- VIOKFEVJPNHDDM-UHFFFAOYSA-N C=C(C)C1=CC=C(C2OCCO2)C=N1.CC(CCl)CBr.CC1(C2=CC=C(C3=C(C#N)C(=O)NC(=S)C3)C=N2)CC1.CC1(C2=CC=C(C3OCCO3)C=N2)CC1.CC1(C2=CC=C(C=O)C=N2)CC1.CC1CSC2=NC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1.CCOC(=O)CC#N.NC(N)=S Chemical compound C=C(C)C1=CC=C(C2OCCO2)C=N1.CC(CCl)CBr.CC1(C2=CC=C(C3=C(C#N)C(=O)NC(=S)C3)C=N2)CC1.CC1(C2=CC=C(C3OCCO3)C=N2)CC1.CC1(C2=CC=C(C=O)C=N2)CC1.CC1CSC2=NC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1.CCOC(=O)CC#N.NC(N)=S VIOKFEVJPNHDDM-UHFFFAOYSA-N 0.000 description 1
- BYCKEPMIUBBYTA-UHFFFAOYSA-N C=C(C)C1=NC=C(C2OCCO2)C=C1 Chemical compound C=C(C)C1=NC=C(C2OCCO2)C=C1 BYCKEPMIUBBYTA-UHFFFAOYSA-N 0.000 description 1
- YVAJTIIWAALGMI-UHFFFAOYSA-N C=C(CCl)CCl.C=C1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1 Chemical compound C=C(CCl)CCl.C=C1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1 YVAJTIIWAALGMI-UHFFFAOYSA-N 0.000 description 1
- OLAZASJPOPZAIE-NXMILNHGSA-N C=C1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CCOC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(C)CSC3=N2)C=N1.COC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(C)CSC3=N2)C=N1.COC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.C[C@@H]1CSC2=NC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1.C[C@H]1CSC2=NC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1 Chemical compound C=C1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CCOC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(C)CSC3=N2)C=N1.COC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(C)CSC3=N2)C=N1.COC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.C[C@@H]1CSC2=NC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1.C[C@H]1CSC2=NC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1 OLAZASJPOPZAIE-NXMILNHGSA-N 0.000 description 1
- YHBMYKPDVVAHPV-UHFFFAOYSA-N C=CC1=C(C2=CC=C(C(C)(C)C)C=C2)N=C2CCCCN2C1=O.C=C[Sn](CCCC)(CCCC)CCCC.CC(C)(C)C1=CC=C(C2=C(Br)C(=O)N3CCCCC3=N2)C=C1.CC(C)(C)C1=CC=C(C2=CC(=O)N3C=CC=CC3=N2)C=C1.CC(C)(C)C1=CC=C(C2=CC(=O)N3CCCCC3=N2)C=C1.CCOC(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1.NC1=CC=CC=N1 Chemical compound C=CC1=C(C2=CC=C(C(C)(C)C)C=C2)N=C2CCCCN2C1=O.C=C[Sn](CCCC)(CCCC)CCCC.CC(C)(C)C1=CC=C(C2=C(Br)C(=O)N3CCCCC3=N2)C=C1.CC(C)(C)C1=CC=C(C2=CC(=O)N3C=CC=CC3=N2)C=C1.CC(C)(C)C1=CC=C(C2=CC(=O)N3CCCCC3=N2)C=C1.CCOC(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1.NC1=CC=CC=N1 YHBMYKPDVVAHPV-UHFFFAOYSA-N 0.000 description 1
- KLWUSFCEIOZCQZ-UHFFFAOYSA-N C=CC1=C(C2=CC=C(C(C)(C)C)C=C2)N=C2SCCCN2C1=O Chemical compound C=CC1=C(C2=CC=C(C(C)(C)C)C=C2)N=C2SCCCN2C1=O KLWUSFCEIOZCQZ-UHFFFAOYSA-N 0.000 description 1
- JUXXYVSOEGKHAB-UHFFFAOYSA-N C=CC1=C(C2=CC=C(C(C)(C)C)C=C2)N=C2SCCCN2C1=O.C=C[Sn](CCCC)(CCCC)CCCC.CC(C)(C)C1=CC=C(C2=C(Br)C(=O)N3CCCSC3=N2)C=C1 Chemical compound C=CC1=C(C2=CC=C(C(C)(C)C)C=C2)N=C2SCCCN2C1=O.C=C[Sn](CCCC)(CCCC)CCCC.CC(C)(C)C1=CC=C(C2=C(Br)C(=O)N3CCCSC3=N2)C=C1 JUXXYVSOEGKHAB-UHFFFAOYSA-N 0.000 description 1
- DBEXHPKKXPFWLV-CGZXBOCSSA-N C=CC1=C(C2=CN=C(C(C)(C)C)C=C2)N=C2SCCCN2C1=O.CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=N)N3CCCSC3=N2)C=N1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=N)N3CCCSC3=N2)C=N1.CC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1.CC1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1.C[C@H]1CSC2=NC(C3=CN=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N2C1 Chemical compound C=CC1=C(C2=CN=C(C(C)(C)C)C=C2)N=C2SCCCN2C1=O.CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=N)N3CCCSC3=N2)C=N1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=N)N3CCCSC3=N2)C=N1.CC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1.CC1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1.C[C@H]1CSC2=NC(C3=CN=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N2C1 DBEXHPKKXPFWLV-CGZXBOCSSA-N 0.000 description 1
- GBBSAMQTQCPOBF-UHFFFAOYSA-N CB1OB(C)OB(C)O1 Chemical compound CB1OB(C)OB(C)O1 GBBSAMQTQCPOBF-UHFFFAOYSA-N 0.000 description 1
- HPOQFDAQDAPPLI-UHFFFAOYSA-N CB1OB(C)OB(C)O1.CC(C)(C)C1=CC=C(C2=C(Br)C(=O)N3CCCSC3=N2)C=C1.CC1=C(C2=CC=C(C(C)(C)C)C=C2)N=C2SCCCN2C1=O Chemical compound CB1OB(C)OB(C)O1.CC(C)(C)C1=CC=C(C2=C(Br)C(=O)N3CCCSC3=N2)C=C1.CC1=C(C2=CC=C(C(C)(C)C)C=C2)N=C2SCCCN2C1=O HPOQFDAQDAPPLI-UHFFFAOYSA-N 0.000 description 1
- AVFPMAIGORNWQB-UHFFFAOYSA-N CB1OB(C)OB(C)O1.CC(C)(C)C1=NC=C(C2=C(Br)C(=O)N3CCCSC3=N2)C=C1.CC1=C(C2=CN=C(C(C)(C)C)C=C2)N=C2SCCCN2C1=O Chemical compound CB1OB(C)OB(C)O1.CC(C)(C)C1=NC=C(C2=C(Br)C(=O)N3CCCSC3=N2)C=C1.CC1=C(C2=CN=C(C(C)(C)C)C=C2)N=C2SCCCN2C1=O AVFPMAIGORNWQB-UHFFFAOYSA-N 0.000 description 1
- GSOREGXVPGGRSA-UHFFFAOYSA-N CC(=O)C1=CC(F)=C(C(C)(C)C)N=C1 Chemical compound CC(=O)C1=CC(F)=C(C(C)(C)C)N=C1 GSOREGXVPGGRSA-UHFFFAOYSA-N 0.000 description 1
- MHXCBXFPROWNRB-LEIXHNMOSA-M CC(=O)C1=CC(F)=C(C(C)(C)C)N=C1.CC(=O)C1=CC(F)=CN=C1.CC(C)(C)C(=O)O.CCOC.CCOC(=O)/C(C#N)=C(\C)C1=CN=C(C(C)(C)C)C(F)=C1.CCOC(=O)/C(C#N)=C(\C=C1/SCCCN1C(=O)OC(C)(C)C)C1=CC(F)=C(C(C)(C)C)N=C1.CON(C)C(=O)C1=CC(F)=CN=C1.CSC1=[N+](C)CCCS1.C[Mg]Br.O=C(O)C1=CC(F)=CN=C1.[C-]#[N+]CC(=O)OCC.[I-] Chemical compound CC(=O)C1=CC(F)=C(C(C)(C)C)N=C1.CC(=O)C1=CC(F)=CN=C1.CC(C)(C)C(=O)O.CCOC.CCOC(=O)/C(C#N)=C(\C)C1=CN=C(C(C)(C)C)C(F)=C1.CCOC(=O)/C(C#N)=C(\C=C1/SCCCN1C(=O)OC(C)(C)C)C1=CC(F)=C(C(C)(C)C)N=C1.CON(C)C(=O)C1=CC(F)=CN=C1.CSC1=[N+](C)CCCS1.C[Mg]Br.O=C(O)C1=CC(F)=CN=C1.[C-]#[N+]CC(=O)OCC.[I-] MHXCBXFPROWNRB-LEIXHNMOSA-M 0.000 description 1
- ZCTUODGGGMVDNJ-UHFFFAOYSA-N CC(=O)C1=CC(F)=C(C2(C)CC2)N=C1 Chemical compound CC(=O)C1=CC(F)=C(C2(C)CC2)N=C1 ZCTUODGGGMVDNJ-UHFFFAOYSA-N 0.000 description 1
- CGAMVBZOCLLHRO-PLJKPNJOSA-N CC(=O)C1=CC(F)=C(C2(C)CC2)N=C1.CC(=O)C1=CC(F)=CN=C1.CC1(C(=O)O)CC1.CC1CSC2=CC(C3=CC(F)=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1.CCOC(=O)/C(C#N)=C(\C)C1=CN=C(C2(C)CC2)C(F)=C1.CCOC(=O)/C(C#N)=C(\C=C1/SCC(C)CN1C(=O)OC(C)(C)C)C1=CC(F)=C(C2(C)CC2)N=C1.CSC1=[N+](C)CC(C)CS1.[C-]#[N+]CC(=O)OCC.[I-] Chemical compound CC(=O)C1=CC(F)=C(C2(C)CC2)N=C1.CC(=O)C1=CC(F)=CN=C1.CC1(C(=O)O)CC1.CC1CSC2=CC(C3=CC(F)=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1.CCOC(=O)/C(C#N)=C(\C)C1=CN=C(C2(C)CC2)C(F)=C1.CCOC(=O)/C(C#N)=C(\C=C1/SCC(C)CN1C(=O)OC(C)(C)C)C1=CC(F)=C(C2(C)CC2)N=C1.CSC1=[N+](C)CC(C)CS1.[C-]#[N+]CC(=O)OCC.[I-] CGAMVBZOCLLHRO-PLJKPNJOSA-N 0.000 description 1
- ODMHRPNXXIEPSP-UHFFFAOYSA-N CC(=O)C1=CC=C(Br)C=N1.CC(C)(O)C1=CC=C(Br)C=N1.CC(CCl)CBr.CCOC(=O)CC#N.COC(C)(C)C1=CC=C(Br)C=N1.COC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(C)CSC3=N2)C=N1.COC(C)(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1.COC(C)(C)C1=CC=C(C=O)C=N1 Chemical compound CC(=O)C1=CC=C(Br)C=N1.CC(C)(O)C1=CC=C(Br)C=N1.CC(CCl)CBr.CCOC(=O)CC#N.COC(C)(C)C1=CC=C(Br)C=N1.COC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(C)CSC3=N2)C=N1.COC(C)(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1.COC(C)(C)C1=CC=C(C=O)C=N1 ODMHRPNXXIEPSP-UHFFFAOYSA-N 0.000 description 1
- CQGRRZQZVTWJTR-VZKNRYQFSA-M CC(=O)C1=CC=C(C(C)(C)C)C=C1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=C2)C=C1.CCOC(=O)/C(C#N)=C(\C)C1=CC=C(C(C)(C)C)C=C1.CCOC(=O)/C(C#N)=C(\C=C1/SCCCN1C(=O)OC(C)(C)C)C1=CC=C(C(C)(C)C)C=C1.CSC1=N(C)CCCS1.[C-]#[N+]CC(=O)OCC.[I-] Chemical compound CC(=O)C1=CC=C(C(C)(C)C)C=C1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=C2)C=C1.CCOC(=O)/C(C#N)=C(\C)C1=CC=C(C(C)(C)C)C=C1.CCOC(=O)/C(C#N)=C(\C=C1/SCCCN1C(=O)OC(C)(C)C)C1=CC=C(C(C)(C)C)C=C1.CSC1=N(C)CCCS1.[C-]#[N+]CC(=O)OCC.[I-] CQGRRZQZVTWJTR-VZKNRYQFSA-M 0.000 description 1
- TYFATCLZCNIWFO-UHFFFAOYSA-N CC(=O)C1=CC=C(C2(C)CC2)N=C1.CC(=O)C1=CC=CN=C1.CC1(C(=O)O)CC1 Chemical compound CC(=O)C1=CC=C(C2(C)CC2)N=C1.CC(=O)C1=CC=CN=C1.CC1(C(=O)O)CC1 TYFATCLZCNIWFO-UHFFFAOYSA-N 0.000 description 1
- GXUXTGDJWXYCSU-GPFGRTHNSA-N CC(=O)NCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CC(=O)NC[C@@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CC(=O)NC[C@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC(=O)NCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CC(=O)NC[C@@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CC(=O)NC[C@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 GXUXTGDJWXYCSU-GPFGRTHNSA-N 0.000 description 1
- VOOMSVNIYOQGHC-UHFFFAOYSA-N CC(=O)NCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(CN)CSC3=N2)C=N1.CC(C)(C)OC(=O)CCC1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CC1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CC1CSC2=NC(C3=CC=C(C45CC(C4)C5)N=C3)=C(C#N)C(=O)N2C1.CCOC(=O)NCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC(=O)NCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(CN)CSC3=N2)C=N1.CC(C)(C)OC(=O)CCC1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CC1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CC1CSC2=NC(C3=CC=C(C45CC(C4)C5)N=C3)=C(C#N)C(=O)N2C1.CCOC(=O)NCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 VOOMSVNIYOQGHC-UHFFFAOYSA-N 0.000 description 1
- RCBIORWPZJKLEN-HSGSZXNLSA-N CC(=O)NC[C@@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=C1.CC(C)(C)OCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.COCOCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.COCOC[C@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC(=O)NC[C@@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=C1.CC(C)(C)OCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.COCOCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.COCOC[C@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 RCBIORWPZJKLEN-HSGSZXNLSA-N 0.000 description 1
- PVIIBAQJYOTNML-YDALLXLXSA-N CC(=O)NC[C@@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.S Chemical compound CC(=O)NC[C@@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.S PVIIBAQJYOTNML-YDALLXLXSA-N 0.000 description 1
- NXLHPAWREMSOAI-DFYDOQJSSA-N CC(=O)NC[C@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3CC(C(=O)N4CCOCC4)CSC3=N2)C=N1.CCC(=O)C1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CN(C)C(=O)C1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.COC[C@@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.COC[C@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC(=O)NC[C@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3CC(C(=O)N4CCOCC4)CSC3=N2)C=N1.CCC(=O)C1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CN(C)C(=O)C1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.COC[C@@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.COC[C@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 NXLHPAWREMSOAI-DFYDOQJSSA-N 0.000 description 1
- KDYYVMRSSAINAL-ASICCRSXSA-N CC(=O)OC(=O)C(F)(F)F.CC(C)(C)C1=CC=C(C2=C(C#N)/C(=N/C(=O)C(F)(F)F)N3CCCSC3=N2)C=C1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=N)N3CCCSC3=N2)C=C1 Chemical compound CC(=O)OC(=O)C(F)(F)F.CC(C)(C)C1=CC=C(C2=C(C#N)/C(=N/C(=O)C(F)(F)F)N3CCCSC3=N2)C=C1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=N)N3CCCSC3=N2)C=C1 KDYYVMRSSAINAL-ASICCRSXSA-N 0.000 description 1
- GHSWWXAOCQKCFS-UHFFFAOYSA-N CC(C)(C#N)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1 Chemical compound CC(C)(C#N)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1 GHSWWXAOCQKCFS-UHFFFAOYSA-N 0.000 description 1
- LUWILLGTOUPFNP-UHFFFAOYSA-N CC(C)(C#N)C1=CC=C(C=O)C=N1 Chemical compound CC(C)(C#N)C1=CC=C(C=O)C=N1 LUWILLGTOUPFNP-UHFFFAOYSA-N 0.000 description 1
- QPGZXRBEFGFCED-UHFFFAOYSA-N CC(C)(C)C(=O)O.[H]C(=O)C1=CN=C(C(C)(C)C)C(OC)=C1.[H]C(=O)C1=CN=CC(OC)=C1 Chemical compound CC(C)(C)C(=O)O.[H]C(=O)C1=CN=C(C(C)(C)C)C(OC)=C1.[H]C(=O)C1=CN=CC(OC)=C1 QPGZXRBEFGFCED-UHFFFAOYSA-N 0.000 description 1
- LNPLBEXLOTTXFJ-UHFFFAOYSA-N CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3CC(C(=O)O)CSC3=N2)C=N1.CN(C)C(=O)C1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CNC Chemical compound CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3CC(C(=O)O)CSC3=N2)C=N1.CN(C)C(=O)C1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CNC LNPLBEXLOTTXFJ-UHFFFAOYSA-N 0.000 description 1
- VRTYDAWFXAIQTM-QOZDLSOHSA-N CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3CC(CN4CCCC4)CSC3=N2)C=N1.CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3C[C@@H](CO)CSC3=N2)C=N1.CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3C[C@H](CO)CSC3=N2)C=N1.CCC(C)(CF)C1=CC=C(C2=C(C#N)C(=O)N3CC(C)CSC3=N2)C=N1.CCC(C)(CF)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.CN(C)CC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3CC(CN4CCCC4)CSC3=N2)C=N1.CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3C[C@@H](CO)CSC3=N2)C=N1.CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3C[C@H](CO)CSC3=N2)C=N1.CCC(C)(CF)C1=CC=C(C2=C(C#N)C(=O)N3CC(C)CSC3=N2)C=N1.CCC(C)(CF)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.CN(C)CC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 VRTYDAWFXAIQTM-QOZDLSOHSA-N 0.000 description 1
- QDAKUUINVAVUHX-DKWNGVGWSA-N CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3CC(CO)CSC3=N2)C=N1.CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3C[C@@H](CO)CSC3=N2)C=N1.CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3C[C@H](CO)CSC3=N2)C=N1 Chemical compound CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3CC(CO)CSC3=N2)C=N1.CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3C[C@@H](CO)CSC3=N2)C=N1.CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3C[C@H](CO)CSC3=N2)C=N1 QDAKUUINVAVUHX-DKWNGVGWSA-N 0.000 description 1
- YTDHUJSNNXSICD-UHFFFAOYSA-N CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3CC(CO)CSC3=N2)C=N1.COCOC.COCOCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3CC(CO)CSC3=N2)C=N1.COCOC.COCOCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 YTDHUJSNNXSICD-UHFFFAOYSA-N 0.000 description 1
- CAGVSYGMOBEUAN-UHFFFAOYSA-N CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3CC(CO)CSC3=N2)C=N1.CSCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3CC(CO)CSC3=N2)C=N1.CSCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 CAGVSYGMOBEUAN-UHFFFAOYSA-N 0.000 description 1
- GKAPEVMOZNFENK-PPHPATTJSA-N CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3C[C@@H](CO)CSC3=N2)C=N1.S Chemical compound CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)N3C[C@@H](CO)CSC3=N2)C=N1.S GKAPEVMOZNFENK-PPHPATTJSA-N 0.000 description 1
- YXZUTTMXDZPYHN-UHFFFAOYSA-N CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1 Chemical compound CC(C)(C)C1=C(F)C=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1 YXZUTTMXDZPYHN-UHFFFAOYSA-N 0.000 description 1
- MRXLPBQORVWIAF-UHFFFAOYSA-N CC(C)(C)C1=C(O)C=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.CC1CSC2=NC(C3=CC(O)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CCOC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.COCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.COCC1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.COCC1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC(C)(C)C1=C(O)C=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.CC1CSC2=NC(C3=CC(O)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CCOC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.COCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.COCC1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.COCC1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 MRXLPBQORVWIAF-UHFFFAOYSA-N 0.000 description 1
- WXGUDQPSTBXZPC-UHFFFAOYSA-N CC(C)(C)C1=C(O)C=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1 Chemical compound CC(C)(C)C1=C(O)C=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1 WXGUDQPSTBXZPC-UHFFFAOYSA-N 0.000 description 1
- CSELJIAEVUPVQF-UHFFFAOYSA-N CC(C)(C)C1=C(O)C=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1.CC(CCl)CBr.CC1CSC2=NC(C3=CC(O)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CCOC(=O)CC#N.NC(N)=S.[H]C(=O)C1=CN=C(C(C)(C)C)C(O)=C1.[H]C(=O)C1=CN=C(C(C)(C)C)C(OC)=C1.[H]C(=O)C1=CN=C(C(C)(C)C)C(O[Si](C)(C)C(C)(C)C)=C1 Chemical compound CC(C)(C)C1=C(O)C=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1.CC(CCl)CBr.CC1CSC2=NC(C3=CC(O)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CCOC(=O)CC#N.NC(N)=S.[H]C(=O)C1=CN=C(C(C)(C)C)C(O)=C1.[H]C(=O)C1=CN=C(C(C)(C)C)C(OC)=C1.[H]C(=O)C1=CN=C(C(C)(C)C)C(O[Si](C)(C)C(C)(C)C)=C1 CSELJIAEVUPVQF-UHFFFAOYSA-N 0.000 description 1
- RKPCGXJISNUVMV-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C(=O)Cl)C=N1 Chemical compound CC(C)(C)C1=CC=C(C(=O)Cl)C=N1 RKPCGXJISNUVMV-UHFFFAOYSA-N 0.000 description 1
- YKJUYKDJTAFERY-XPNALAFXSA-N CC(C)(C)C1=CC=C(C(=O)Cl)C=N1.CC(C)(C)C1=CC=C(C(=O)O)C=N1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CCCOC3=N2)C=C1.CCOC(=O)/C(C#N)=C(\N)C1=CN=C(C(C)(C)C)C=C1.CCOC(=O)CC#N.COCC(=O)/C(C#N)=C(/Cl)C1=CC=C(C(C)(C)C)N=C1.COCC(=O)/C(C#N)=C(/O)C1=CC=C(C(C)(C)C)N=C1.O=C=NCCCCl.O=S(Cl)Cl.[H]N1C(=O)N(CCCO)C(=O)C(C#N)=C1C1=CN=C(C(C)(C)C)C=C1 Chemical compound CC(C)(C)C1=CC=C(C(=O)Cl)C=N1.CC(C)(C)C1=CC=C(C(=O)O)C=N1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CCCOC3=N2)C=C1.CCOC(=O)/C(C#N)=C(\N)C1=CN=C(C(C)(C)C)C=C1.CCOC(=O)CC#N.COCC(=O)/C(C#N)=C(/Cl)C1=CC=C(C(C)(C)C)N=C1.COCC(=O)/C(C#N)=C(/O)C1=CC=C(C(C)(C)C)N=C1.O=C=NCCCCl.O=S(Cl)Cl.[H]N1C(=O)N(CCCO)C(=O)C(C#N)=C1C1=CN=C(C(C)(C)C)C=C1 YKJUYKDJTAFERY-XPNALAFXSA-N 0.000 description 1
- DRLUERAXNFIFQO-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C(N)=C(C#N)C#N)C=C1 Chemical compound CC(C)(C)C1=CC=C(C(N)=C(C#N)C#N)C=C1 DRLUERAXNFIFQO-UHFFFAOYSA-N 0.000 description 1
- YTQMTEQNJINKMD-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C(N=C2CCCCC2)=C(C#N)C#N)C=C1 Chemical compound CC(C)(C)C1=CC=C(C(N=C2CCCCC2)=C(C#N)C#N)C=C1 YTQMTEQNJINKMD-UHFFFAOYSA-N 0.000 description 1
- ZONCKAJKBHLLSP-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(Br)C(=O)N3CCCCC3=N2)C=C1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCCC3=N2)C=C1.N#C[Zn]C#N Chemical compound CC(C)(C)C1=CC=C(C2=C(Br)C(=O)N3CCCCC3=N2)C=C1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCCC3=N2)C=C1.N#C[Zn]C#N ZONCKAJKBHLLSP-UHFFFAOYSA-N 0.000 description 1
- AFHNRKCVUSEGOB-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(Br)C(=O)N3CCCCC3=N2)C=C1.CS(=O)C1=C(C2=CC=C(C(C)(C)C)C=C2)N=C2CCCCN2C1=O.CSC1=C(C2=CC=C(C(C)(C)C)C=C2)N=C2CCCCN2C1=O Chemical compound CC(C)(C)C1=CC=C(C2=C(Br)C(=O)N3CCCCC3=N2)C=C1.CS(=O)C1=C(C2=CC=C(C(C)(C)C)C=C2)N=C2CCCCN2C1=O.CSC1=C(C2=CC=C(C(C)(C)C)C=C2)N=C2CCCCN2C1=O AFHNRKCVUSEGOB-UHFFFAOYSA-N 0.000 description 1
- TUIOSHUBFGPDOR-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(Br)C(=O)N3CCCSC3=N2)C=N1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CC(F)(F)CSC3=N2)C=C1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CC(F)CSC3=N2)C=C1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CC(F)CSC3=N2)C=N1.CC1=C(C2=CN=C(C(C)(C)C)C=C2)N=C2SCCCN2C1=O.CSC1=C(C2=CN=C(C(C)(C)C)C=C2)N=C2SCCCN2C1=O Chemical compound CC(C)(C)C1=CC=C(C2=C(Br)C(=O)N3CCCSC3=N2)C=N1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CC(F)(F)CSC3=N2)C=C1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CC(F)CSC3=N2)C=C1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CC(F)CSC3=N2)C=N1.CC1=C(C2=CN=C(C(C)(C)C)C=C2)N=C2SCCCN2C1=O.CSC1=C(C2=CN=C(C(C)(C)C)C=C2)N=C2SCCCN2C1=O TUIOSHUBFGPDOR-UHFFFAOYSA-N 0.000 description 1
- KELURUJNXCBCHV-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=N)N3C=CC=CC3=N2)C=C1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=N)N3C=CC=CC3=N2)C=C1 KELURUJNXCBCHV-UHFFFAOYSA-N 0.000 description 1
- OVDPPSPFZSOYBX-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=N)N3C=CC=CC3=N2)C=C1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C=CC=CC3=N2)C=C1.NC1=CC=CC=N1.[C-]#[N+]CC#N.[H]C(=O)C1=CC=C(C(C)(C)C)C=C1.[H]C(C1=CC=C(C(C)(C)C)C=C1)=C(C#N)C#N Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=N)N3C=CC=CC3=N2)C=C1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C=CC=CC3=N2)C=C1.NC1=CC=CC=N1.[C-]#[N+]CC#N.[H]C(=O)C1=CC=C(C(C)(C)C)C=C1.[H]C(C1=CC=C(C(C)(C)C)C=C1)=C(C#N)C#N OVDPPSPFZSOYBX-UHFFFAOYSA-N 0.000 description 1
- CDKUOVZACQTOIA-LLZNVLRPSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=N)N3CCCSC3=N2)C=C1.CN(C)C(=O)/N=C1/C(C#N)=C(C2=CC=C(C(C)(C)C)C=C2)N=C2SCCCN21.CN(C)C(=O)Cl Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=N)N3CCCSC3=N2)C=C1.CN(C)C(=O)/N=C1/C(C#N)=C(C2=CC=C(C(C)(C)C)C=C2)N=C2SCCCN21.CN(C)C(=O)Cl CDKUOVZACQTOIA-LLZNVLRPSA-N 0.000 description 1
- HXLVSGITRMUJNU-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)C3CC(O)CSC3=N2)C=C1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)C3CC4(CC4)CSC3=N2)C=C1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)C3CC4(COC4)CSC3=N2)C=C1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)C3CCCSC3=N2)C=C1.N#CC1=C([Ar])CC(=S)NC1=O Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)C3CC(O)CSC3=N2)C=C1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)C3CC4(CC4)CSC3=N2)C=C1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)C3CC4(COC4)CSC3=N2)C=C1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)C3CCCSC3=N2)C=C1.N#CC1=C([Ar])CC(=S)NC1=O HXLVSGITRMUJNU-UHFFFAOYSA-N 0.000 description 1
- VTCNZGBGTWMWSZ-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C(N)=CSC3=N2)C=C1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C(N)=CSC3=N2)C=C1 VTCNZGBGTWMWSZ-UHFFFAOYSA-N 0.000 description 1
- PEARHSAMUYUGBZ-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C(N)=CSC3=N2)C=C1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=C1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C(N)=CSC3=N2)C=C1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=C1 PEARHSAMUYUGBZ-UHFFFAOYSA-N 0.000 description 1
- BQGWGTAUQMXBPR-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(C(=O)O)CSC3=N2)C=N1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(C(=O)O)CSC3=N2)C=N1 BQGWGTAUQMXBPR-UHFFFAOYSA-N 0.000 description 1
- ZILMOQJOFUKGFR-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(C(=O)O)CSC3=N2)C=N1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(CF)CSC3=N2)C=N1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(CO)CSC3=N2)C=N1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CC(CO)CSC3=N2)C=N1.CC1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.COC(=O)C1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(C(=O)O)CSC3=N2)C=N1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(CF)CSC3=N2)C=N1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(CO)CSC3=N2)C=N1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CC(CO)CSC3=N2)C=N1.CC1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.COC(=O)C1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 ZILMOQJOFUKGFR-UHFFFAOYSA-N 0.000 description 1
- OQEJZGINUFQIFS-SJNRJLCUSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(CF)CSC3=N2)C=N1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C[C@@H](CF)CSC3=N2)C=N1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C[C@H](CF)CSC3=N2)C=N1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(CF)CSC3=N2)C=N1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C[C@@H](CF)CSC3=N2)C=N1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C[C@H](CF)CSC3=N2)C=N1 OQEJZGINUFQIFS-SJNRJLCUSA-N 0.000 description 1
- KQPLZNZIKNSKSX-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(CN)CSC3=N2)C=N1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(CN=[N+]=[N-])CSC3=N2)C=N1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(CO)CSC3=N2)C=N1.CC(C)(C)OC(=O)CCC1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CCC1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.[H]Cl.[N-]=[N+]=N[Na] Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(CN)CSC3=N2)C=N1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(CN=[N+]=[N-])CSC3=N2)C=N1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(CO)CSC3=N2)C=N1.CC(C)(C)OC(=O)CCC1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CCC1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.[H]Cl.[N-]=[N+]=N[Na] KQPLZNZIKNSKSX-UHFFFAOYSA-N 0.000 description 1
- ZHAPGDUDROQISC-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(CN=[N+]=[N-])CSC3=N2)C=N1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(CN=[N+]=[N-])CSC3=N2)C=N1 ZHAPGDUDROQISC-UHFFFAOYSA-N 0.000 description 1
- AFUQXPGMYCPMIV-SJNRJLCUSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(CO)CSC3=N2)C=N1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C[C@@H](CO)CSC3=N2)C=N1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C[C@H](CO)CSC3=N2)C=N1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(CO)CSC3=N2)C=N1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C[C@@H](CO)CSC3=N2)C=N1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C[C@H](CO)CSC3=N2)C=N1 AFUQXPGMYCPMIV-SJNRJLCUSA-N 0.000 description 1
- GDIUWWVHZIMQOT-GGPVTFAPSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C[C@@H](CF)CSC3=N2)C=N1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C[C@H](CF)CSC3=N2)C=N1.C[C@@H]1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@H]1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C[C@@H](CF)CSC3=N2)C=N1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C[C@H](CF)CSC3=N2)C=N1.C[C@@H]1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@H]1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 GDIUWWVHZIMQOT-GGPVTFAPSA-N 0.000 description 1
- ZKRDJZWKBAVFHV-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)N=C1.CC1=NC(C(C)(C)C)=CC=C1C1=C(C#N)C(=O)N2CCCSC2=N1.N#CC1=C(C2=CN=C(C3CC3)C=C2)N=C2SCCCN2C1=O.N#CC1=C(C2=NC(C3CC3)=NC=C2)N=C2SCCCN2C1=O Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)N=C1.CC1=NC(C(C)(C)C)=CC=C1C1=C(C#N)C(=O)N2CCCSC2=N1.N#CC1=C(C2=CN=C(C3CC3)C=C2)N=C2SCCCN2C1=O.N#CC1=C(C2=NC(C3CC3)=NC=C2)N=C2SCCCN2C1=O ZKRDJZWKBAVFHV-UHFFFAOYSA-N 0.000 description 1
- WICHGZUMQZBDOZ-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)S1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.CC(C)(C)C1=NC=CC(C2=C(C#N)C(=O)N3CCCSC3=N2)=C1.CC1CSC2=NC(C3=CN=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N2C1.N#CC1=C(C2=CN=C(C3CC3)N=C2)N=C2SCCCN2C1=O Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)S1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.CC(C)(C)C1=NC=CC(C2=C(C#N)C(=O)N3CCCSC3=N2)=C1.CC1CSC2=NC(C3=CN=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N2C1.N#CC1=C(C2=CN=C(C3CC3)N=C2)N=C2SCCCN2C1=O WICHGZUMQZBDOZ-UHFFFAOYSA-N 0.000 description 1
- JCWJHDFBLUNFAI-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CN(C4=CC=CC=C4)CSC3=N2)C=C1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=C1.CCOC(=O)CC#N.NC(N)=S.NC1=CC=CC=C1.[H]C(=O)C1=CC=C(C(C)(C)C)C=C1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CN(C4=CC=CC=C4)CSC3=N2)C=C1.CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=C1.CCOC(=O)CC#N.NC(N)=S.NC1=CC=CC=C1.[H]C(=O)C1=CC=C(C(C)(C)C)C=C1 JCWJHDFBLUNFAI-UHFFFAOYSA-N 0.000 description 1
- BVXDRVJCLHYLSR-RFVHGSKJSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C[C@@H](CF)CSC3=N2)C=N1.S Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C[C@@H](CF)CSC3=N2)C=N1.S BVXDRVJCLHYLSR-RFVHGSKJSA-N 0.000 description 1
- FRQQYMWSJHHCRK-NSHDSACASA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C[C@@H](CO)CSC3=N2)C=N1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C[C@@H](CO)CSC3=N2)C=N1 FRQQYMWSJHHCRK-NSHDSACASA-N 0.000 description 1
- LTVYWSKQYCPFNG-MERQFXBCSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C[C@@H](CO)CSC3=N2)C=N1.S Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C[C@@H](CO)CSC3=N2)C=N1.S LTVYWSKQYCPFNG-MERQFXBCSA-N 0.000 description 1
- MALCIUFEHCLLFY-NSHDSACASA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C[C@H](CF)CSC3=N2)C=N1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C[C@H](CF)CSC3=N2)C=N1 MALCIUFEHCLLFY-NSHDSACASA-N 0.000 description 1
- BVXDRVJCLHYLSR-MERQFXBCSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C[C@H](CF)CSC3=N2)C=N1.S Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3C[C@H](CF)CSC3=N2)C=N1.S BVXDRVJCLHYLSR-MERQFXBCSA-N 0.000 description 1
- HWHIRIKPRMSTEA-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=C1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=C1 HWHIRIKPRMSTEA-UHFFFAOYSA-N 0.000 description 1
- KZYFGSPXLBXOFS-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=C1.CC1CSC2=NC(C3=CC=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N2C1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=C1.CC1CSC2=NC(C3=CC=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N2C1 KZYFGSPXLBXOFS-UHFFFAOYSA-N 0.000 description 1
- JHFRTTXOFOSHJE-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1 JHFRTTXOFOSHJE-UHFFFAOYSA-N 0.000 description 1
- YXKQUAXTWLILSC-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1.CC(C)(C)[Si](C)(C)Cl.CC(CCO)SC1=NC(C2=CC=C(C(C)(C)C)N=C2)=C(C#N)C(=O)N1.CC(CCO[Si](C)(C)C(C)(C)C)SC1=NC(C2=CC=C(C(C)(C)C)N=C2)=C(C#N)C(=O)N1.CC(O)CCO.CC(O)CCO[Si](C)(C)C(C)(C)C.CC1=CC=C(S(=O)(=O)Cl)C=C1.CC1=CC=C(S(=O)(=O)OC(C)CCO[Si](C)(C)C(C)(C)C)C=C1.CC1CCN2C(=O)C(C#N)=C(C3=CC=C(C(C)(C)C)N=C3)N=C2S1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1.CC(C)(C)[Si](C)(C)Cl.CC(CCO)SC1=NC(C2=CC=C(C(C)(C)C)N=C2)=C(C#N)C(=O)N1.CC(CCO[Si](C)(C)C(C)(C)C)SC1=NC(C2=CC=C(C(C)(C)C)N=C2)=C(C#N)C(=O)N1.CC(O)CCO.CC(O)CCO[Si](C)(C)C(C)(C)C.CC1=CC=C(S(=O)(=O)Cl)C=C1.CC1=CC=C(S(=O)(=O)OC(C)CCO[Si](C)(C)C(C)(C)C)C=C1.CC1CCN2C(=O)C(C#N)=C(C3=CC=C(C(C)(C)C)N=C3)N=C2S1 YXKQUAXTWLILSC-UHFFFAOYSA-N 0.000 description 1
- ZPPMCNRGWVUFHY-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1.CC1(C)OCC(CO)CO1.COCC(CBr)CBr.COCC(CO)CO.COCC1COC(C)(C)OC1.COCC1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1.CC1(C)OCC(CO)CO1.COCC(CBr)CBr.COCC(CO)CO.COCC1COC(C)(C)OC1.COCC1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 ZPPMCNRGWVUFHY-UHFFFAOYSA-N 0.000 description 1
- MLFPUTDMAGWZQT-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1.CC1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.FC(F)(F)C(CBr)CBr Chemical compound CC(C)(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1.CC1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.FC(F)(F)C(CBr)CBr MLFPUTDMAGWZQT-UHFFFAOYSA-N 0.000 description 1
- GGSATGPQFIPVFL-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=CC(=O)N3CCCCC3=N2)C=C1 Chemical compound CC(C)(C)C1=CC=C(C2=CC(=O)N3CCCCC3=N2)C=C1 GGSATGPQFIPVFL-UHFFFAOYSA-N 0.000 description 1
- XXIHBACTADNZQJ-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=CC(=O)N3CCCSC3=N2)C=C1 Chemical compound CC(C)(C)C1=CC=C(C2=CC(=O)N3CCCSC3=N2)C=C1 XXIHBACTADNZQJ-UHFFFAOYSA-N 0.000 description 1
- ZVAZOISJGHXQQD-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=CC(=O)N3CCCSC3=N2)C=N1 Chemical compound CC(C)(C)C1=CC=C(C2=CC(=O)N3CCCSC3=N2)C=N1 ZVAZOISJGHXQQD-UHFFFAOYSA-N 0.000 description 1
- FYXPIIWDNDHWFQ-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=CC(=O)NC(=S)C2)C=C1 Chemical compound CC(C)(C)C1=CC=C(C2=CC(=O)NC(=S)C2)C=C1 FYXPIIWDNDHWFQ-UHFFFAOYSA-N 0.000 description 1
- DFXZKGDAUYHSDB-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2=CC(=O)NC(=S)C2)C=N1 Chemical compound CC(C)(C)C1=CC=C(C2=CC(=O)NC(=S)C2)C=N1 DFXZKGDAUYHSDB-UHFFFAOYSA-N 0.000 description 1
- FAAQGONYZKWBKC-UHFFFAOYSA-N CC(C)(C)C1=NC=C(Br)C=N1 Chemical compound CC(C)(C)C1=NC=C(Br)C=N1 FAAQGONYZKWBKC-UHFFFAOYSA-N 0.000 description 1
- QJEJQYUYCRTZAR-PBGKQYICSA-M CC(C)(C)C1=NC=C(C(N)=C(C#N)C#N)C=C1.CC(CN)CO.CC(CN)COS(=O)(=O)O.CC1=N(C(=O)OC(C)(C)C)CC(C)CS1.CC1CC/C(=N/C(C2=CN=C(C(C)(C)C)C=C2)=C(C#N)C#N)SC1.CC1CNC(=S)SC1.CC1CSC(=S)N(C(=O)OC(C)(C)C)C1.CC1CSC2=NC(C3=CN=C(C(C)(C)C)C=C3)=C(C#N)C(=N)N2C1.O=S(=O)(O)Cl.[I-] Chemical compound CC(C)(C)C1=NC=C(C(N)=C(C#N)C#N)C=C1.CC(CN)CO.CC(CN)COS(=O)(=O)O.CC1=N(C(=O)OC(C)(C)C)CC(C)CS1.CC1CC/C(=N/C(C2=CN=C(C(C)(C)C)C=C2)=C(C#N)C#N)SC1.CC1CNC(=S)SC1.CC1CSC(=S)N(C(=O)OC(C)(C)C)C1.CC1CSC2=NC(C3=CN=C(C(C)(C)C)C=C3)=C(C#N)C(=N)N2C1.O=S(=O)(O)Cl.[I-] QJEJQYUYCRTZAR-PBGKQYICSA-M 0.000 description 1
- QEVGBHILMMOWJM-DKWNGVGWSA-N CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CC(CF)CSC3=N2)C=N1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3C[C@@H](CF)CSC3=N2)C=N1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3C[C@H](CF)CSC3=N2)C=N1 Chemical compound CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CC(CF)CSC3=N2)C=N1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3C[C@@H](CF)CSC3=N2)C=N1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3C[C@H](CF)CSC3=N2)C=N1 QEVGBHILMMOWJM-DKWNGVGWSA-N 0.000 description 1
- OHAYNVKCBPRVDC-DKWNGVGWSA-N CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CC(CO)CSC3=N2)C=N1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3C[C@@H](CO)CSC3=N2)C=N1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3C[C@H](CO)CSC3=N2)C=N1 Chemical compound CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CC(CO)CSC3=N2)C=N1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3C[C@@H](CO)CSC3=N2)C=N1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3C[C@H](CO)CSC3=N2)C=N1 OHAYNVKCBPRVDC-DKWNGVGWSA-N 0.000 description 1
- IROXSLYNSCEOKR-UHFFFAOYSA-N CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CC(F)(F)CSC3=N2)C=C1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)NC(=S)C2)C=C1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)NC(SCC(F)(F)CO)=N2)C=C1.CC1=CC=C(S(=O)(=O)OCC(F)(F)CO)C=C1.O=S(=O)(OS(=O)(=O)C(F)(F)F)C(F)(F)F.OCC(F)(F)CO Chemical compound CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CC(F)(F)CSC3=N2)C=C1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)NC(=S)C2)C=C1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)NC(SCC(F)(F)CO)=N2)C=C1.CC1=CC=C(S(=O)(=O)OCC(F)(F)CO)C=C1.O=S(=O)(OS(=O)(=O)C(F)(F)F)C(F)(F)F.OCC(F)(F)CO IROXSLYNSCEOKR-UHFFFAOYSA-N 0.000 description 1
- DHGSLEGUBOOSSH-UHFFFAOYSA-N CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CC(F)CSC3=N2)C=C1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)NC(=S)C2)C=C1.CCC(F)COS(=O)(=O)C1=CC=C(C)C=C1.CCOC(=O)C(F)C(C)=O.OCC(F)CO Chemical compound CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3CC(F)CSC3=N2)C=C1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)NC(=S)C2)C=C1.CCC(F)COS(=O)(=O)C1=CC=C(C)C=C1.CCOC(=O)C(F)C(C)=O.OCC(F)CO DHGSLEGUBOOSSH-UHFFFAOYSA-N 0.000 description 1
- KQXRKSQKOKGMRU-SNVBAGLBSA-N CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3C[C@@H](CF)CSC3=N2)C=N1 Chemical compound CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3C[C@@H](CF)CSC3=N2)C=N1 KQXRKSQKOKGMRU-SNVBAGLBSA-N 0.000 description 1
- QVPTYJMUPLOSCO-KCNQMMHDSA-N CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3C[C@@H](CF)CSC3=N2)C=N1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3C[C@@H](CO)CSC3=N2)C=N1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3C[C@H](CF)CSC3=N2)C=N1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3C[C@H](CO)CSC3=N2)C=N1.C[C@@H]1CSC2=NC(C3=CC(O)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@H]1CSC2=NC(C3=CC(O)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3C[C@@H](CF)CSC3=N2)C=N1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3C[C@@H](CO)CSC3=N2)C=N1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3C[C@H](CF)CSC3=N2)C=N1.CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3C[C@H](CO)CSC3=N2)C=N1.C[C@@H]1CSC2=NC(C3=CC(O)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@H]1CSC2=NC(C3=CC(O)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 QVPTYJMUPLOSCO-KCNQMMHDSA-N 0.000 description 1
- YSKGFZZSLVOUFQ-HNCPQSOCSA-N CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3C[C@@H](CF)CSC3=N2)C=N1.S Chemical compound CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3C[C@@H](CF)CSC3=N2)C=N1.S YSKGFZZSLVOUFQ-HNCPQSOCSA-N 0.000 description 1
- MXOGRJHXJNKXRZ-PPHPATTJSA-N CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3C[C@@H](CO)CSC3=N2)C=N1.S Chemical compound CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)N3C[C@@H](CO)CSC3=N2)C=N1.S MXOGRJHXJNKXRZ-PPHPATTJSA-N 0.000 description 1
- QWMPKBWWBVIWHA-UHFFFAOYSA-N CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1 Chemical compound CC(C)(C)C1=NC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1 QWMPKBWWBVIWHA-UHFFFAOYSA-N 0.000 description 1
- HDBFXGPZRVWFJB-UHFFFAOYSA-N CC(C)(C)C1=NC=C(C2=CC(=O)N3CCCCC3=N2)C=C1 Chemical compound CC(C)(C)C1=NC=C(C2=CC(=O)N3CCCCC3=N2)C=C1 HDBFXGPZRVWFJB-UHFFFAOYSA-N 0.000 description 1
- HGWSSKPJULKLLU-UHFFFAOYSA-N CC(C)(C)C1=NC=C(C2=CC(=O)N3CCCCC3=N2)C=C1.CCOC(=O)CC(=O)C1=CC=C(C(C)(C)C)N=C1.CI.CN1CCCN2C(=O)C(Br)=C(C3=CN=C(C(C)(C)C)C=C3)N=C12.CN1CCCN2C(=O)C(C#N)=C(C3=CN=C(C(C)(C)C)C=C3)N=C12.CN1CCCN2C(=O)C=C(C3=CN=C(C(C)(C)C)C=C3)N=C12.Cl.N#C[Cu].N=C1NCCCN1 Chemical compound CC(C)(C)C1=NC=C(C2=CC(=O)N3CCCCC3=N2)C=C1.CCOC(=O)CC(=O)C1=CC=C(C(C)(C)C)N=C1.CI.CN1CCCN2C(=O)C(Br)=C(C3=CN=C(C(C)(C)C)C=C3)N=C12.CN1CCCN2C(=O)C(C#N)=C(C3=CN=C(C(C)(C)C)C=C3)N=C12.CN1CCCN2C(=O)C=C(C3=CN=C(C(C)(C)C)C=C3)N=C12.Cl.N#C[Cu].N=C1NCCCN1 HGWSSKPJULKLLU-UHFFFAOYSA-N 0.000 description 1
- JZEACUVBHQGYPZ-UHFFFAOYSA-N CC(C)(C)C1=NC=C(C2OCCO2)C=C1Br Chemical compound CC(C)(C)C1=NC=C(C2OCCO2)C=C1Br JZEACUVBHQGYPZ-UHFFFAOYSA-N 0.000 description 1
- COIKHMPDRCCCEK-UHFFFAOYSA-N CC(C)(C)C1=NC=C(C2OCCO2)C=C1Br.CSC1=CC(C2OCCO2)=CN=C1C(C)(C)C.OCCO.[H]C(=O)C1=CN=C(C(C)(C)C)C(Br)=C1.[H]C(=O)C1=CN=C(C(C)(C)C)C(SC)=C1 Chemical compound CC(C)(C)C1=NC=C(C2OCCO2)C=C1Br.CSC1=CC(C2OCCO2)=CN=C1C(C)(C)C.OCCO.[H]C(=O)C1=CN=C(C(C)(C)C)C(Br)=C1.[H]C(=O)C1=CN=C(C(C)(C)C)C(SC)=C1 COIKHMPDRCCCEK-UHFFFAOYSA-N 0.000 description 1
- UYCUWGSMCUCDQS-UHFFFAOYSA-N CC(C)(C)C1=NC=C(C=O)C=N1 Chemical compound CC(C)(C)C1=NC=C(C=O)C=N1 UYCUWGSMCUCDQS-UHFFFAOYSA-N 0.000 description 1
- WAHYGAFYHYJSKW-UHFFFAOYSA-N CC(C)(C)OC(=O)CCC1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC(C)(C)OC(=O)CCC1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 WAHYGAFYHYJSKW-UHFFFAOYSA-N 0.000 description 1
- FFDKFOIMQISMCX-UHFFFAOYSA-N CC(C)(C)OCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC(C)(C)OCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 FFDKFOIMQISMCX-UHFFFAOYSA-N 0.000 description 1
- OTBSDLOPRMDLRR-UHFFFAOYSA-N CC(C)(C)c(c(F)c1)ncc1C(N=C(N(C1)C2=O)SCC1C(NC)=O)=C2C#N Chemical compound CC(C)(C)c(c(F)c1)ncc1C(N=C(N(C1)C2=O)SCC1C(NC)=O)=C2C#N OTBSDLOPRMDLRR-UHFFFAOYSA-N 0.000 description 1
- RCXDTXHOIHRSBF-UHFFFAOYSA-N CC(C)(C)c(c(F)c1)ncc1C(N=C(N(C1)C2=O)SCC1C(O)=O)=C2C#N Chemical compound CC(C)(C)c(c(F)c1)ncc1C(N=C(N(C1)C2=O)SCC1C(O)=O)=C2C#N RCXDTXHOIHRSBF-UHFFFAOYSA-N 0.000 description 1
- CBKDYQGHYNMIMA-UHFFFAOYSA-N CC(C)(C)c(c(F)c1)ncc1C(N=C1SCC(COS(C)(=O)=O)CN1C1=O)=C1C#N Chemical compound CC(C)(C)c(c(F)c1)ncc1C(N=C1SCC(COS(C)(=O)=O)CN1C1=O)=C1C#N CBKDYQGHYNMIMA-UHFFFAOYSA-N 0.000 description 1
- QGIHNFHHGQAZAJ-UHFFFAOYSA-N CC(C)(C)c(c(F)c1)ncc1C(N=C1SCC(CSC)CN1C1=O)=C1C#N Chemical compound CC(C)(C)c(c(F)c1)ncc1C(N=C1SCC(CSC)CN1C1=O)=C1C#N QGIHNFHHGQAZAJ-UHFFFAOYSA-N 0.000 description 1
- XKEBSWQBEOYQPH-UHFFFAOYSA-N CC(C)(C)c(c(F)c1)ncc1C(NC(NC1=O)=S)=C1C#N Chemical compound CC(C)(C)c(c(F)c1)ncc1C(NC(NC1=O)=S)=C1C#N XKEBSWQBEOYQPH-UHFFFAOYSA-N 0.000 description 1
- JSHYMTRAGXFPFC-UHFFFAOYSA-N CC(C)(C)c(cc1)ncc1C(N=C1SCC(CN=C)CN1C1=O)=C1C#N Chemical compound CC(C)(C)c(cc1)ncc1C(N=C1SCC(CN=C)CN1C1=O)=C1C#N JSHYMTRAGXFPFC-UHFFFAOYSA-N 0.000 description 1
- DJNMTEUHISKHCC-UHFFFAOYSA-N CC(C)(C)c(cc1)ncc1C(NC(N1)=S)=CC1=O Chemical compound CC(C)(C)c(cc1)ncc1C(NC(N1)=S)=CC1=O DJNMTEUHISKHCC-UHFFFAOYSA-N 0.000 description 1
- KQMOAAJUIGJZGJ-IBGZPJMESA-N CC(C)(C)c(nc1)ncc1C(C=C(N(C1)C2=O)SC[C@@]1(C)C#[I])=C2C#N Chemical compound CC(C)(C)c(nc1)ncc1C(C=C(N(C1)C2=O)SC[C@@]1(C)C#[I])=C2C#N KQMOAAJUIGJZGJ-IBGZPJMESA-N 0.000 description 1
- VRDCIPGFVZQLBA-UHFFFAOYSA-N CC(C)(N)C1=CC=C(Br)C=N1 Chemical compound CC(C)(N)C1=CC=C(Br)C=N1 VRDCIPGFVZQLBA-UHFFFAOYSA-N 0.000 description 1
- RDQCATQYMZDJLU-UHFFFAOYSA-N CC(C)(O)C1=CC=C(Br)C=N1 Chemical compound CC(C)(O)C1=CC=C(Br)C=N1 RDQCATQYMZDJLU-UHFFFAOYSA-N 0.000 description 1
- UJBXBHBGPPMKOS-IBGZPJMESA-N CC(C)(c(cc1)ncc1C(N=C(N(C1)C2=O)SC[C@@]1(C)O)=C2C#N)N(C)C Chemical compound CC(C)(c(cc1)ncc1C(N=C(N(C1)C2=O)SC[C@@]1(C)O)=C2C#N)N(C)C UJBXBHBGPPMKOS-IBGZPJMESA-N 0.000 description 1
- BJRLLTSRJUHFML-UHFFFAOYSA-N CC(C)(c(cc1)ncc1C(NC(NC1=O)=S)=C1C#N)C#N Chemical compound CC(C)(c(cc1)ncc1C(NC(NC1=O)=S)=C1C#N)C#N BJRLLTSRJUHFML-UHFFFAOYSA-N 0.000 description 1
- FSOGRHUDKJYKOD-UHFFFAOYSA-N CC(C)(c(cc1)ncc1C(NC(NC1=O)=S)=C1C#N)OC Chemical compound CC(C)(c(cc1)ncc1C(NC(NC1=O)=S)=C1C#N)OC FSOGRHUDKJYKOD-UHFFFAOYSA-N 0.000 description 1
- AGHKPXLGYUQFBK-UHFFFAOYSA-N CC(C)C(=O)CCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.COCC(=O)CCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC(C)C(=O)CCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.COCC(=O)CCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 AGHKPXLGYUQFBK-UHFFFAOYSA-N 0.000 description 1
- SCZAFPCUFVOMAT-UHFFFAOYSA-N CC(C)C(CBr)CBr Chemical compound CC(C)C(CBr)CBr SCZAFPCUFVOMAT-UHFFFAOYSA-N 0.000 description 1
- VVOISBSEMFDYNE-UHFFFAOYSA-N CC(C)C(CO)CO Chemical compound CC(C)C(CO)CO VVOISBSEMFDYNE-UHFFFAOYSA-N 0.000 description 1
- WIOPLVDZNLMVAS-UHFFFAOYSA-N CC(C1)(C1(F)F)c(cc1)ncc1C(NC(NC1=O)=S)=C1C#N Chemical compound CC(C1)(C1(F)F)c(cc1)ncc1C(NC(NC1=O)=S)=C1C#N WIOPLVDZNLMVAS-UHFFFAOYSA-N 0.000 description 1
- MAQFKTOKIPVTFG-UHFFFAOYSA-N CC(CCO[Si](C)(C)C(C)(C)C)SC1=NC(C2=CC=C(C(C)(C)C)N=C2)=C(C#N)C(=O)N1 Chemical compound CC(CCO[Si](C)(C)C(C)(C)C)SC1=NC(C2=CC=C(C(C)(C)C)N=C2)=C(C#N)C(=O)N1 MAQFKTOKIPVTFG-UHFFFAOYSA-N 0.000 description 1
- ZQQDTCITIPBDNX-UHFFFAOYSA-N CC(CCl)CBr.CC1CSC2=NC(C3=CC=C(C4(C(F)(F)F)CC4)C=C3)=C(C#N)C(=O)N2C1.CCOC(=O)CC#N.N#CC1=C(C2=CC=C(C3(C(F)(F)F)CC3)C=C2)CC(=S)NC1=O.[H]C(=O)C1=CC=C(C2(C(F)(F)F)CC2)C=C1 Chemical compound CC(CCl)CBr.CC1CSC2=NC(C3=CC=C(C4(C(F)(F)F)CC4)C=C3)=C(C#N)C(=O)N2C1.CCOC(=O)CC#N.N#CC1=C(C2=CC=C(C3(C(F)(F)F)CC3)C=C2)CC(=S)NC1=O.[H]C(=O)C1=CC=C(C2(C(F)(F)F)CC2)C=C1 ZQQDTCITIPBDNX-UHFFFAOYSA-N 0.000 description 1
- QCIZNLZYEMWPOV-UHFFFAOYSA-N CC(CF)(CF)C(=O)O.CC1CSC2=NC(C3=CC=C(C(C)(CF)CF)N=C3)=C(C#N)C(=O)N2C1.CC1CSC2=NC(C3=CC=CN=C3)=C(C#N)C(=O)N2C1 Chemical compound CC(CF)(CF)C(=O)O.CC1CSC2=NC(C3=CC=C(C(C)(CF)CF)N=C3)=C(C#N)C(=O)N2C1.CC1CSC2=NC(C3=CC=CN=C3)=C(C#N)C(=O)N2C1 QCIZNLZYEMWPOV-UHFFFAOYSA-N 0.000 description 1
- SHJMRLIXTQJPTO-UHFFFAOYSA-N CC(CN)COS(=O)(=O)O Chemical compound CC(CN)COS(=O)(=O)O SHJMRLIXTQJPTO-UHFFFAOYSA-N 0.000 description 1
- OHMNOZFOIUWBSS-JGARZUFISA-N CC(F)(F)C1=NC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=C1.CC1CCSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N21.CC1CSC2=NC(C3=CC=C(N4CC(C)(C)C4)N=C3)=C(C#N)C(=O)N2C1.CC1CSC2=NC(C3=CC=C(N4CC(C)(C)C4)N=C3)=C(C#N)C(=O)N2C1.CC1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@@H]1CSC2=NC(C3=CN=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N2C1 Chemical compound CC(F)(F)C1=NC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=C1.CC1CCSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N21.CC1CSC2=NC(C3=CC=C(N4CC(C)(C)C4)N=C3)=C(C#N)C(=O)N2C1.CC1CSC2=NC(C3=CC=C(N4CC(C)(C)C4)N=C3)=C(C#N)C(=O)N2C1.CC1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@@H]1CSC2=NC(C3=CN=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N2C1 OHMNOZFOIUWBSS-JGARZUFISA-N 0.000 description 1
- WTDHHHBGSYERND-UHFFFAOYSA-N CC(O)CCO[Si](C)(C)C(C)(C)C Chemical compound CC(O)CCO[Si](C)(C)C(C)(C)C WTDHHHBGSYERND-UHFFFAOYSA-N 0.000 description 1
- ZXMLTGABTMBSIF-UHFFFAOYSA-N CC1(C)CN(C2=CC=C(C3=C(C#N)C(=O)N4CCCSC4=N3)C=N2)C1 Chemical compound CC1(C)CN(C2=CC=C(C3=C(C#N)C(=O)N4CCCSC4=N3)C=N2)C1 ZXMLTGABTMBSIF-UHFFFAOYSA-N 0.000 description 1
- XOWCAPHVUPDPIU-UHFFFAOYSA-N CC1(C)CN(C2=CC=C(C3=C(C#N)C(=O)N4CCCSC4=N3)C=N2)C1.CC1(C)CN(C2=CC=C(C3=C(C#N)C(=O)N4CCCSC4=N3)C=N2)C1.CC1(F)CN(C2=CC=C(C3=C(C#N)C(=O)N4CCCSC4=N3)C=N2)C1.CC1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.CC1CSC2=NC(C3=CC=C(N4CC(C)(F)C4)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1(C)CN(C2=CC=C(C3=C(C#N)C(=O)N4CCCSC4=N3)C=N2)C1.CC1(C)CN(C2=CC=C(C3=C(C#N)C(=O)N4CCCSC4=N3)C=N2)C1.CC1(F)CN(C2=CC=C(C3=C(C#N)C(=O)N4CCCSC4=N3)C=N2)C1.CC1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.CC1CSC2=NC(C3=CC=C(N4CC(C)(F)C4)N=C3)=C(C#N)C(=O)N2C1 XOWCAPHVUPDPIU-UHFFFAOYSA-N 0.000 description 1
- SEPUNFFIITVIHC-MLVFSYQMSA-N CC1(C2=CC=C(C3=C(C#N)C(=O)N4CCCSC4=N3)C=N2)CC1.CC1(F)CC1(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.CC1CSC2=NC(C3=CC=C(C4(C)CC4(C)F)N=C3)=C(C#N)C(=O)N2C1.CC1CSC2=NC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1.C[C@@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@H]1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1 Chemical compound CC1(C2=CC=C(C3=C(C#N)C(=O)N4CCCSC4=N3)C=N2)CC1.CC1(F)CC1(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1.CC1CSC2=NC(C3=CC=C(C4(C)CC4(C)F)N=C3)=C(C#N)C(=O)N2C1.CC1CSC2=NC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1.C[C@@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@H]1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1 SEPUNFFIITVIHC-MLVFSYQMSA-N 0.000 description 1
- ZRRTWXDMIUXGMO-UHFFFAOYSA-N CC1(C2=CC=C(C3=C(C#N)C(=O)N4CCCSC4=N3)C=N2)COC1.CC1CSC2=NC(C3=CC=C(C4(C)COC4)N=C3)=C(C#N)C(=O)N2C1.CC1CSC2=NC(C3=CC=C(C45CC(C4)C5)N=C3C34CC(C3)C4)=C(C#N)C(=O)N2C1.CC1CSC2=NC(C3=CC=CN=C3C34CC(C3)C4)=C(C#N)C(=O)N2C1.CCC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(C)CSC3=N2)C=N1.CCC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1 Chemical compound CC1(C2=CC=C(C3=C(C#N)C(=O)N4CCCSC4=N3)C=N2)COC1.CC1CSC2=NC(C3=CC=C(C4(C)COC4)N=C3)=C(C#N)C(=O)N2C1.CC1CSC2=NC(C3=CC=C(C45CC(C4)C5)N=C3C34CC(C3)C4)=C(C#N)C(=O)N2C1.CC1CSC2=NC(C3=CC=CN=C3C34CC(C3)C4)=C(C#N)C(=O)N2C1.CCC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(C)CSC3=N2)C=N1.CCC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CCCSC3=N2)C=N1 ZRRTWXDMIUXGMO-UHFFFAOYSA-N 0.000 description 1
- RRLPKTLWLWHDGI-UHFFFAOYSA-N CC1(C2=CC=C(C3=C(C#N)C(=O)NC(=S)C3)C=N2)CC1 Chemical compound CC1(C2=CC=C(C3=C(C#N)C(=O)NC(=S)C3)C=N2)CC1 RRLPKTLWLWHDGI-UHFFFAOYSA-N 0.000 description 1
- PYHBCOOHJMDKMC-UHFFFAOYSA-N CC1(C2=CC=C(C3=C(C#N)C(=O)NC(=S)C3)C=N2)CC1(F)F Chemical compound CC1(C2=CC=C(C3=C(C#N)C(=O)NC(=S)C3)C=N2)CC1(F)F PYHBCOOHJMDKMC-UHFFFAOYSA-N 0.000 description 1
- LQPNIXAAJYSANB-UHFFFAOYSA-N CC1(C2=CC=C(C3OCCO3)C=N2)CC1 Chemical compound CC1(C2=CC=C(C3OCCO3)C=N2)CC1 LQPNIXAAJYSANB-UHFFFAOYSA-N 0.000 description 1
- QSANVBYKFXENJF-UHFFFAOYSA-N CC1(C2=CC=C(C=O)C=N2)CC1 Chemical compound CC1(C2=CC=C(C=O)C=N2)CC1 QSANVBYKFXENJF-UHFFFAOYSA-N 0.000 description 1
- JDMGNROROVJOEX-UHFFFAOYSA-N CC1(C2=NC=C(C=O)C=C2)CC1(F)F Chemical compound CC1(C2=NC=C(C=O)C=C2)CC1(F)F JDMGNROROVJOEX-UHFFFAOYSA-N 0.000 description 1
- GSEOBYKPWJEZOV-UHFFFAOYSA-N CC1(CC1)c(cc1)ncc1C(NC(NC1=O)=S)=C1C#N Chemical compound CC1(CC1)c(cc1)ncc1C(NC(NC1=O)=S)=C1C#N GSEOBYKPWJEZOV-UHFFFAOYSA-N 0.000 description 1
- LEEYFILGACJQPR-UHFFFAOYSA-N CC1(F)CCl(=N)C1.[H]C(=O)C1=CC=C(Br)N=C1.[H]C(=O)C1=CC=C(N2CC(C)(F)C2)N=C1 Chemical compound CC1(F)CCl(=N)C1.[H]C(=O)C1=CC=C(Br)N=C1.[H]C(=O)C1=CC=C(N2CC(C)(F)C2)N=C1 LEEYFILGACJQPR-UHFFFAOYSA-N 0.000 description 1
- POKPZVNLNHPQPQ-UHFFFAOYSA-N CC1=CC=C(S(=O)(=O)OC(C)CCO[Si](C)(C)C(C)(C)C)C=C1 Chemical compound CC1=CC=C(S(=O)(=O)OC(C)CCO[Si](C)(C)C(C)(C)C)C=C1 POKPZVNLNHPQPQ-UHFFFAOYSA-N 0.000 description 1
- IVYCLAHSEJZWIR-UHFFFAOYSA-N CC1=CC=C(S(=O)(=O)OCC(F)(F)CO)C=C1 Chemical compound CC1=CC=C(S(=O)(=O)OCC(F)(F)CO)C=C1 IVYCLAHSEJZWIR-UHFFFAOYSA-N 0.000 description 1
- UYMXTLRWXATADT-UHFFFAOYSA-N CC1=CN2C(=O)C(C#N)=C(C3=CC=C(C(C)(C)C)N=C3)N=C2C=C1.CC1CCC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1=CN2C(=O)C(C#N)=C(C3=CC=C(C(C)(C)C)N=C3)N=C2C=C1.CC1CCC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 UYMXTLRWXATADT-UHFFFAOYSA-N 0.000 description 1
- ADMSOXQUOHTWCQ-QJOMJCCJSA-N CC1CC/C(=N/C(C2=CN=C(C(C)(C)C)C=C2)=C(C#N)C#N)SC1 Chemical compound CC1CC/C(=N/C(C2=CN=C(C(C)(C)C)C=C2)=C(C#N)C#N)SC1 ADMSOXQUOHTWCQ-QJOMJCCJSA-N 0.000 description 1
- HZBLLOSLYZYXMX-UHFFFAOYSA-N CC1CCC2=NC(C3=CN=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CCC2=NC(C3=CN=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N2C1 HZBLLOSLYZYXMX-UHFFFAOYSA-N 0.000 description 1
- OZHDCTOTZMDWPK-UHFFFAOYSA-N CC1CNC(=S)SC1 Chemical compound CC1CNC(=S)SC1 OZHDCTOTZMDWPK-UHFFFAOYSA-N 0.000 description 1
- XLZAHYUFLIHANJ-UHFFFAOYSA-N CC1CSC(=S)N(C(=O)OC(C)(C)C)C1 Chemical compound CC1CSC(=S)N(C(=O)OC(C)(C)C)C1 XLZAHYUFLIHANJ-UHFFFAOYSA-N 0.000 description 1
- HBLRURUHKOOSQR-SJNRJLCUSA-N CC1CSC2=CC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@@H]1CSC2=CC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@H]1CSC2=CC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=CC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@@H]1CSC2=CC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@H]1CSC2=CC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 HBLRURUHKOOSQR-SJNRJLCUSA-N 0.000 description 1
- ODVFDEYQUVARRN-GPFGRTHNSA-N CC1CSC2=CC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@@H]1CSC2=CC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@H]1CSC2=CC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=CC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@@H]1CSC2=CC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@H]1CSC2=CC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 ODVFDEYQUVARRN-GPFGRTHNSA-N 0.000 description 1
- HLJDPVCDPOYVRA-SJNRJLCUSA-N CC1CSC2=CC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@@H]1CSC2=CC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@H]1CSC2=CC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=CC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@@H]1CSC2=CC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@H]1CSC2=CC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 HLJDPVCDPOYVRA-SJNRJLCUSA-N 0.000 description 1
- GJPRINLLLYOIPD-UHFFFAOYSA-N CC1CSC2=NC(C3=CC(Br)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CC1CSC2=NC(C3=CN=C(C(C)(C)C)C=C3)=C(C#N)C(=N)N2C1.COC1=C(C(C)(C)C)N=CC(C2=C(C#N)C(=O)N3CC(C)CSC3=N2)=C1.COC1=C(C(C)(C)C)N=CC(C2=C(C#N)C(=O)N3CCCSC3=N2)=C1.CSC1=C(C(C)(C)C)N=CC(C2=C(C#N)C(=O)N3CC(C)CSC3=N2)=C1.CSC1=C(C(C)(C)C)N=CC(C2=C(C#N)C(=O)N3CCCSC3=N2)=C1 Chemical compound CC1CSC2=NC(C3=CC(Br)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.CC1CSC2=NC(C3=CN=C(C(C)(C)C)C=C3)=C(C#N)C(=N)N2C1.COC1=C(C(C)(C)C)N=CC(C2=C(C#N)C(=O)N3CC(C)CSC3=N2)=C1.COC1=C(C(C)(C)C)N=CC(C2=C(C#N)C(=O)N3CCCSC3=N2)=C1.CSC1=C(C(C)(C)C)N=CC(C2=C(C#N)C(=O)N3CC(C)CSC3=N2)=C1.CSC1=C(C(C)(C)C)N=CC(C2=C(C#N)C(=O)N3CCCSC3=N2)=C1 GJPRINLLLYOIPD-UHFFFAOYSA-N 0.000 description 1
- QHYIWNXCVZLFME-DKWNGVGWSA-N CC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1.C[C@@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1.C[C@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1 Chemical compound CC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1.C[C@@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1.C[C@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1 QHYIWNXCVZLFME-DKWNGVGWSA-N 0.000 description 1
- PYLDQHLLQHIIPW-DKWNGVGWSA-N CC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 PYLDQHLLQHIIPW-DKWNGVGWSA-N 0.000 description 1
- GPWKAQWNUQOXMT-DKWNGVGWSA-N CC1CSC2=NC(C3=CC(O)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@@H]1CSC2=NC(C3=CC(O)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@H]1CSC2=NC(C3=CC(O)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=NC(C3=CC(O)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@@H]1CSC2=NC(C3=CC(O)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@H]1CSC2=NC(C3=CC(O)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 GPWKAQWNUQOXMT-DKWNGVGWSA-N 0.000 description 1
- AZVDEVBGQRVWCM-SJNRJLCUSA-N CC1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1.C[C@@H]1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1.C[C@H]1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1 Chemical compound CC1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1.C[C@@H]1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1.C[C@H]1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1 AZVDEVBGQRVWCM-SJNRJLCUSA-N 0.000 description 1
- ZCAXFUVNMAWKBO-GPFGRTHNSA-N CC1CSC2=NC(C3=CC=C(C(C)(C)N(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@@H]1CSC2=NC(C3=CC=C(C(C)(C)N(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@H]1CSC2=NC(C3=CC=C(C(C)(C)N(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=NC(C3=CC=C(C(C)(C)N(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@@H]1CSC2=NC(C3=CC=C(C(C)(C)N(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@H]1CSC2=NC(C3=CC=C(C(C)(C)N(C)C)N=C3)=C(C#N)C(=O)N2C1 ZCAXFUVNMAWKBO-GPFGRTHNSA-N 0.000 description 1
- OFQOUZOPYYRIMN-UHFFFAOYSA-N CC1CSC2=NC(C3=CC=C(C(C)(C)O)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=NC(C3=CC=C(C(C)(C)O)N=C3)=C(C#N)C(=O)N2C1 OFQOUZOPYYRIMN-UHFFFAOYSA-N 0.000 description 1
- CXDAONKMRZOPRD-UHFFFAOYSA-N CC1CSC2=NC(C3=CC=C(C(C)(CF)CF)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=NC(C3=CC=C(C(C)(CF)CF)N=C3)=C(C#N)C(=O)N2C1 CXDAONKMRZOPRD-UHFFFAOYSA-N 0.000 description 1
- POUJRSSKTLTLRJ-SJNRJLCUSA-N CC1CSC2=NC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1.C[C@@H]1CSC2=NC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1.C[C@H]1CSC2=NC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=NC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1.C[C@@H]1CSC2=NC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1.C[C@H]1CSC2=NC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1 POUJRSSKTLTLRJ-SJNRJLCUSA-N 0.000 description 1
- OXWJSWKNQQYPJT-UHFFFAOYSA-N CC1CSC2=NC(C3=CC=C(C45CC(C4)C5)N=C3)=C(C#N)C(=O)N2C1.CC1CSC2=NC(C3=CC=C(C45CC(C4)C5)N=C3C34CC(C3)C4)=C(C#N)C(=O)N2C1.CC1CSC2=NC(C3=CC=CN=C3)=C(C#N)C(=O)N2C1.CC1CSC2=NC(C3=CC=CN=C3C34CC(C3)C4)=C(C#N)C(=O)N2C1.O=C(O)C12CC(C1)C2 Chemical compound CC1CSC2=NC(C3=CC=C(C45CC(C4)C5)N=C3)=C(C#N)C(=O)N2C1.CC1CSC2=NC(C3=CC=C(C45CC(C4)C5)N=C3C34CC(C3)C4)=C(C#N)C(=O)N2C1.CC1CSC2=NC(C3=CC=CN=C3)=C(C#N)C(=O)N2C1.CC1CSC2=NC(C3=CC=CN=C3C34CC(C3)C4)=C(C#N)C(=O)N2C1.O=C(O)C12CC(C1)C2 OXWJSWKNQQYPJT-UHFFFAOYSA-N 0.000 description 1
- RPXDGUOJXRETRH-SJNRJLCUSA-N CC1CSC2=NC(C3=CN=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N2C1.C[C@@H]1CSC2=NC(C3=CN=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N2C1.C[C@H]1CSC2=NC(C3=CN=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=NC(C3=CN=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N2C1.C[C@@H]1CSC2=NC(C3=CN=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N2C1.C[C@H]1CSC2=NC(C3=CN=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N2C1 RPXDGUOJXRETRH-SJNRJLCUSA-N 0.000 description 1
- VURSANQIHUINBB-DKWNGVGWSA-N CC1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1.C[C@@H]1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1.C[C@H]1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1 Chemical compound CC1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1.C[C@@H]1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1.C[C@H]1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1 VURSANQIHUINBB-DKWNGVGWSA-N 0.000 description 1
- XXAFCRNHDOZTJD-DKWNGVGWSA-N CC1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@@H]1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@H]1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CC1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@@H]1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.C[C@H]1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 XXAFCRNHDOZTJD-DKWNGVGWSA-N 0.000 description 1
- UHRPQPZQLIEUMR-UHFFFAOYSA-N CCC(F)COS(=O)(=O)C1=CC=C(C)C=C1 Chemical compound CCC(F)COS(=O)(=O)C1=CC=C(C)C=C1 UHRPQPZQLIEUMR-UHFFFAOYSA-N 0.000 description 1
- LFMREYWTKDEOCD-ZRDIBKRKSA-N CCOC(=O)/C(C#N)=C(\C)C1=CN=C(C(C)(C)C)C(F)=C1 Chemical compound CCOC(=O)/C(C#N)=C(\C)C1=CN=C(C(C)(C)C)C(F)=C1 LFMREYWTKDEOCD-ZRDIBKRKSA-N 0.000 description 1
- IRSGIQOIHLSAKM-ZRDIBKRKSA-N CCOC(=O)/C(C#N)=C(\C)C1=CN=C(C2(C)CC2)C(F)=C1 Chemical compound CCOC(=O)/C(C#N)=C(\C)C1=CN=C(C2(C)CC2)C(F)=C1 IRSGIQOIHLSAKM-ZRDIBKRKSA-N 0.000 description 1
- RWTJDPSDJGFGGX-WGNBKDONSA-N CCOC(=O)/C(C#N)=C(\C=C1/SCC(C)CN1C(=O)OC(C)(C)C)C1=CC(F)=C(C2(C)CC2)N=C1 Chemical compound CCOC(=O)/C(C#N)=C(\C=C1/SCC(C)CN1C(=O)OC(C)(C)C)C1=CC(F)=C(C2(C)CC2)N=C1 RWTJDPSDJGFGGX-WGNBKDONSA-N 0.000 description 1
- QBSMBCPUZPVZEP-XJTMBKJVSA-N CCOC(=O)/C(C#N)=C(\C=C1/SCCCN1C(=O)OC(C)(C)C)C1=CC(F)=C(C(C)(C)C)N=C1 Chemical compound CCOC(=O)/C(C#N)=C(\C=C1/SCCCN1C(=O)OC(C)(C)C)C1=CC(F)=C(C(C)(C)C)N=C1 QBSMBCPUZPVZEP-XJTMBKJVSA-N 0.000 description 1
- DXPALYUFAHAGEH-WFOXIITASA-N CCOC(=O)/C(C#N)=C(\C=C1/SCCCN1C(=O)OC(C)(C)C)C1=CC=C(C(C)(C)C)C=C1 Chemical compound CCOC(=O)/C(C#N)=C(\C=C1/SCCCN1C(=O)OC(C)(C)C)C1=CC=C(C(C)(C)C)C=C1 DXPALYUFAHAGEH-WFOXIITASA-N 0.000 description 1
- QGEWLUZGBVXHPI-QBFSEMIESA-N CCOC(=O)/C(C#N)=C(\N)C1=CN=C(C(C)(C)C)C=C1 Chemical compound CCOC(=O)/C(C#N)=C(\N)C1=CN=C(C(C)(C)C)C=C1 QGEWLUZGBVXHPI-QBFSEMIESA-N 0.000 description 1
- DMIFFKCVURTPTG-UHFFFAOYSA-N CCOC(=O)C(C(C)=O)C(C)C Chemical compound CCOC(=O)C(C(C)=O)C(C)C DMIFFKCVURTPTG-UHFFFAOYSA-N 0.000 description 1
- HIXBLSGNIMXMCA-UHFFFAOYSA-N CCOC(=O)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1 Chemical compound CCOC(=O)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1 HIXBLSGNIMXMCA-UHFFFAOYSA-N 0.000 description 1
- AEGOOHDAUMBYHG-UHFFFAOYSA-N CCOC(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 Chemical compound CCOC(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 AEGOOHDAUMBYHG-UHFFFAOYSA-N 0.000 description 1
- HRBKLIZPXRMCIE-UHFFFAOYSA-N CCOC(=O)CC(=O)C1=CC=C(C(C)(C)C)N=C1 Chemical compound CCOC(=O)CC(=O)C1=CC=C(C(C)(C)C)N=C1 HRBKLIZPXRMCIE-UHFFFAOYSA-N 0.000 description 1
- OARATNJLPCUHNI-MOHJPFBDSA-N CN(C)C(=O)/N=C1/C(C#N)=C(C2=CC=C(C(C)(C)C)C=C2)N=C2SCCCN21 Chemical compound CN(C)C(=O)/N=C1/C(C#N)=C(C2=CC=C(C(C)(C)C)C=C2)N=C2SCCCN21 OARATNJLPCUHNI-MOHJPFBDSA-N 0.000 description 1
- DTYPUWBTTXIFHI-UHFFFAOYSA-N CN(C)C(C)(C)C1=CC=C(Br)C=N1 Chemical compound CN(C)C(C)(C)C1=CC=C(Br)C=N1 DTYPUWBTTXIFHI-UHFFFAOYSA-N 0.000 description 1
- JYQVQJKFPUHVTI-UHFFFAOYSA-N CN(C)C(C)(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1 Chemical compound CN(C)C(C)(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1 JYQVQJKFPUHVTI-UHFFFAOYSA-N 0.000 description 1
- OVKRFSMOWGGBLX-UHFFFAOYSA-N CN(C)C(C)(C)C1=CC=C(C=O)C=N1 Chemical compound CN(C)C(C)(C)C1=CC=C(C=O)C=N1 OVKRFSMOWGGBLX-UHFFFAOYSA-N 0.000 description 1
- HLUIYGVTAGXCRZ-UHFFFAOYSA-N CN(C)C1=CC=C(C(N)=O)C=N1 Chemical compound CN(C)C1=CC=C(C(N)=O)C=N1 HLUIYGVTAGXCRZ-UHFFFAOYSA-N 0.000 description 1
- RWJAHBJKJJFWTM-UHFFFAOYSA-N CN(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1 Chemical compound CN(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1 RWJAHBJKJJFWTM-UHFFFAOYSA-N 0.000 description 1
- YIZXYFJKSCABES-UHFFFAOYSA-N CN(C)c(cc1)ncc1C#N Chemical compound CN(C)c(cc1)ncc1C#N YIZXYFJKSCABES-UHFFFAOYSA-N 0.000 description 1
- OONXAJGBBDGKJZ-UHFFFAOYSA-N CN(C)c(cc1)ncc1C(NC(NC1=O)=S)=C1C#N Chemical compound CN(C)c(cc1)ncc1C(NC(NC1=O)=S)=C1C#N OONXAJGBBDGKJZ-UHFFFAOYSA-N 0.000 description 1
- LXHBAVXWXKKNCK-UHFFFAOYSA-N CN1CCCN2C(=O)C(Br)=C(C3=CN=C(C(C)(C)C)C=C3)N=C12 Chemical compound CN1CCCN2C(=O)C(Br)=C(C3=CN=C(C(C)(C)C)C=C3)N=C12 LXHBAVXWXKKNCK-UHFFFAOYSA-N 0.000 description 1
- PYZDACJLYQLERI-UHFFFAOYSA-N CN1CCCN2C(=O)C=C(C3=CN=C(C(C)(C)C)C=C3)N=C12 Chemical compound CN1CCCN2C(=O)C=C(C3=CN=C(C(C)(C)C)C=C3)N=C12 PYZDACJLYQLERI-UHFFFAOYSA-N 0.000 description 1
- IHTRFWAUNDFPKH-UHFFFAOYSA-N COC(C)(C)C1=CC=C(Br)C=N1 Chemical compound COC(C)(C)C1=CC=C(Br)C=N1 IHTRFWAUNDFPKH-UHFFFAOYSA-N 0.000 description 1
- COIMKAPUGCQEHF-UHFFFAOYSA-N COC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(C)CSC3=C2)C=N1 Chemical compound COC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(C)CSC3=C2)C=N1 COIMKAPUGCQEHF-UHFFFAOYSA-N 0.000 description 1
- OLCIGROYIJYWAD-UHFFFAOYSA-N COC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(C)CSC3=N2)C=N1 Chemical compound COC(C)(C)C1=CC=C(C2=C(C#N)C(=O)N3CC(C)CSC3=N2)C=N1 OLCIGROYIJYWAD-UHFFFAOYSA-N 0.000 description 1
- XOIJAUSXWHABJV-UHFFFAOYSA-N COC(C)(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1 Chemical compound COC(C)(C)C1=CC=C(C2=C(C#N)C(=O)NC(=S)C2)C=N1 XOIJAUSXWHABJV-UHFFFAOYSA-N 0.000 description 1
- FUDLFAKXVWGHIW-SDNWHVSQSA-N COCC(=O)/C(C#N)=C(/Cl)C1=CC=C(C(C)(C)C)N=C1 Chemical compound COCC(=O)/C(C#N)=C(/Cl)C1=CC=C(C(C)(C)C)N=C1 FUDLFAKXVWGHIW-SDNWHVSQSA-N 0.000 description 1
- ISEQAPDMRKFQMS-UHFFFAOYSA-N COCC(CBr)CBr Chemical compound COCC(CBr)CBr ISEQAPDMRKFQMS-UHFFFAOYSA-N 0.000 description 1
- WCOCACOWLDIOSI-UHFFFAOYSA-N COCC(CO)CO Chemical compound COCC(CO)CO WCOCACOWLDIOSI-UHFFFAOYSA-N 0.000 description 1
- RCCLTZRYYYYIDT-UHFFFAOYSA-N COCC1COC(C)(C)OC1 Chemical compound COCC1COC(C)(C)OC1 RCCLTZRYYYYIDT-UHFFFAOYSA-N 0.000 description 1
- CYUYBAYIBIQFAL-SJNRJLCUSA-N COCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.COC[C@@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.COC[C@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound COCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.COC[C@@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.COC[C@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 CYUYBAYIBIQFAL-SJNRJLCUSA-N 0.000 description 1
- BGNBQVCWXZHBPQ-GPFGRTHNSA-N COCOCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.COCOC[C@@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.COCOC[C@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound COCOCC1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.COCOC[C@@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.COCOC[C@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 BGNBQVCWXZHBPQ-GPFGRTHNSA-N 0.000 description 1
- OCKJRQNQHWLHKB-LBPRGKRZSA-N COCOC[C@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound COCOC[C@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 OCKJRQNQHWLHKB-LBPRGKRZSA-N 0.000 description 1
- UZKGSFJWAZYGRD-YDALLXLXSA-N COCOC[C@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.S Chemical compound COCOC[C@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.S UZKGSFJWAZYGRD-YDALLXLXSA-N 0.000 description 1
- ZXTQMLUYQPWWTD-UHFFFAOYSA-N COCSC(=O)C1COC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound COCSC(=O)C1COC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 ZXTQMLUYQPWWTD-UHFFFAOYSA-N 0.000 description 1
- KYXXWFKNMIZXSG-UHFFFAOYSA-N COCSCC1COC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound COCSCC1COC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 KYXXWFKNMIZXSG-UHFFFAOYSA-N 0.000 description 1
- MPGQGFMFKRJLBS-MERQFXBCSA-N COC[C@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.S Chemical compound COC[C@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.S MPGQGFMFKRJLBS-MERQFXBCSA-N 0.000 description 1
- RFGBJCUYNNXCDP-UHFFFAOYSA-N CON(C)C(=O)C1=CC(F)=CN=C1 Chemical compound CON(C)C(=O)C1=CC(F)=CN=C1 RFGBJCUYNNXCDP-UHFFFAOYSA-N 0.000 description 1
- CYZKSDWCCNFZJW-UHFFFAOYSA-N CSC1=C(C2=CN=C(C(C)(C)C)C=C2)N=C2SCCCN2C1=O Chemical compound CSC1=C(C2=CN=C(C(C)(C)C)C=C2)N=C2SCCCN2C1=O CYZKSDWCCNFZJW-UHFFFAOYSA-N 0.000 description 1
- FCLNBEIDUGJGLF-UHFFFAOYSA-M CSC1=N(C(=O)OC(C)(C)C)CC(C)CS1.[I-] Chemical compound CSC1=N(C(=O)OC(C)(C)C)CC(C)CS1.[I-] FCLNBEIDUGJGLF-UHFFFAOYSA-M 0.000 description 1
- SKURQYLXWCFDJG-UHFFFAOYSA-N CSCC1COC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound CSCC1COC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 SKURQYLXWCFDJG-UHFFFAOYSA-N 0.000 description 1
- MLJHMKYXWWRDRC-LBPRGKRZSA-N C[C@@H]1CSC2=CC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound C[C@@H]1CSC2=CC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 MLJHMKYXWWRDRC-LBPRGKRZSA-N 0.000 description 1
- VPNCQRFXSBVHBI-YDALLXLXSA-N C[C@@H]1CSC2=CC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.S Chemical compound C[C@@H]1CSC2=CC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.S VPNCQRFXSBVHBI-YDALLXLXSA-N 0.000 description 1
- XTBLFUYSTAYBLM-YDALLXLXSA-N C[C@@H]1CSC2=CC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1.S Chemical compound C[C@@H]1CSC2=CC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1.S XTBLFUYSTAYBLM-YDALLXLXSA-N 0.000 description 1
- HSNRIYSEANDYLN-MERQFXBCSA-N C[C@@H]1CSC2=CC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.S Chemical compound C[C@@H]1CSC2=CC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.S HSNRIYSEANDYLN-MERQFXBCSA-N 0.000 description 1
- YPBDCUJTRKGNMX-JTQLQIEISA-N C[C@@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1 Chemical compound C[C@@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1 YPBDCUJTRKGNMX-JTQLQIEISA-N 0.000 description 1
- ZJLXSZPLNURTDK-PPHPATTJSA-N C[C@@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1.S Chemical compound C[C@@H]1CSC2=NC(C3=CC(F)=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1.S ZJLXSZPLNURTDK-PPHPATTJSA-N 0.000 description 1
- LLHJDQJVUWXAOK-JTQLQIEISA-N C[C@@H]1CSC2=NC(C3=CC(O)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound C[C@@H]1CSC2=NC(C3=CC(O)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 LLHJDQJVUWXAOK-JTQLQIEISA-N 0.000 description 1
- HQYGQSUPNKEDCA-PPHPATTJSA-N C[C@@H]1CSC2=NC(C3=CC(O)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.S Chemical compound C[C@@H]1CSC2=NC(C3=CC(O)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.S HQYGQSUPNKEDCA-PPHPATTJSA-N 0.000 description 1
- NQTIWQSNDRRNTH-NSHDSACASA-N C[C@@H]1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1 Chemical compound C[C@@H]1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1 NQTIWQSNDRRNTH-NSHDSACASA-N 0.000 description 1
- KUVXWHIQSIYGGQ-MERQFXBCSA-N C[C@@H]1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1.S Chemical compound C[C@@H]1CSC2=NC(C3=CC=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1.S KUVXWHIQSIYGGQ-MERQFXBCSA-N 0.000 description 1
- VUDFOQWEJPEQLY-YDALLXLXSA-N C[C@@H]1CSC2=NC(C3=CC=C(C(C)(C)N(C)C)N=C3)=C(C#N)C(=O)N2C1.S Chemical compound C[C@@H]1CSC2=NC(C3=CC=C(C(C)(C)N(C)C)N=C3)=C(C#N)C(=O)N2C1.S VUDFOQWEJPEQLY-YDALLXLXSA-N 0.000 description 1
- FRPAQDXYWIMNEF-MERQFXBCSA-N C[C@@H]1CSC2=NC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1.S Chemical compound C[C@@H]1CSC2=NC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1.S FRPAQDXYWIMNEF-MERQFXBCSA-N 0.000 description 1
- OJLJCCFFAUHAFT-NSHDSACASA-N C[C@@H]1CSC2=NC(C3=CN=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N2C1 Chemical compound C[C@@H]1CSC2=NC(C3=CN=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N2C1 OJLJCCFFAUHAFT-NSHDSACASA-N 0.000 description 1
- JVMGUZXWPICHEK-MERQFXBCSA-N C[C@@H]1CSC2=NC(C3=CN=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N2C1.S Chemical compound C[C@@H]1CSC2=NC(C3=CN=C(C(C)(C)C)C=C3)=C(C#N)C(=O)N2C1.S JVMGUZXWPICHEK-MERQFXBCSA-N 0.000 description 1
- ZSLADFFOFDPYEN-JTQLQIEISA-N C[C@@H]1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1 Chemical compound C[C@@H]1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1 ZSLADFFOFDPYEN-JTQLQIEISA-N 0.000 description 1
- QATXQBLCXKKCOR-PPHPATTJSA-N C[C@@H]1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1.S Chemical compound C[C@@H]1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=N)N2C1.S QATXQBLCXKKCOR-PPHPATTJSA-N 0.000 description 1
- NRVKDBYTVIXQGL-JTQLQIEISA-N C[C@@H]1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound C[C@@H]1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 NRVKDBYTVIXQGL-JTQLQIEISA-N 0.000 description 1
- WILBCBFBOWCTQT-PPHPATTJSA-N C[C@@H]1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.S Chemical compound C[C@@H]1CSC2=NC(C3=CN=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1.S WILBCBFBOWCTQT-PPHPATTJSA-N 0.000 description 1
- DOOKJCUUQJNQSH-GSNJHRCOSA-N C[C@H]1CSC2=CC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1.C[C@H]1CSC2=CC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1.C[C@H]1CSC2=CC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1 Chemical compound C[C@H]1CSC2=CC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1.C[C@H]1CSC2=CC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1.C[C@H]1CSC2=CC(C3=CC=C(C4(C)CC4)N=C3)=C(C#N)C(=O)N2C1 DOOKJCUUQJNQSH-GSNJHRCOSA-N 0.000 description 1
- LLHJDQJVUWXAOK-SNVBAGLBSA-N C[C@H]1CSC2=NC(C3=CC(O)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 Chemical compound C[C@H]1CSC2=NC(C3=CC(O)=C(C(C)(C)C)N=C3)=C(C#N)C(=O)N2C1 LLHJDQJVUWXAOK-SNVBAGLBSA-N 0.000 description 1
- WOALZHUFLRBASK-UHFFFAOYSA-N FC(F)(F)C1(C2=CC=C(Br)C=C2)CC1.O=CC1=CC=C(C2(C(F)(F)F)CC2)C=C1 Chemical compound FC(F)(F)C1(C2=CC=C(Br)C=C2)CC1.O=CC1=CC=C(C2(C(F)(F)F)CC2)C=C1 WOALZHUFLRBASK-UHFFFAOYSA-N 0.000 description 1
- FEQMAYINHHTWND-UHFFFAOYSA-N N#CC(C(N1)=O)=C(c2ccc(C3(CC3)C(F)(F)F)cc2)NC1=S Chemical compound N#CC(C(N1)=O)=C(c2ccc(C3(CC3)C(F)(F)F)cc2)NC1=S FEQMAYINHHTWND-UHFFFAOYSA-N 0.000 description 1
- YXGCLSSXKFMQJY-UHFFFAOYSA-N N#CC1=C(C2=CC=C(Br)C=C2F)N=C2SCCCN2C1=O.N#CC1=C(C2=CC=C(C3=CC=CC=C3)C=C2F)N=C2SCCCN2C1=O Chemical compound N#CC1=C(C2=CC=C(Br)C=C2F)N=C2SCCCN2C1=O.N#CC1=C(C2=CC=C(C3=CC=CC=C3)C=C2F)N=C2SCCCN2C1=O YXGCLSSXKFMQJY-UHFFFAOYSA-N 0.000 description 1
- XAJZNFWRKDEAOO-UHFFFAOYSA-N N#CC1=C(C2=CC=C(C3(C(F)(F)F)CC3)C=C2)CC(=S)NC1=O Chemical compound N#CC1=C(C2=CC=C(C3(C(F)(F)F)CC3)C=C2)CC(=S)NC1=O XAJZNFWRKDEAOO-UHFFFAOYSA-N 0.000 description 1
- NWIQTMVDEWDMAM-UHFFFAOYSA-N OCC(F)CO Chemical compound OCC(F)CO NWIQTMVDEWDMAM-UHFFFAOYSA-N 0.000 description 1
- VITAORXOBZCVLI-UHFFFAOYSA-N [C-]#[N+]C1=CC=C(N(C)C)N=C1 Chemical compound [C-]#[N+]C1=CC=C(N(C)C)N=C1 VITAORXOBZCVLI-UHFFFAOYSA-N 0.000 description 1
- XBLFNMSIXCWGOU-UHFFFAOYSA-N [H]C(=O)C1=CN=C(C(=C)C)C=C1 Chemical compound [H]C(=O)C1=CN=C(C(=C)C)C=C1 XBLFNMSIXCWGOU-UHFFFAOYSA-N 0.000 description 1
- QKIQNIWEAPPUGO-UHFFFAOYSA-N [H]C(=O)C1=CN=C(C(C)(C)C)C(O)=C1 Chemical compound [H]C(=O)C1=CN=C(C(C)(C)C)C(O)=C1 QKIQNIWEAPPUGO-UHFFFAOYSA-N 0.000 description 1
- PLRMOHIILNOMIE-UHFFFAOYSA-N [H]C(=O)C1=CN=C(C(C)(C)C)C(O[Si](C)(C)C(C)(C)C)=C1 Chemical compound [H]C(=O)C1=CN=C(C(C)(C)C)C(O[Si](C)(C)C(C)(C)C)=C1 PLRMOHIILNOMIE-UHFFFAOYSA-N 0.000 description 1
- VNTIBGZNKGBXPF-UHFFFAOYSA-N [H]C(=O)C1=CN=C(C(C)(C)C)C(SC)=C1 Chemical compound [H]C(=O)C1=CN=C(C(C)(C)C)C(SC)=C1 VNTIBGZNKGBXPF-UHFFFAOYSA-N 0.000 description 1
- NGRNPCRKWWPGJG-UHFFFAOYSA-N [H]C(C1=CC=C(C(C)(C)C)C=C1)=C(C#N)C#N Chemical compound [H]C(C1=CC=C(C(C)(C)C)C=C1)=C(C#N)C#N NGRNPCRKWWPGJG-UHFFFAOYSA-N 0.000 description 1
- XILQRCKWQVHGAZ-UHFFFAOYSA-N [H]N1C(=O)N(CCCO)C(=O)C(C#N)=C1C1=CN=C(C(C)(C)C)C=C1 Chemical compound [H]N1C(=O)N(CCCO)C(=O)C(C#N)=C1C1=CN=C(C(C)(C)C)C=C1 XILQRCKWQVHGAZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/20—Spiro-condensed systems
Definitions
- Neurons that utilize glutamate as neurotransmitter comprise the vast majority of the neurons in the mammalian brain and form the core brain architecture. Glutamate synaptic transmission is mediated by 3 types of ionotropic glutamate receptors, AMPA, KA, and NMDA, and a family of metabotropic receptors (mGluRs). AMPA receptors mediate fast excitatory transmission, whereas KA and mGluRs are primarily involved in pre- and post-synaptic modulatory functions. NMDA receptors mediate slow excitatory synaptic transmission and play a role in integrating synaptic inputs.
- AMPA ionotropic glutamate receptors
- KA and mGluRs are primarily involved in pre- and post-synaptic modulatory functions.
- NMDA receptors mediate slow excitatory synaptic transmission and play a role in integrating synaptic inputs.
- NMDA receptors also regulate the strength of glutamate synapses by signaling the insertion or removal of AMPA receptors in response to the strength and timing of pre- and post-synaptic activity.
- the plasticity of glutamate synapses is a principal molecular mechanism for modifying the informational content and flow in brain neuronal networks and so is critical to the adaptive functions of the brain including learning and memory. Given these functions of NMDA receptors, in mediation of excitatory glutamatergic synaptic transmission, in the integration of synaptic inputs, and in regulation of synaptic plasticity, there are broad therapeutic utilities for agents that modulate the activity of these receptors to treat neurological and neuropsychiatric disease.
- the NMDA receptor is a tetramer consisting of 2 GluN1 subunits and 2 GluN2 subunits, arranged as a dimer of GluN1/GluN2 dimers.
- Each subunit is comprised of 4 modules: a ligand binding domain for the neurotransmitter glutamate (GluN2) or co-transmitter glycine/D-serine (GluN1), a transmembrane domain that forms the ion channel pore, an amino terminal domain that serves a modulatory function, and an intracellular c-terminal domain involved in anchoring the receptors to intracellular scaffolds and signaling complexes.
- GluN2 subunits There are 4 GluN2 subunits, GluN2A-D, coded by individual genes.
- the single GluN1 subunit is expressed as 8 variants resulting from alternative RNA splicing.
- NMDA receptors may be di-heteromeric, consisting of a single type of GluN2 subunit and GluN1 (e.g., GluN2D/GluN1), or tri-heteromeric consisting of 2 different GluN2 subunits and GluN1 (e.g., GluN2B/GluN2D/GluN1).
- NMDA receptors confers specific physiological characteristics including differences in glutamate and glycine affinities, channel kinetics, and interaction with allosteric modulators and intracellular complexes.
- NMDA receptors with different GluN2 subunit compositions are deployed by different populations of neurons to fine-tune NMDA receptor activity.
- forebrain principal neurons and striatal projection neurons express primarily GluN2A and GluN2B di-heteromers and GluN2A/GluN2B tri-heteromers.
- GluN2C is co-expressed primarily with GluN2A by forebrain interneurons, thalamic neurons, and cerebellar neurons.
- GluN2D is co-expressed primarily with GluN2B in forebrain interneurons as well as pallidal, dopaminergic, and subthalamic nucleus neurons of the basal ganglia circuit.
- the subunit composition of NMDA receptors also changes over the course of brain development, with GluN2B and GluN2D subunits predominating early in development.
- NMDA receptor antagonists that act as channel blockers or as glutamate- or glycine-binding site competitive inhibitors. These agents have similar potencies and efficacies across NMDA receptors with different GluN2 subunits and so have the potential to affect activity across essentially all neuronal circuits. Such broad activity can result in unwanted side effects, which have in some cases limited therapeutic utility.
- agents that selectively modulate the activity of NMDA receptors comprised of distinct GluN2 subunits since such agents may have more circuit and neuron specific activities.
- GluN2B negative allosteric modulators More recently disclosed are very limited classes of GluN2A NAMs and GluN2C or GluN2C/D NAMs.
- NMDA receptor activity There are significantly fewer pharmacological agents that can increase NMDA receptor activity. The majority of these are agents that act as ligands at the glutamate or glycine binding sites and so, again, have the potential to broadly affect brain neuronal circuits. Recently, very limited classes of subunit-selective positive allosteric modulators (PAMs) of NMDA receptors have been disclosed. This includes GluN2A PAMs, GluN2C PAMs and GluN2C/D PAMs.
- PAMs subunit-selective positive allosteric modulators
- NMDA receptor function continues to be an area of importance.
- glutamate is the major excitatory neurotransmitter
- dysfunction of glutamate neurotransmission and NMDA receptor-dependent mechanisms of synaptic transmission, plasticity, and neuronal network connectivity are broadly implicated in diseases of the nervous system.
- compounds that are capable of modulating NMDA receptors may be useful for the treatment of nervous system disorders and diseases, for example, schizophrenia, Alzheimer's disease, attention deficit and hyperactivity disorder, and autism.
- the present disclosure provides, for example, compounds which are modulators of NMDA receptors (e.g., positive allosteric modulators of NMDA receptors, e.g., GluN2C and GluN2D PAMs) and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions containing them as an active ingredient.
- the disclosure provides for the use of disclosed compounds as medicaments and/or in the manufacture of medicaments for the modulation of NMDA receptors in warm-blooded animals such as humans.
- this disclosure relates to compounds useful for the treatment of psychiatric, neurological and/or neurodevelopmental disorders and/or diseases of the nervous system, for example, schizophrenia, Alzheimer's disease, attention deficit and hyperactivity, autism, and other nervous system-associated conditions.
- pharmaceutical compositions comprising at least one disclosed compound and a pharmaceutically acceptable carrier.
- Ring A is optionally substituted phenyl or 5-7 membered heteroaryl having one, two or three heteroatoms each independently selected from the group consisting of N, S, and O, and p is 0, 1, 2 or 3;
- R 8 is selected from the group consisting of hydrogen, (C 1-6 )alkyl, C 1-6 alkoxycarbonyl, or (NR a R b )carbonyl-;
- alkyl refers to a saturated straight or branched hydrocarbon.
- exemplary alkyl groups include, but are not limited to, straight or branched hydrocarbons of 1-6, 1-4, or 1-3 carbon atoms, referred to herein as C 1-6 alkyl, C 1-4 alkyl, and C 1-3 alkyl, respectively.
- Exemplary alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, 2-methyl-1-butyl, 3-methyl-2-butyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, etc.
- alkenyl refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon double bond.
- alkenyl groups include, but are not limited to, a straight or branched group of 2-6 or 3-4 carbon atoms, referred to herein as C 2-6 alkenyl, and C 3-4 alkenyl, respectively.
- alkenyl groups include, but are not limited to, vinyl, allyl, butenyl, pentenyl, etc.
- alkoxy refers to a straight or branched alkyl group attached to oxygen (alkyl-O—).
- exemplary alkoxy groups include, but are not limited to alkoxy groups of 1-6 or 2-6 carbon atoms, referred to herein as C 1-6 alkoxy, and C 2-6 alkoxy, respectively.
- Exemplary alkoxy groups include, but are not limited to methoxy, ethoxy, isopropoxy, etc.
- alkylcarbonyl refers to a straight or branched alkyl group attached to a carbonyl group (alkyl-C(O)—).
- exemplary alkylcarbonyl groups include, but are not limited to, alkylcarbonyl groups of 1-6 atoms, referred to herein as C 1-6 alkylcarbonyl groups.
- Exemplary alkylcarbonyl groups include, but are not limited to, acetyl, propanoyl, isopropanoyl, butanoyl, etc.
- alkynyl refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon triple bond.
- exemplary alkynyl groups include, but are not limited to, straight or branched groups of 2-6, or 3-6 carbon atoms, referred to herein as C 2-6 alkynyl, and C 3-6 alkynyl, respectively.
- exemplary alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, hexynyl, methylpropynyl, etc.
- each of said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, and C 3-6 cycloalkyl wherever they occur, including particularly when referring to R 5 and R 3 , may be optionally independently substituted by one or more substituents each independently selected from the group consisting of halogen, hydroxyl, cyano, CF3, NR a R b , C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkyl-S—, C 1-6 alkoxyC 1-6 alkoxy, C 1-6 alkoxyC 1-6 alkyl-S—, C 1-6 alkoxycarbonyl, and (NR a R b )carbonyl-
- carbonyl refers to the radical —C(O)—.
- cyano refers to the radical —CN.
- cycloalkyl or a “carbocyclic group” as used herein refers to a saturated or partially unsaturated hydrocarbon group of, for example, 3-6, or 4-6 carbons, referred to herein as C 3-6 cycloalkyl or C 4-6 cycloalkyl, respectively, may optionally contain one, two or more non cumulative non aromatic double or triple bonds.
- exemplary cycloalkyl groups include, but are not limited to, cyclohexyl, cyclopentyl, cyclopentenyl, cyclobutyl or cyclopropyl.
- Such cycloalkyl may include replacement of one or more ring carbon atoms with Nitrogen or Oxygen heteroatoms.
- cycloalkyl includes “bicycloalkyl” which is defined to include a cycloalkyl as defined above which is bridged to a second carbocyclic ring (e.g., bicyclo[2.2.1]heptanyl, bicyclo[3.2.1]octanyl and bicyclo[5.2.0]nonanyl, etc.).
- the bicycloalkyl group has 6 to 20 carbon atoms. More preferably, the bicycloalkyl group has 6 to 15 carbon atoms. Most preferably, the bicycloalkyl group has 6 to 12 carbon atoms.
- the bicycloalkyl is optionally substituted by 1 to 5 suitable substituents. In one embodiment the bicycloalkyl may optionally contain one, two or more non cumulative non aromatic double or triple bonds.
- cycloalkoxy refers to a cycloalkyl group attached to oxygen (cycloalkyl-O—).
- exemplary cycloalkoxy groups include, but are not limited to, cycloalkoxy groups of 3-6 carbon atoms, referred to herein as C 3-6 cycloalkoxy groups.
- Exemplary cycloalkoxy groups include, but are not limited to, cyclopropoxy, cyclobutoxy, cyclohexyloxy, etc.
- halo or halogen as used herein refer to F, Cl, Br, or I.
- aryl is defined to include all-carbon monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of carbon atoms) groups having a completely conjugated pi-electron system.
- the aryl group has 6, 8, 9, 10 or 12 carbon atoms in the ring(s).
- the aryl group has 6 or 10 carbon atoms in the ring(s).
- One aryl group of particular interest is the 6 carbon atom phenyl ring.
- aryl means aromatic radicals containing from 6 to 10 carbon atoms such as phenyl, naphthyl, tetrahydronaphthyl, anthracenyl, indanyl and the like.
- the aryl group is optionally substituted by 1 to 5 suitable substituents.
- Substituents of particular interest include alkyl, alkoxymethyl, hydroxymethyl, aminomethyl, amidomethyl, carbamoylmethyl, and fluoromethyl.
- heteroaryl or “heteroaromatic group” as used herein refers to a monocyclic aromatic 5-6 membered ring system containing one or more heteroatoms, for example one to three heteroatoms, such as nitrogen, oxygen, and sulfur. Where possible, said heteroaryl ring may be linked to the adjacent radical though carbon or nitrogen.
- heteroaryl rings include but are not limited to furanyl, thiophenyl, pyrrolyl, thiazolyl, oxazolyl, isothiazolyl, isoxazolyl, imidazolyl, pyrazolyl, triazolyl, pyridinyl, pyrimidinyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, furyl, imidazolyl, pyrrolyl, oxazolyl (e.g., 1,3-oxazolyl, 1,2-oxazolyl), thiazolyl (e.g., 1,2-thiazolyl, 1,3-thiazolyl), pyrazolyl, tetrazolyl, triazolyl (e.g., 1,2,3-triazolyl, 1,2,4-triazolyl), oxadiazolyl (e.g., 1,2,3-oxadia
- heterocyclyl or “heterocyclic group” are art-recognized and refer to saturated or partially unsaturated, 4-10 membered ring structures, including bridged or fused rings, and whose ring structures include one to three heteroatoms, such as nitrogen, oxygen, and sulfur. Where possible, heterocyclyl rings may be linked to the adjacent radical through carbon or nitrogen. Examples of heterocyclyl groups include, but are not limited to, pyrrolidine, piperidine, morpholine, thiomorpholine, piperazine, oxetane, azetidine, tetrahydrofuran or dihydrofuran.
- heterocycloalkyl rings include azetidinyl, tetrahydrofuranyl, imidazolidinyl, pyrrolidinyl, piperidinyl, piperazinyl, oxazolidinyl, thiazolidinyl, pyrazolidinyl, thiomorpholinyl, tetrahydrothiazinyl, tetrahydro-thiadiazinyl, morpholinyl, oxetanyl, tetrahydrodiazinyl, oxazinyl, oxathiazinyl, indolinyl, isoindolinyl, quinuclidinyl, chromanyl, isochromanyl, benzoxazinyl, and the like.
- heterocycloalkyl rings are tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, imidazolidin-1-yl, imidazolidin-2-yl, imidazolidin-4-yl, pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperazin-1-yl, piperazin-2-yl, piperazin-3-yl, 1,3-oxazolidin-3-yl, isothiazolidine, 1,3-thiazolidin-3-yl, 1,2 pyrazolidin-2-yl, 1,3-pyrazolidin-1-yl, 1,2-tetrahydrothiazin-2-yl, 1,3 tetrahydrothiazin-3-yl, 1,2-tetrahydrodiazin-2-yl, 1,3 tetrahydrodiazin
- heterocyclyloxy refers to a heterocyclyl group attached to oxygen (heterocyclyl-O—).
- heteroaryloxy refers to a heteroaryl group attached to oxygen (heteroaryl-O—).
- hydroxy and “hydroxyl” as used herein refers to an OH functionality.
- oxo refers to a carbonyl functionality (e.g., C ⁇ O).
- “Pharmaceutically or pharmacologically acceptable” include molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, or a human, as appropriate.
- preparations should meet sterility, pyrogenicity, and general safety and purity standards as required by FDA Office of Biologics standards.
- the compounds of Formula I may exist in the form of pharmaceutically acceptable salts such as, e.g., acid addition salts and base addition salts of the compounds of Formula I.
- pharmaceutically acceptable salt(s) includes salts of acidic or basic groups which may be present in the compounds of Formula I.
- Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include the acetate, adipate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, pyroglutamate, saccharate, ste
- Suitable base salts are formed from bases which form non-toxic salts. Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts.
- Hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts.
- Form I and “Formula I or pharmaceutically acceptable salts thereof” (including all subgeneric Formulae Ia io)) are defined to include all forms of the compound of Formula I, including hydrates, solvates, isomers, crystalline and non-crystalline forms, isomorphs, polymorphs, metabolites, and prodrugs thereof.
- compositions may also contain other active compounds providing supplemental, additional, or enhanced therapeutic functions.
- composition refers to a composition comprising at least one compound as disclosed herein formulated together with one or more pharmaceutically acceptable carriers.
- Treating includes any effect, e.g., lessening, reducing, modulating, or eliminating, that results in the improvement of the condition, disease, disorder and the like.
- “Individual,” “patient,” or “subject” are used interchangeably and include any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.
- the compounds of the invention can be administered to a mammal, such as a human, but can also be administered to other mammals such as an animal in need of veterinary treatment, e.g., domestic animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like) and laboratory animals (e.g., rats, mice, guinea pigs, and the like).
- the mammal treated in the methods of the invention is desirably a mammal in which treatment of e.g., schizophrenia desired.
- “Modulation” includes antagonism (e.g., inhibition), agonism, partial antagonism and/or partial agonism.
- the term “therapeutically effective amount” means the amount of the subject compound that will elicit the biological or medical response of a tissue, system or animal, (e.g., mammal or human) that is being sought by the researcher, veterinarian, medical doctor or other clinician.
- the compounds of the invention are administered in therapeutically effective amounts to treat a disease.
- a therapeutically effective amount of a compound is the quantity required to achieve a desired therapeutic and/or prophylactic effect, such as an amount which results in substantially relief of symptoms associated with schizophrenia.
- pharmaceutically acceptable salt(s) refers to salts of acidic or basic groups that may be present in compounds used in the compositions.
- Compounds included in the present compositions that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids.
- the acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, including, but not limited to, malate, oxalate, chloride, bromide, iodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate (i.e., 1,1′-methylene-
- Compounds included in the present compositions that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations.
- Examples of such salts include alkali metal or alkaline earth metal salts, particularly calcium, magnesium, sodium, lithium, zinc, potassium, and iron salts.
- Compounds included in the present compositions that include a basic or acidic moiety may also form pharmaceutically acceptable salts with various amino acids.
- the compounds of the disclosure may contain both acidic and basic groups; for example, one amino and one carboxylic acid group. In such a case, the compound can exist as an acid addition salt, a zwitterion, or a base salt.
- the compounds of the disclosure may be chiral or exist as stereoisomers.
- stereoisomers when used herein consist of all enantiomers or diastereomers. These compounds may be designated by the symbols “(+),” “( ⁇ ),” “R” or “S,” depending on the configuration of substituents around the stereogenic carbon atom, but the skilled artisan will recognize that a structure may denote a stereogenic center implicitly.
- the present invention encompasses various stereoisomers of these compounds and mixtures thereof. Mixtures of enantiomers or diastereomers may be designated “( ⁇ )” in nomenclature, but the skilled artisan will recognize that a structure may denote a stereogenic center implicitly.
- the compounds of the disclosure may contain one or more double bonds and, therefore, exist as geometric isomers resulting from the arrangement of substituents around a carbon-carbon double bond.
- the symbol denotes a bond that may be a single, double or triple bond as described herein.
- Substituents around a carbon-carbon double bond are designated as being in the “Z” or “E” configuration wherein the terms “Z” and “E” are used in accordance with IUPAC standards. Unless otherwise specified, structures depicting double bonds encompass both the “E” and “Z” isomers.
- Substituents around a carbon-carbon double bond alternatively can be referred to as “cis” or “trans,” where “cis” represents substituents on the same side of the double bond and “trans” represents substituents on opposite sides of the double bond.
- Compounds of the disclosure may contain a carbocyclic or heterocyclic ring and therefore, exist as geometric isomers resulting from the arrangement of substituents around the ring.
- the arrangement of substituents around a carbocyclic or heterocyclic ring are designated as being in the “Z” or “E” configuration wherein the terms “Z” and “E” are used in accordance with IUPAC standards.
- structures depicting carbocyclic or heterocyclic rings encompass both “Z” and “E” isomers.
- Substituents around a carbocyclic or heterocyclic rings may also be referred to as “cis” or “trans”, where the term “cis” represents substituents on the same side of the plane of the ring and the term “trans” represents substituents on opposite sides of the plane of the ring. Mixtures of compounds wherein the substituents are disposed on both the same and opposite sides of plane of the ring are designated “cis/trans.”
- Individual enantiomers and diasteriomers of compounds of the present invention can be prepared synthetically from commercially available starting materials that contain asymmetric or stereogenic centers, or by preparation of racemic mixtures followed by resolution methods well known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary, (2) salt formation employing an optically active resolving agent, (3) direct separation of the mixture of optical enantiomers on chiral liquid chromatographic columns or (4) kinetic resolution using stereoselective chemical or enzymatic reagents.
- Racemic mixtures can also be resolved into their component enantiomers by well known methods, such as chiral-phase liquid chromatography or crystallizing the compound in a chiral solvent.
- Stereoselective syntheses a chemical or enzymatic reaction in which a single reactant forms an unequal mixture of stereoisomers during the creation of a new stereocenter or during the transformation of a pre-existing one, are well known in the art.
- Stereoselective syntheses encompass both enantio- and diastereoselective transformations, and may involve the use of chiral auxiliaries. For examples, see Carreira and Kvaerno, Classics in Stereoselective Synthesis , Wiley-VCH: Weinheim, 2009.
- the compounds of the invention may exist in a continuum of solid states ranging from fully amorphous to fully crystalline.
- amorphous refers to a state in which the material lacks long range order at the molecular level and, depending upon temperature, may exhibit the physical properties of a solid or a liquid. Typically such materials do not give distinctive X-ray diffraction patterns and, while exhibiting the properties of a solid, are more formally described as a liquid.
- a change from solid to liquid properties occurs which is characterised by a change of state, typically second order (‘glass transition’).
- crystalline refers to a solid phase in which the material has a regular ordered internal structure at the molecular level and gives a distinctive X-ray diffraction pattern with defined peaks. Such materials when heated sufficiently will also exhibit the properties of a liquid, but the change from solid to liquid is characterised by a phase change, typically first order (‘melting point’).
- the compounds of the invention may also exist in unsolvated and solvated forms.
- solvate is used herein to describe a molecular complex comprising the compound of the invention and one or more pharmaceutically acceptable solvent molecules, for example, ethanol.
- solvent molecules for example, ethanol.
- hydrate is employed when said solvent is water.
- Isolated site hydrates are ones in which the water molecules are isolated from direct contact with each other by intervening organic molecules.
- channel hydrates the water molecules lie in lattice channels where they are next to other water molecules.
- metal-ion coordinated hydrates the water molecules are bonded to the metal ion.
- the complex When the solvent or water is tightly bound, the complex will have a well-defined stoichiometry independent of humidity. When, however, the solvent or water is weakly bound, as in channel solvates and hygroscopic compounds, the water/solvent content will be dependent on humidity and drying conditions. In such cases, non-stoichiometry will be the norm.
- multi-component complexes other than salts and solvates
- complexes of this type include clathrates (drug-host inclusion complexes) and co-crystals.
- the latter are typically defined as crystalline complexes of neutral molecular constituents which are bound together through non-covalent interactions, but could also be a complex of a neutral molecule with a salt.
- Co-crystals may be prepared by melt crystallisation, by recrystallisation from solvents, or by physically grinding the components together—see Chem Commun, 17, 1889-1896, by O. Almarsson and M. J. Zaworotko (2004).
- the compounds of the invention may also exist in a mesomorphic state (mesophase or liquid crystal) when subjected to suitable conditions.
- the mesomorphic state is intermediate between the true crystalline state and the true liquid state (either melt or solution).
- Mesomorphism arising as the result of a change in temperature is described as ‘thermotropic’ and that resulting from the addition of a second component, such as water or another solvent, is described as ‘lyotropic’.
- lyotropic mesophases Compounds that have the potential to form lyotropic mesophases are described as ‘amphiphilic’ and consist of molecules which possess an ionic (such as —COO—Na+, —COO—K+, or —SO 3 —Na+) or non-ionic (such as —N—N+(CH 3 ) 3 ) polar head group.
- an ionic such as —COO—Na+, —COO—K+, or —SO 3 —Na+
- non-ionic such as —N—N+(CH 3 ) 3
- references to compounds of formula I include references to salts, solvates, multi-component complexes and liquid crystals thereof and to solvates, multi-component complexes and liquid crystals of salts thereof.
- the compounds of the invention include compounds of formula I as hereinbefore defined, including all polymorphs and crystal habits thereof, prodrugs and isomers thereof (including optical, geometric and tautomeric isomers) as hereinafter defined and isotopically-labeled compounds of formula I.
- the invention also embraces isotopically labeled compounds of the invention which are identical to those recited herein, except that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
- isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, such as 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 O, 31 P, 32 P, 35 S, 18 F, and 36 Cl, respectively.
- a compound of the invention may have one or more H atom replaced with deuterium.
- isotopically-labeled disclosed compounds are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3 H) and carbon-14 (i.e., 14 C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2 H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances.
- Isotopically labeled compounds of the invention can generally be prepared by following procedures analogous to those disclosed in the examples herein by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
- prodrug refers to compounds that are transformed in vivo to yield a disclosed compound or a pharmaceutically acceptable salt, hydrate or solvate of the compound. The transformation may occur by various mechanisms (such as by esterase, amidase, phosphatase, oxidative and or reductive metabolism) in various locations (such as in the intestinal lumen or upon transit of the intestine, blood or liver). Prodrugs are well known in the art (for example, see Rautio, Kumpulainen, et al., Nature Reviews Drug Discovery 2008, 7, 255).
- a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as (C 1-8 )alkyl, (C 2-12 )alkylcarbonyloxymethyl, 1-(alkylcarbonyloxy)ethyl having from 4 to 9 carbon atoms, 1-methyl-1-(alkylcarbonyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1-(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1-(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N-(alkoxycarbonyl)amino)eth
- a group such as (C 1-8 )alkyl, (C 2-12 )alkylcarbonyloxymethyl, 1-(alkyl
- a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as (C 1-6 )alkylcarbonyloxymethyl, 1-((C 1-6 )alkylcarbonyloxy)ethyl, 1-methyl-1-((C 1-6 )alkylcarbonyloxy)ethyl (C 1-6 )alkoxycarbonyloxymethyl, N—(C 1-6 )alkoxycarbonylaminomethyl, succinoyl, (C 1-6 )alkylcarbonyl, ⁇ -amino(C 1-4 )alkylcarbonyl, arylalkylcarbonyl and ⁇ -aminoalkylcarbonyl, or ⁇ -aminoalkylcarbonyl- ⁇ -aminoalkylcarbonyl, where each ⁇ -aminoalkylcarbonyl group is independently selected from the naturally occurring L-amino acids, P(O)(
- a prodrug can be formed, for example, by creation of an amide or carbamate, an N-alkylcarbonyloxyalkyl derivative, an (oxodioxolenyl)methyl derivative, an N-Mannich base, imine or enamine.
- a secondary amine can be metabolically cleaved to generate a bioactive primary amine, or a tertiary amine can metabolically cleaved to generate a bioactive primary or secondary amine.
- R C is selected from the group consisting of cyano, hydrogen, halogen, C(O)NR a R b , —C(O)OH, —C(O)O(C 1-6 )alkyl, (C 2-6 )alkenyl, (C 2-6 )alkynyl and heteroaryl (optionally substituted by C 1-4 alkyl or halogen).
- R 1 is selected from the group consisting of hydrogen, halogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 3-6 cycloalkyl, —C(O)OH, —C(O)OC 1-6 alkyl, (C 3-6 )cycloalkyl and phenyl (optionally substituted by one, two or three substituents each selected from halogen, C 1-6 alkyl, C 1-6 alkoxy, —C(O)OH, —C(O)OC 1-6 alkyl and NR a R b ); t is 0, 1 or 2.
- R 2 , R 3 and R 4 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 3-6 cycloalkyl and phenyl (optionally substituted by one or two substituents each selected from halogen or methyl); or when q or m is two, each of said R 3 or R 4 may be taken together with the carbon to which they are attached to form a 3-5 membered carbocyclic ring or a 4-5 membered heterocyclic ring having at least one heteroatom;
- R 4 for each occurrence is independently selected from the group consisting of hydrogen, halogen, hydroxyl, (C 1-6 )alkyl, (C 2-6 )alkenyl, (C 2-6 )alkynyl, (C 1-6 )alkoxy, (C 3-6 )cycloalkyl and phenyl (optionally substituted by one or two substituents each selected from halogen or methyl);
- An embodiment of the invention relates to compounds of Formula I, wherein when R 2 , R 3 or R 4 is bound to a carbon adjacent to a ring nitrogen, R 2 , R 3 or R 4 must be other than halogen, hydroxyl or C1-6alkoxy.
- An embodiment of the invention relates to compounds of Formula I, wherein R 5 independently for each occurrence is selected from the group consisting of hydrogen, C1-6alkyl, C1-6alkoxy, halogen, cyano, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, heteroaryl, phenyl, —NR a R b , —C(O)OH, C 1-6 alkylcarbonyl, C 1-6 alkoxycarbonyl, (NR a R b )carbonyl-, C 1-6 alkyl-S(O) w — (where w is 0, 1 or 2), and R a R b N—SO w — (where w is 0, 1 or 2); wherein heteroaryl and phenyl may optionally be substituted by one, two or three substituents each selected from the group consisting of halogen, cyano, C 1-6 alkyl, C 1-6 alkoxy, and —NR a R b
- An embodiment of the invention relates to compounds of Formula I, wherein R 6 for each occurrence is independently selected from the group consisting of hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, —C(O)—C 1-6 alkyl, and phenyl (optionally substituted by one or two substituents each selected from halogen or methyl);
- R 7 is selected from the group consisting of hydrogen or (C 1-6 )alkyl
- R 8 is selected from the group consisting of hydrogen or (C 1-6 )alkyl
- each of said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, and C 3-6 cycloalkyl wherever they occur may be optionally independently substituted by one or more substituents each independently selected from the group consisting of halogen, hydroxyl, cyano, and NR a R b ;
- R a and R b are independently selected, for each occurrence, from the group consisting of: hydrogen, C 1-4 alkylcarbonyl, cyclopropyl, and C 1-3 alkyl; wherein C 1-3 alkyl may optionally be substituted on a carbon not bound to the nitrogen by one or more substituents each selected from the group consisting of fluorine, cyano, oxo and hydroxyl; or
- R a and R b together with the nitrogen to which they are attached, form a 4-6 membered heterocyclic ring which may have an additional heteroatom selected from O, S, or N (optionally substituted by one or two methyl groups); and wherein the 4-6 membered heterocyclic ring may optionally be substituted on a carbon not bound to the nitrogen by one or more substituents each selected from the group consisting of fluorine, methyl, cyano, oxo and hydroxyl.
- R 3 is selected from the group consisting of hydrogen, halogen, hydroxyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, —CO 2 H, —CO 2 C 1-6 alkyl, —CO 2 NR a R b , NR a R b , C 3-6 cycloalkyl and phenyl; wherein each of said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, and C 3-6 cycloalkyl wherever they occur may be optionally independently substituted by one or more substituents each independently selected from the group consisting of halogen, hydroxyl, cyano, C 3-6 cycloalkyl (wherein one or more ring carbon atoms is replaced by N, O or S), CF 3 , NR a R b , C 1-6 alkyl, C 1-6 alkoxy, C
- An embodiment of the invention relates to compounds of Formula I, wherein R 3 are each independently selected from the group consisting of hydrogen, fluoro, methoxy, methyl, hydroxyl, C 1-6 alkoxymethyl, hydroxymethyl, aminomethyl, amidomethyl, carbamoylmethyl, fluoromethyl.
- a disclosed compound may be represented by Formula I which has the formula
- a disclosed compound may be represented by Formula I which has the formula
- a disclosed compound may be represented by Formula I which has the formula
- a disclosed compound may be represented by Formula I which has the formula
- a disclosed compound may be represented by Formula I which has the formula
- a disclosed compound may be represented by Formula I which has the formula
- a disclosed compound may be represented by Formula I which has the formula
- a disclosed compound may be represented by Formula I which has the formula
- a disclosed compound may be represented by Formula I which has the formula
- a disclosed compound may be represented by Formula I which has the formula
- a disclosed compound may be represented by Formula I which has the formula
- a disclosed compound may be represented by Formula I which has the formula
- a disclosed compound may be represented by Formula I which has the formula
- a disclosed compound may be represented by Formula I which has the formula
- a disclosed compound may be represented by Formula I which has the formula
- a disclosed compound may be represented by Formula I which has the formula
- a disclosed compound may be represented by Formula I which has the formula
- a disclosed compound may be represented by Formula I which has the formula
- a disclosed compound may be represented by Formula I which has the formula
- Another embodiment of the invention includes compounds of Formulae If-Im, wherein ring A is phenyl.
- Another embodiment of the invention includes compounds of Formulae If-Im, wherein ring A is 5-7 membered heteroaryl having one, two or three heteroatoms each independently selected from the group consisting of N, S, and O. More particularly wherein said ring A is pyridinyl, pyrimidinyl or pyridazinyl.
- R 5 is independently for each occurrence selected from the group consisting of hydrogen, halogen, methoxy, methyl, ethyl, propyl, isopropyl, cyclopropyl, t-butyl, t-butyloxy, t-butylthio, pyridinyl (optionally substituted by halogen), and phenyl (optionally substituted by halogen).
- R 5 is t-butyl.
- Another embodiment of the invention includes compounds wherein R c is —CN.
- Another embodiment of the invention includes compounds wherein p is 0, 1 or 2.
- Another embodiment of the invention includes compounds wherein p is 1.
- Another embodiment of the invention includes compounds wherein p is 2.
- Another embodiment of the invention includes compounds wherein n is 1. Another embodiment of the invention includes compounds wherein n is 0.
- Another embodiment of the invention includes compounds, wherein R 4 is selected from the group consisting of hydrogen, C 1-4 alkyl, and phenyl. Another embodiment of the invention, includes compounds, wherein R 4 is hydrogen.
- R 1 is selected from the group consisting of hydrogen, (C 1-6 )alkyl, (C 2-6 )alkenyl, (C 2-6 )alkynyl, (C 3-6 )cycloalkyl and phenyl (optionally substituted by one or two substituents each selected from halogen or methyl), t is 0, 1 or 2.
- R 1 is hydrogen.
- Another embodiment of the invention includes compounds wherein one of said R 3 is selected from the group consisting of hydrogen, methoxy, methyl and hydroxyl; and the other of said R 3 is selected from the group consisting of hydrogen or methyl; wherein when R 3 is bound to a carbon adjacent to a ring nitrogen, R 3 cannot be methoxy or hydroxyl.
- R 3 are each independently selected from the group consisting of hydrogen, fluoro, methoxy, methyl, and hydroxyl.
- Another embodiment of the invention includes compounds wherein each R 3 is hydrogen.
- Another embodiment of the invention includes compounds wherein the compound is represented by:
- Another embodiment of the invention includes compounds wherein the compound is represented by:
- Another embodiment of the invention includes compounds wherein the compound is represented by:
- Another embodiment of the invention includes compounds wherein R 5 is t-butyl.
- ring A may be pyridinyl, pyrimidinyl or pyridazinyl. In certain other embodiments, wherein R c may be cyano.
- A′ may be S
- C′ may be Carbon
- B′ may be CNR a R b .
- A′ may be NR 6 , C′ may be N and B′ may be CR 3 .
- A′ may be NR 6 , C′ may be Carbon and B′ may be N.
- a disclosed compound may be selected from the group consisting of:
- a disclosed compound may be represented by:
- Each R 5 is independently selected from the group consisting of hydrogen, C 1-6 alkyl, C 1-6 alkoxy, halogen, cyano, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, heteroaryl, phenyl, —NR a R b , —C(O)OH, C 1-6 alkylcarbonyl, C 1-6 alkoxycarbonyl, NR a R b carbonyl-, C 1-6 alkyl-S(O) w — (where w is 0, 1 or 2), and R a R b N—SO w — (where w is 0, 1 or 2); wherein heteroaryl and phenyl are optionally substituted by one, two or three substituents each selected from the group consisting of halogen, cyano, C 1-6 alkyl, C 1-6 alkoxy, and —NR a R b ;
- Compounds of any of Formula I, as depicted above, or any of the intermediates described below, can be further derivatised by using one or more standard synthetic methods known to those skilled in the art. Such methods can involve substitution, oxidation or reduction reactions. These methods can also be used to obtain or modify compounds of Formula I or any preceding intermediates by modifying, introducing or removing appropriate functional groups. Particular substitution approaches include alkylation, arylation, heteroarylation, acylation, thioacylation, halogenation, sulfonylation, nitration, formylation, hydrolysis and coupling procedures.
- alcohol or phenol groups can be converted to ether groups by coupling a phenol with an alcohol in a solvent (such as tetrahydrofuran) in the presence of a phosphine (such as triphenylphosphine) and a dehydrating agent (such as diethyl, diisopropyl or dimethyl azodicarboxylate).
- a solvent such as tetrahydrofuran
- phosphine such as triphenylphosphine
- a dehydrating agent such as diethyl, diisopropyl or dimethyl azodicarboxylate
- ether groups can be prepared by deprotonation of an alcohol, using a suitable base (such as sodium hydride) followed by the addition of an alkylating agent (such as an alkyl halide or an alkyl sulfonate).
- a suitable base such as sodium hydride
- an alkylating agent such as an alkyl halide or an alkyl sulfonate
- a primary or secondary amine can be alkylated using a reductive alkylation procedure.
- the amine can be treated with an aldehyde and a borohydride (such as sodium triacetoxyborohydride, or sodium cyanoborohydride in a solvent (such as a halogenated hydrocarbon, for example dichloromethane, or an alcohol, for example ethanol) and, where necessary, in the presence of an acid (such as acetic acid).
- a borohydride such as sodium triacetoxyborohydride, or sodium cyanoborohydride in a solvent (such as a halogenated hydrocarbon, for example dichloromethane, or an alcohol, for example ethanol)
- an acid such as acetic acid
- hydroxy groups can be converted into leaving groups, such as halogen atoms or sulfonyloxy groups (such as alkylsulfonyloxy, for example trifluoromethanesulfonyloxy, or aryl sulphonyloxy, for example p-toluenesulfonyloxy) using conditions known to those skilled in the art.
- leaving groups such as halogen atoms or sulfonyloxy groups (such as alkylsulfonyloxy, for example trifluoromethanesulfonyloxy, or aryl sulphonyloxy, for example p-toluenesulfonyloxy) using conditions known to those skilled in the art.
- a halogenated hydrocarbon such as dichloromethane
- a base such as triethylamine
- ester groups can be converted to the corresponding carboxylic acid group by acid- or base-catalysed hydrolysis depending on the nature of the ester group.
- Acid catalysed hydrolysis can be achieved by treatment with an organic or inorganic acid (such as trifluoroacetic acid in an aqueous solvent, or a mineral acid such as hydrochloric acid in a solvent such as dioxane).
- Base catalysed hydrolysis can be achieved by treatment with an alkali metal hydroxide (such as lithium hydroxide in an aqueous alcohol, for example methanol).
- aromatic halogen substituents in the compounds may be subjected to halogen-metal exchange by treatment with a base (such as a lithium base, for example n-butyl or t-butyllithium) optionally at a low temperature (such as ⁇ 78° C.) in a solvent (such as tetrahydrofuran) and the mixture may then be quenched with an electrophile to introduce a desired substituent.
- a base such as a lithium base, for example n-butyl or t-butyllithium
- a solvent such as tetrahydrofuran
- Aromatic halogen substituents can also be subjected to palladium catalysed reactions to introduce groups such as carboxylic acids, esters, cyano or amino substituents.
- an aryl, or heteroaryl ring substituted with an appropriate leaving group can undergo a palladium catalysed coupling reaction with a wide variety of substrates to form a carbon-carbon bond.
- an appropriate leaving group such as a halogen or sulfonyl ester, for example a triflate
- a Heck reaction can be used to couple such a ring system to an alkene (which may, or may not, be further substituted) by treatment with an organopalladium complex (such as tetrakis(triphenylphosphine)palladium(0), palladium (II) acetate or palladium (II) chloride) in the presence of a ligand (such as a phosphine, for example triphenylphosphine) in the presence of a base (such as potassium carbonate or a tertiary amine, for example, triethylamine), in an appropriate solvent (such as tetrahydrofuran or DMF), under appropriate conditions (such as heating to, for example, 50-120° C.).
- organopalladium complex such as tetrakis(triphenylphosphine)palladium(0), palladium (II) acetate or palladium (II) chloride
- a ligand such as a
- a Sonogashira reaction can be used to couple such a ring system to an alkyne (which may, or may not be further substituted) by treatment with a palladium complex (such as tetrakis(triphenylphosphine)palladium(0)) and a halide salt of copper (I) (such as copper (I) iodide), in the presence of a base (such as a potassium carbonate or a tertiary amine, for example, triethylamine), in an appropriate solvent (such as tetrahydrofuran or dimethylformamide), under appropriate conditions (such as heating to, for example, 50-120° C.).
- a palladium complex such as tetrakis(triphenylphosphine)palladium(0)
- a halide salt of copper (I) such as copper (I) iodide
- a base such as a potassium carbonate or a tertiary amine, for example, trieth
- a Stille reaction can be used to couple such a ring system to an alkene, by treatment with an organotin compound (such as an alkynylation or alkenyltin reagent, for example an alkenyltributylstannane) in the presence of a palladium complex (such as tetrakis(triphenylphosphine)palladium(0)), with, or without the presence of a salt (such as a copper (I) halide), in an appropriate solvent (such as dioxane or dimethylformamide), under appropriate conditions (such as heating to, for example, 50-120° C.).
- organotin compound such as an alkynylation or alkenyltin reagent, for example an alkenyltributylstannane
- a palladium complex such as tetrakis(triphenylphosphine)palladium(0)
- a salt such as a copper (I) halide
- solvent such as di
- aldehyde groups can be prepared by oxidation of the corresponding alcohol using conditions well known to those skilled in the art.
- an alcohol can be treated with an oxidising agent (such as Dess-Martin periodinane) in a solvent (such as a halogenated hydrocarbon, for example dichloromethane).
- oxidising agents such as Dess-Martin periodinane
- solvent such as a halogenated hydrocarbon, for example dichloromethane
- Alternative oxidising conditions can be used, such as treatment with oxalyl chloride and an activating amount of dimethylsulfoxide and subsequent quenching by the addition of an amine (such as triethylamine).
- Such a reaction can be carried out in an appropriate solvent (such as a halogenated hydrocarbon, for example dichloromethane) and under appropriate conditions (such as cooling below room temperature, for example to ⁇ 78° C. followed by warming to room temperature).
- an appropriate solvent such as a halogenated hydrocarbon, for example dichloromethane
- sulfur atoms can be oxidised to the corresponding sulfoxide or sulfone using an oxidising agent (such as a peroxy acid, for example 3-chloroperoxybenzoic acid) in an inert solvent (such as a halogenated hydrocarbon, for example dichloromethane) at around ambient temperature.
- an oxidising agent such as a peroxy acid, for example 3-chloroperoxybenzoic acid
- an inert solvent such as a halogenated hydrocarbon, for example dichloromethane
- Particular reduction approaches include the removal of oxygen atoms from particular functional groups or saturation (or partial saturation) of unsaturated compounds including aromatic or heteroaromatic rings.
- primary alcohols can be generated from the corresponding ester or aldehyde by reduction, using a metal hydride (such as lithium aluminium hydride or sodium borohydride in a solvent such as methanol).
- a metal hydride such as lithium aluminium hydride or sodium borohydride in a solvent such as methanol
- CH 2 OH groups can be generated from the corresponding carboxylic acid by reduction, using a metal hydride (such as lithium aluminium hydride in a solvent such as tetrahydrofuran).
- a nitro group may be reduced to an amine by catalytic hydrogenation in the presence of a metal catalyst (such as palladium on a solid support such as carbon) in a solvent (such as an ether, for example tetrahydrofuran, or an alcohol, such as methanol), or by chemical reduction using a metal (such as zinc, tin or iron) in the presence of an acid (such as acetic acid or hydrochloric acid).
- a metal catalyst such as palladium on a solid support such as carbon
- a solvent such as an ether, for example tetrahydrofuran, or an alcohol, such as methanol
- an acid such as acetic acid or hydrochloric acid
- an amine can be obtained by reduction of a nitrile, for example by catalytic hydrogenation in the presence of a metal catalyst (such as palladium on a solid support such as carbon), or Raney nickel in a solvent (such as tetrahydrofuran) and under suitable conditions (such as cooling to below room temperature, for example to ⁇ 78° C., or heating, for example to reflux).
- a metal catalyst such as palladium on a solid support such as carbon
- Raney nickel in a solvent (such as tetrahydrofuran) and under suitable conditions (such as cooling to below room temperature, for example to ⁇ 78° C., or heating, for example to reflux).
- Salts of compounds of Formula I can be prepared by the reaction of a compound of Formula I with an appropriate acid or base in a suitable solvent, or mixture of solvents (such as an ether, for example, diethyl ether, or an alcohol, for example ethanol, or an aqueous solvent) using conventional procedures. Salts of compound of Formula I can be exchanged for other salts by treatment using conventional ion-exchange chromatography procedures.
- a suitable solvent such as an ether, for example, diethyl ether, or an alcohol, for example ethanol, or an aqueous solvent
- enantiomer of a compound of Formula I this may be produced from a corresponding mixture of enantiomers by employing any suitable conventional procedure for resolving enantiomers.
- diastereomeric derivatives such as salts
- a mixture of enantiomers of a compound of Formula I such a racemate
- an appropriate chiral compound such as a chiral base
- the diastereomers can then be separated by any conventional means such as crystallisation, and the desired enantiomer recovered (such as by treatment with an acid in the instance where the diastereomer is a salt).
- a racemic mixture of esters can be resolved by kinetic hydrolysis using a variety of biocatalysts (for example, see Patel Stereoselective Biocatalysts, Marcel Decker; New York 2000).
- a racemate of compounds of Formula I can be separated using chiral High Performance Liquid Chromatography.
- a particular enantiomer can be obtained by using an appropriate chiral intermediate in one of the processes described above. Chromatography, recrystallisation and other conventional separation procedures may also be used with intermediates or final products where it is desired to obtain a particular geometric isomer of the invention.
- Another aspect of the disclosure provides methods of modulating the activity of the NMDA receptor. Such methods may for example, comprise exposing said receptor to a compound described herein.
- the compound utilized by one or more of the foregoing methods is one of the generic, subgeneric, or specific compounds described herein, such as a compound of Formula I.
- the ability of compounds described herein to modulate the NMDA receptor can be evaluated by procedures known in the art and/or described herein.
- the present disclosure provides a method of treating and or ameliorating a disease and/or disorder of the nervous system in a patient in need thereof by administering an effective amount of a disclosed compound.
- exemplary diseases and disorders of the nervous system include psychiatric diseases, neurological diseases, and neurodevelopmental disorders, further described below.
- an exemplary psychiatric disease is schizophrenia.
- Schizophrenia is a debilitating mental disorder encompassing three symptom domains: positive (psychosis, hallucination, delusions), negative (withdrawal), and cognitive (global reduction in cognitive ability).
- Positive symptoms of Schizophrenia typically emerge early in adulthood and are treated with antipsychotic medications.
- cognitive deficits are severe, emerge in the adolescent prodromal stage, are resistant to antipsychotic therapy, and are the leading cause of lifetime disability as measured by impaired global function (inability to live independently, unemployment, etc).
- NMDA receptor hypofunction is the leading hypothesis for the cause of schizophrenia. This hypothesis is supported by substantial clinical evidence including clinical pharmacology, electrophysiology, imaging, cognition, computational neuroscience, neuroanatomical studies, and genetics.
- the present disclosure provides herein a method of treating schizophrenia, including positive, negative, and cognitive symptoms, in a patient in need thereof, comprising administering an effective amount of a disclosed compound.
- a method of treating schizophrenia including positive, negative, and cognitive symptoms, in a patient in need thereof, comprising administering an effective amount of a disclosed compound.
- methods of ameliorating positive, negative, and cognitive symptoms of a patient not adequately treated by approved antipsychotic medications for example the treatment of cognitive impairments in schizophrenia, by administering an effective amount of a disclosed compound to such a patient.
- exemplary psychiatric disorders including major depressive disorder, and including but not limited to those suffering from bipolar disorder, obsessive-compulsive disorder, dysphobic disorder, dysthymic disorder, psychotic depression, post-traumatic stress disorder, and other anxiety disorders.
- a disclosed compound for example, provided herein are methods of treating attention deficit disorder, ADHD (attention deficit hyperactivity disorder), schizophrenia, anxiety, amelioration of opiate, nicotine and/or ethanol addiction (e.g., method of treating such addiction or ameliorating the side effects of withdrawing from such addiction), spinal cord injury, diabetic retinopathy, traumatic brain injury, and/or post-traumatic stress syndrome in a patient in need thereof, that includes administering a disclosed compound.
- ADHD attention deficit hyperactivity disorder
- schizophrenia anxiety, amelioration of opiate
- nicotine and/or ethanol addiction e.g., method of treating such addiction or ameliorating the side effects of withdrawing from such addiction
- spinal cord injury diabetic retinopathy
- traumatic brain injury traumatic brain injury
- post-traumatic stress syndrome e.g., post-traumatic stress syndrome
- provided herein is a method of treating and/or ameliorating cognitive and emotional deficits and other symptoms resulting from neurological diseases, including but not limited to a patient suffering from Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, and seizure disorders comprising administering to the patient an effective amount of a disclosed compound.
- the present disclosure contemplates a method of treating and/or ameliorating dysfunction caused by neurodevelopmental disorders, e.g., abnormal brain development, including but not limited to Rett Syndrome, Attention Deficit and Hyperactivity Disorder, autism and autism spectrum disorders such as Phelan-McDermid Syndrome, and other forms of intellectual disability such as Fragile X syndrome, tuberous sclerosis, Smith-Lemli-Opitz Syndrome, and Down's syndrome.
- a method is also provided to treat patients suffering from abnormal brain function resulting from infections of the central nervous system, exposure to toxic agents or other xenobiotics or naturally occurring toxins, and/or autoimmune disorders including, but not limited to anti-NMDA receptor encephalitis comprising administering an effective amount of a disclosed compound.
- the disclosure provides a method of treating, preventing, and/or preventing the development of the above medical indications comprising administering to a subject in need thereof a therapeutically effective amount of a compound described herein, such as a compound of Formula I.
- the compound utilized by one or more of the foregoing methods is one of the generic, subgeneric, or specific compounds described herein, such as a compound of Formula I.
- Disclosed compounds may be administered to patients in need of such treatment in dosages that will provide optimal pharmaceutical efficacy. It will be appreciated that the dose required for use in any particular application will vary from patient to patient, not only with the particular compound or composition selected, but also with the route of administration, the nature of the condition being treated, the age and condition of the patient, concurrent medication or special diets then being followed by the patient, and other factors which those skilled in the art will recognize, with the appropriate dosage ultimately being at the discretion of the attendant physician.
- a compound of this invention may be administered orally, subcutaneously, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. Parenteral administration may include subcutaneous injections, intravenous or intramuscular injections or infusion techniques.
- compositions may be administered on a regimen of, for example, one to four or more times per day.
- a suitable treatment period can be, for example, at least about one week, at least about two weeks, at least about one month, at least about six months, at least about 1 year, or indefinitely.
- a treatment regimen can include a corrective phase, during which dose sufficient to maintain cognitive and/or emotional function is administered, and can be followed by a maintenance phase, during which, e.g., a lower dose sufficient to prevent a deficit in cognitive and/or emotional function is administered.
- a suitable maintenance dose is likely to be found in the lower parts of the dose ranges provided herein, but corrective and maintenance doses can readily be established for individual subjects by those of skill in the art without undue experimentation, based on the disclosure herein.
- the compound of Formula I or a pharmaceutically acceptable salt thereof is optionally used in combination with another active agent.
- an active agent may be, for example, neurological diseases, including but not limited to a patient suffering from Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, and seizure disorders.
- another embodiment of the invention provides methods of treating neurological and psychiatric disorders associated with NR2D, comprising administering to a mammal an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof and further comprising administering another active agent.
- another active agent refers to any therapeutic agent, other than the compound of Formula I (or Formulae Ia-Io), or salt thereof, that is useful for the treatment of a subject disorder.
- additional therapeutic agents include antidepressants, antipsychotics, anti-pain, anti-Alzheimer's and anti-anxiety agents.
- Examples of particular classes of antidepressants that can be used in combination with the compounds of the invention include norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors (SSRIs), NK-1 receptor antagonists, monoamine oxidase inhibitors (MAOIs), reversible inhibitors of monoamine oxidase (RIMAs), serotonin and noradrenaline reuptake inhibitors (SNRIs), corticotropin releasing factor (CRF) antagonists, ⁇ -adrenoreceptor antagonists, and atypical antidepressants.
- Suitable norepinephrine reuptake inhibitors include tertiary amine tricyclics and secondary amine tricyclics.
- Suitable tertiary amine tricyclics and secondary amine tricyclics include amitriptyline, clomipramine, doxepin, imipramine, trimipramine, dothiepin, butriptyline, iprindole, lofepramine, nortriptyline, protriptyline, amoxapine, desipramine and maprotiline.
- suitable selective serotonin reuptake inhibitors include fluoxetine, fluvoxamine, paroxetine, and sertraline.
- monoamine oxidase inhibitors include isocarboxazid, phenelzine, and tranylcyclopramine.
- Suitable reversible inhibitors of monoamine oxidase include moclobemide.
- suitable serotonin and noradrenaline reuptake inhibitors of use in the present invention include venlafaxine.
- suitable atypical anti-depressants include bupropion, lithium, nefazodone, trazodone and viloxazine.
- anti-Alheimer's agents include Dimebon, NMDA receptor antagonists such as memantine; and cholinesterase inhibitors such as donepezil and galantamine.
- Suitable classes of anti-anxiety agents include benzodiazepines and serotonin 1A (5-HT1A) agonists or antagonists, 5-HT1A partial agonists, and corticotropin releasing factor (CRF) antagonists.
- Suitable benzodiazepines include alprazolam, chlordiazepoxide, clonazepam, chlorazepate, diazepam, halazepam, lorazepam, oxazepam, and prazepam.
- Suitable 5-HT1A receptor agonists or antagonists include buspirone, flesinoxan, gepirone and ipsapirone.
- Suitable atypical antipsychotics include paliperidone, bifeprunox, ziprasidone, risperidone, aripiprazole, olanzapine, and quetiapine.
- Suitable nicotine acetylcholine agonists include ispronicline, varenicline and MEM 3454.
- Anti-pain agents include pregabalin, gabapentin, clonidine, neostigmine, baclofen, midazolam, ketamine and ziconotide.
- compositions comprising compounds as disclosed herein formulated together with a pharmaceutically acceptable carrier.
- pharmaceutical compositions comprising compounds as disclosed herein formulated together with one or more pharmaceutically acceptable carriers.
- These formulations include those suitable for oral, rectal, topical, buccal, parenteral (e.g., subcutaneous, intramuscular, intradermal, or intravenous) rectal, vaginal, or aerosol administration, although the most suitable form of administration in any given case will depend on the degree and severity of the condition being treated and on the nature of the particular compound being used.
- disclosed compositions may be formulated as a unit dose, and/or may be formulated for oral or subcutaneous administration.
- compositions of this invention may be used in the form of a pharmaceutical preparation, for example, in solid, semisolid or liquid form, which contains one or more of the compound of the invention, as an active ingredient, in admixture with an organic or inorganic carrier or excipient suitable for external, enteral or parenteral applications.
- the active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use.
- the active object compound is included in the pharmaceutical composition in an amount sufficient to produce the desired effect upon the process or condition of the disease.
- the principal active ingredient may be mixed with a pharmaceutical carrier, e.g., conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g., water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the invention, or a non-toxic pharmaceutically acceptable salt thereof.
- a pharmaceutical carrier e.g., conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g., water
- a pharmaceutical carrier e.g., conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stea
- the subject composition is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, acetyl
- compositions may also comprise buffering agents.
- Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
- a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent.
- Molded tablets may be made by molding in a suitable machine a mixture of the subject composition moistened with an inert liquid diluent. Tablets, and other solid dosage forms, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art.
- compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, cyclodextrins and mixtures thereof.
- inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate
- Suspensions in addition to the subject composition, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- Formulations for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing a subject composition with one or more suitable non-irritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the body cavity and release the active agent.
- suitable non-irritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the body cavity and release the active agent.
- Dosage forms for transdermal administration of a subject composition include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
- the active component may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which may be required.
- the ointments, pastes, creams and gels may contain, in addition to a subject composition, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- Powders and sprays may contain, in addition to a subject composition, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
- Sprays may additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
- compositions and compounds of the present invention may alternatively be administered by aerosol. This is accomplished by preparing an aqueous aerosol, liposomal preparation or solid particles containing the compound.
- a non-aqueous (e.g., fluorocarbon propellant) suspension could be used.
- Sonic nebulizers may be used because they minimize exposing the agent to shear, which may result in degradation of the compounds contained in the subject compositions.
- an aqueous aerosol is made by formulating an aqueous solution or suspension of a subject composition together with conventional pharmaceutically acceptable carriers and stabilizers.
- the carriers and stabilizers vary with the requirements of the particular subject composition, but typically include non-ionic surfactants (Tweens, Pluronics, or polyethylene glycol), innocuous proteins like serum albumin, sorbitan esters, oleic acid, lecithin, amino acids such as glycine, buffers, salts, sugars or sugar alcohols. Aerosols generally are prepared from isotonic solutions.
- compositions of the present disclosure suitable for parenteral administration comprise a subject composition in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
- aqueous and non-aqueous carriers examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate and cyclodextrins.
- polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
- vegetable oils such as olive oil
- injectable organic esters such as ethyl oleate and cyclodextrins.
- Proper fluidity may be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants
- the invention provides enteral pharmaceutical formulations including a disclosed compound and an enteric material; and a pharmaceutically acceptable carrier or excipient thereof.
- Enteric materials refer to polymers that are substantially insoluble in the acidic environment of the stomach, and that are predominantly soluble in intestinal fluids at specific pHs.
- the small intestine is the part of the gastrointestinal tract (gut) between the stomach and the large intestine, and includes the duodenum, jejunum, and ileum.
- the pH of the duodenum is about 5.5
- the pH of the jejunum is about 6.5
- the pH of the distal ileum is about 7.5.
- enteric materials are not soluble, for example, until a pH of about 5.0, of about 5.2, of about 5.4, of about 5.6, of about 5.8, of about 6.0, of about 6.2, of about 6.4, of about 6.6, of about 6.8, of about 7.0, of about 7.2, of about 7.4, of about 7.6, of about 7.8, of about 8.0, of about 8.2, of about 8.4, of about 8.6, of about 8.8, of about 9.0, of about 9.2, of about 9.4, of about 9.6, of about 9.8, or of about 10.0.
- Exemplary enteric materials include cellulose acetate phthalate (CAP), hydroxypropyl methylcellulose phthalate (HPMCP), polyvinyl acetate phthalate (PVAP), hydroxypropyl methylcellulose acetate succinate (HPMCAS), cellulose acetate trimellitate, hydroxypropyl methylcellulose succinate, cellulose acetate succinate, cellulose acetate hexahydrophthalate, cellulose propionate phthalate, cellulose acetate maleate, cellulose acetate butyrate, cellulose acetate propionate, copolymer of methylmethacrylic acid and methyl methacrylate, copolymer of methyl acrylate, methylmethacrylate and methacrylic acid, copolymer of methylvinyl ether and maleic anhydride (Gantrez ES series), ethyl methylacrylate-methylmethacrylate-chlorotrimethylammonium ethyl acrylate copolymer, natural resins such
- compositions of the present disclosure may also be administered by the use of monoclonal antibodies as individual carriers to which the disclosed compounds are coupled.
- the disclosed compounds can also be coupled with soluble polymers as targetable drug carriers.
- Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspanamidephenol, or polyethyleneoxidepolylysine substituted with palmitoyl residues.
- Disclosed compounds can be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
- a drug for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
- Disclosed compounds are not covalently bound to a polymer, e.g., a polycarboxylic acid polymer, or a polyacrylate.
- kits for use by, e.g., a consumer in need of a disclosed NMDA modulator.
- kits include a suitable dosage form such as those described above and instructions describing the method of using such dosage form to mediate, reduce or prevent inflammation.
- the instructions would direct the consumer or medical personnel to administer the dosage form according to administration modes known to those skilled in the art.
- kits could advantageously be packaged and sold in single or multiple kit units.
- An example of such a kit is a so-called blister pack.
- Blister packs are well known in the packaging industry and are being widely used for the packaging of pharmaceutical unit dosage forms (tablets, capsules, and the like). Blister packs generally consist of a sheet of relatively stiff material covered with a foil of a preferably transparent plastic material.
- the packaging process recesses are formed in the plastic foil.
- the recesses have the size and shape of the tablets or capsules to be packed.
- the tablets or capsules are placed in the recesses and the sheet of relatively stiff material is sealed against the plastic foil at the face of the foil which is opposite from the direction in which the recesses were formed.
- the tablets or capsules are sealed in the recesses between the plastic foil and the sheet.
- the strength of the sheet is such that the tablets or capsules can be removed from the blister pack by manually applying pressure on the recesses whereby an opening is formed in the sheet at the place of the recess. The tablet or capsule can then be removed via said opening.
- a memory aid on the kit, e.g., in the form of numbers next to the tablets or capsules whereby the numbers correspond with the days of the regimen which the tablets or capsules so specified should be ingested.
- a memory aid is a calendar printed on the card, e.g., as follows “First Week, Monday, Tuesday, . . . etc. . . . Second Week, Monday, Tuesday, . . . ” etc.
- a “daily dose” can be a single tablet or capsule or several pills or capsules to be taken on a given day.
- a daily dose of a first compound can consist of one tablet or capsule while a daily dose of the second compound can consist of several tablets or capsules and vice versa.
- the memory aid should reflect this.
- the compounds described herein can be prepared in a number of ways based on the teachings contained herein and synthetic procedures known in the art.
- synthetic procedures known in the art.
- all proposed reaction conditions including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and workup procedures, can be chosen to be the conditions standard for that reaction, unless otherwise indicated.
- the functionality present on various portions of the molecule should be compatible with the reagents and reactions proposed.
- Substituents not compatible with the reaction conditions will be apparent to one skilled in the art, and alternate methods are therefore indicated.
- the starting materials for the examples are either commercially available or are readily prepared by standard methods from known materials.
- Analytical HPLC/MS instrumentation Analysis are performed using a Waters 2545 Binary Gradient Module (Waters Corporation, Milford, Mass.), a Waters SFO System Fluidics Organizer, a Waters 2996 Diode Array Detector and a Waters 2767 auto-sampler, 3100 mass detector. Data are acquired using MassLynxTM 4.0 software, with OpenLynxTM and AutoLynxTM processing.
- Analytical HPLC conditions 4.6 ⁇ 50 mm column; UV 10 spectra/sec, 220-340 nm summed; flow rate 2.0 mL/min; injection volume 5 ⁇ L; Gradient condition: mobile phase A is Water with 0.1% formic acid; mobile phase B is acetonitrile with 0.1% formic acid, and the gradient is 1.50 minutes 99.0% A to 95.0% B; 0.5 minutes hold; then recycle to 99.0% A over 0.5 minutes.
- a solution of sodium ethoxide in ethanol [14.5 mL of the solution obtained by dissolving sodium (1.38 g, 60.03 mmol) in dry ethanol (24 mL)] was added carefully to a stirred mixture of pivalamidine hydrochloride (5.19 g, 38.01 mmol) and dry ethanol (5 mL) at 40° C.
- a solution of mucobromic acid [5.4 mL of the solution obtained by dissolving mucobromic acid (1, 5.16 g, 20.01 mmol) in ethanol (8 mL)] was added to the mixture drop wise resulting in an exothermic reaction during which the temperature raise to 65° C.
- reaction mixture was cooled to room temperature, diluted with water (20 mL) and extracted with ethyl acetate (2 ⁇ 50 mL). The combined organic layer was washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated.
- the crude product was purified by preparative HPLC (column: Inertsil ODS 3V (250 mm ⁇ 4.6 mm ⁇ 5 mic), mobile phase (A): 0.1% ammonia in water, mobile phase (B): acetonitrile, flow rate: 1.0 mL/min, T/%/B: 0/20, 10/80, 25/90, 27/20, 30/20) to afford the title compound 2-(4-(tert-butyl)phenyl)-3-vinyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (5 (example 14), 0.03 g, 23.6% yield) as an off white solid.
- reaction mixture was purged with argon for 10 min and then 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (0.084 g, 0.67 mmol) was added.
- the reaction mixture was stirred at 105° C. for 16 h.
- the reaction mixture was quenched with water (50 mL) and extracted with ethyl acetate (2 ⁇ 40 mL). The combined organic layer was dried over anhydrous sodium sulfate, filtered and concentrated.
- the chiral resolution was performed using the analytical condition: Column: CHIRALPAK IA (250 mm ⁇ 4.6 mm ⁇ 5 mic), mobile phase A: n-hexane, mobile phase B: 0.1% diethyl amine in isopropyl alcohol, composition: 70:30, flow rate: 1.0 mL/min.
- the analytical data for the enantiomers are given below.
- reaction mixture was concentrated, the residue was diluted with saturated sodium bicarbonate solution (20 mL) and extracted with ethyl acetate (2 ⁇ 30 mL). The combined organic layer was washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated.
- 2-isopropylpropane-1,3-diol (3, 0.6 g, 5.07 mmol) was placed in a 10 mL 2 necked round bottomed flask fitted with a reflux condenser holding a calcium chloride guard tube.
- the diol was warmed to 70° C. and phosphorus tribromide (0.35 mL, 3.75 mmol) was added, with stirring, at such a rate as to maintain the temperature at 65-75° C. Stirring and heating at 70° C. were continued for 12 h.
- the reaction mixture was cooled to room temperature, poured into ice-water (20 mL) and extracted with ether (2 ⁇ 50 mL).
- reaction mixture was cooled to room temperature diluted with water (30 mL) and extracted with ethyl acetate (2 ⁇ 25 mL). The combined organic layer was washed with brine (30 mL), dried over anhydrous sodium sulphate, filtered and concentrated.
- the chiral resolution was performed using the analytical condition: column: CHIRALPAK IA (250 mm ⁇ 4.6 mm ⁇ 5 mic), mobile phase A: n-hexane, mobile phase B: 0.1% diethyl amine in isopropyl alcohol (50:50), flow rate: 1.0 mL/min.
- mobile phase A n-hexane
- mobile phase B 0.1% diethyl amine in isopropyl alcohol (50:50)
- flow rate 1.0 mL/min.
- the chiral resolution was performed using the analytical condition: column: CHIRALPAK IA (250 mm ⁇ 4.6 mm ⁇ 5 mic), mobile phase A: methyl tert-butyl ether, mobile phase B: 0.1% diethyl amine in isopropyl alcohol (70:30), flow rate: 1.0 mL/min.
- mobile phase A methyl tert-butyl ether
- mobile phase B 0.1% diethyl amine in isopropyl alcohol (70:30)
- flow rate 1.0 mL/min.
- the chiral resolution was performed using the analytical condition: column: CHIRALPAK IA (250 mm ⁇ 4.6 mm ⁇ 5 mic), mobile phase A: methyl tertiary butyl ether, mobile phase B: 0.1% diethyl amine in isopropyl alcohol, composition: 70:30, flow rate: 1.0 mL/min.
- mobile phase A methyl tertiary butyl ether
- mobile phase B 0.1% diethyl amine in isopropyl alcohol
- composition 70:30
- flow rate 1.0 mL/min.
- the chiral resolution was performed using the analytical condition: column: CHIRALPAK IA (250 mm ⁇ 4.6 mm ⁇ 5 mic), mobile phase A: hexane, mobile phase B: 0.1% diethyl amine in ethanol, composition: 50:50, flow rate: 1.0 mL/min.
- mobile phase A hexane
- mobile phase B 0.1% diethyl amine in ethanol
- composition 50:50
- flow rate 1.0 mL/min.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/471,880 US11274107B2 (en) | 2016-12-22 | 2017-12-22 | NMDA receptor modulators and uses thereof |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662438086P | 2016-12-22 | 2016-12-22 | |
US201662438080P | 2016-12-22 | 2016-12-22 | |
US201662438070P | 2016-12-22 | 2016-12-22 | |
US16/471,880 US11274107B2 (en) | 2016-12-22 | 2017-12-22 | NMDA receptor modulators and uses thereof |
PCT/US2017/068135 WO2018119374A1 (en) | 2016-12-22 | 2017-12-22 | Nmda receptor modulators and uses thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/068135 A-371-Of-International WO2018119374A1 (en) | 2016-12-22 | 2017-12-22 | Nmda receptor modulators and uses thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/585,849 Division US11807650B2 (en) | 2016-12-22 | 2022-01-27 | NMDA receptor modulators and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
US20200087323A1 US20200087323A1 (en) | 2020-03-19 |
US11274107B2 true US11274107B2 (en) | 2022-03-15 |
Family
ID=62627975
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/471,880 Active US11274107B2 (en) | 2016-12-22 | 2017-12-22 | NMDA receptor modulators and uses thereof |
US17/585,849 Active 2038-01-01 US11807650B2 (en) | 2016-12-22 | 2022-01-27 | NMDA receptor modulators and uses thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/585,849 Active 2038-01-01 US11807650B2 (en) | 2016-12-22 | 2022-01-27 | NMDA receptor modulators and uses thereof |
Country Status (7)
Country | Link |
---|---|
US (2) | US11274107B2 (ja) |
EP (1) | EP3558318B1 (ja) |
JP (1) | JP7332472B2 (ja) |
AU (1) | AU2017382339B2 (ja) |
CA (1) | CA3047403A1 (ja) |
ES (1) | ES2975336T3 (ja) |
WO (1) | WO2018119374A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11807650B2 (en) | 2016-12-22 | 2023-11-07 | Novartis Ag | NMDA receptor modulators and uses thereof |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3386591T (pt) | 2015-12-09 | 2020-10-01 | Cadent Therapeutics Inc | Moduladores de recetores nmda heteroaromáticos e suas utilizações |
EP4006038A1 (en) | 2015-12-09 | 2022-06-01 | Cadent Therapeutics, Inc. | Thienopyrimidinone nmda receptor modulators and uses thereof |
EA202190431A1 (ru) | 2018-08-03 | 2021-06-11 | Кэйдент Терапьютикс, Инк. | Гетероароматические модуляторы nmda рецептора и их применение |
US11358971B2 (en) * | 2019-07-03 | 2022-06-14 | H. Lundbeck A/S | Prodrugs of modulators of the NMDA receptor |
CN116940545A (zh) * | 2021-03-05 | 2023-10-24 | Agc株式会社 | 含氟化合物的制造方法和含氟化合物 |
WO2024119067A1 (en) | 2022-12-02 | 2024-06-06 | Neumora Therapeutics, Inc. | Methods of treating neurological disorders |
Citations (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1588166A (en) | 1976-07-22 | 1981-04-15 | Yamanouchi Pharma Co Ltd | Nitrogen-containing heterocyclic compounds |
JPS6051190A (ja) | 1983-07-25 | 1985-03-22 | サノフイ | トリアゾロ−ピリミジン誘導体、その製法ならびにそれを含有する強心剤 |
US4921854A (en) | 1986-12-30 | 1990-05-01 | Egis Gyogyszergyar | Condensed thiazolopyrimidine, pyrimido-thiazine or thiazepine pyrimidine compounds |
US5298502A (en) | 1988-12-12 | 1994-03-29 | Fmc Corporation | Method and composition for photodynamic treatment and detection of tumors |
WO1994027975A1 (de) | 1993-05-21 | 1994-12-08 | Pentapharm Ag | 3-(mercaptoalkyl)- bzw. 3-(alkylthioalkyl)-pyrimidin-2,4 (1h, 3h)-dione |
WO1998000401A1 (en) | 1996-06-28 | 1998-01-08 | Merck & Co., Inc. | Fibrinogen receptor antagonist prodrugs |
WO2002000629A1 (en) | 2000-06-26 | 2002-01-03 | Merck & Co., Inc. | Iminopyrimidine nmda nr2b receptor antagonists |
US20030114447A1 (en) | 2001-09-18 | 2003-06-19 | Ingrid Choong | Small molecule inhibitors of caspases |
US6852731B2 (en) | 2002-01-14 | 2005-02-08 | Pfizer | Antiviral compounds |
US20060014945A1 (en) | 2004-07-13 | 2006-01-19 | Guido Galley | Sulfonamides |
WO2006095014A1 (en) | 2005-03-11 | 2006-09-14 | N.V. Organon | 2- (4-0x0-4h-quinaz0lin-3-yl) acetamides and their use as vasopressin v3 antagonists |
US20070093509A1 (en) | 2005-10-26 | 2007-04-26 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists |
US20080064678A1 (en) | 2006-09-11 | 2008-03-13 | N.V. Organon | 2-(1-oxo-1h-isoquinolin-2-yl)acetamide derivatives |
WO2008033764A2 (en) | 2006-09-11 | 2008-03-20 | N.V. Organon | Quinazolinone and isoquinolinone acetamide derivatives |
WO2008076883A2 (en) | 2006-12-15 | 2008-06-26 | Abraxis Bioscience, Inc. | Triazine derivatives and their therapeutical applications |
WO2008078196A2 (en) | 2006-12-20 | 2008-07-03 | Sanofi-Aventis | Substituted heteroaryl pyridopyrimidone derivatives |
WO2008097538A1 (en) | 2007-02-08 | 2008-08-14 | Merck & Co., Inc. | Therapeutic agents |
WO2008128982A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thioxoquinazolinone derivatives as glutaminyl cyclase inhibitors |
US20080280900A1 (en) | 2007-05-09 | 2008-11-13 | Hassan Pajouhesh | Bicyclic pyrimidine derivatives as calcium channel blockers |
WO2009025784A1 (en) | 2007-08-21 | 2009-02-26 | Merck & Co., Inc. | Heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
WO2009062930A1 (en) | 2007-11-13 | 2009-05-22 | N.V. Organon | Heterocyclic derivatives |
WO2009134973A1 (en) | 2008-05-01 | 2009-11-05 | Sirtris Pharmaceuticals, Inc. | Quenolines and related analogs as sirtuin modulators |
WO2009146358A1 (en) | 2008-05-29 | 2009-12-03 | Sirtris Pharmaceuticals, Inc. | Imidazopyridine and related analogs as sirtuin modulators |
WO2009156864A2 (en) | 2008-06-26 | 2009-12-30 | Mitsubishi Tanabe Pharma Corporation | Substituted alkyl pyrimidin-4-one derivatives |
WO2010003048A1 (en) | 2008-07-03 | 2010-01-07 | Sirtris Pharmaceuticals, Inc. | Benzimidazoles and related analogs as sirtuin modulators |
WO2010006496A1 (zh) | 2008-07-18 | 2010-01-21 | 中国科学院广州生物医药与健康研究院 | 用作雌激素相关受体调节剂的化合物及其应用 |
WO2010037127A1 (en) | 2008-09-29 | 2010-04-01 | Sirtris Pharmaceuticals, Inc. | Chromenone analogs as sirtuin modulators |
WO2010079443A1 (en) | 2009-01-12 | 2010-07-15 | Pfizer Limited | Sulfonamide derivatives |
WO2010111573A1 (en) | 2009-03-27 | 2010-09-30 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
WO2010139483A1 (en) | 2009-06-04 | 2010-12-09 | Merz Pharma Gmbh & Co. Kgaa | Glycine b antagonists |
WO2011045258A1 (en) | 2009-10-13 | 2011-04-21 | N.V. Organon | Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor |
WO2011117381A1 (en) | 2010-03-26 | 2011-09-29 | Boehringer Ingelheim International Gmbh | B-raf kinase inhibitors |
WO2011117382A1 (en) | 2010-03-26 | 2011-09-29 | Boehringer Ingelheim International Gmbh | Pyridyltriazoles |
WO2012009688A1 (en) | 2010-07-16 | 2012-01-19 | Rockefeller University | Organic compounds |
CN102336768A (zh) | 2011-10-24 | 2012-02-01 | 中国科学院上海有机化学研究所 | N’-芳亚甲基-2-(4-氧代噻吩[2,3-d]嘧啶-3-基)乙酰腙类化合物、制备方法和用途 |
WO2012052540A1 (en) | 2010-10-21 | 2012-04-26 | Universitaet Des Saarlandes | Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases |
US20120165330A1 (en) | 2010-12-22 | 2012-06-28 | Sirtris Pharmaceuticals, Inc. | Quinazolinone and related analogs as sirtuin modulators |
US20120178742A1 (en) | 2009-08-05 | 2012-07-12 | Merz Pharma Gmbh & Co. Kgaa | Metabotropic glutamate receptor modulators |
WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
WO2012154760A1 (en) | 2011-05-10 | 2012-11-15 | Gilead Sciences, Inc. | Fused heterocyclic compounds as sodium channel modulators |
WO2013048942A1 (en) | 2011-09-30 | 2013-04-04 | Bristol-Myers Squibb Company | Quinolinone carboxamide inhibitors of endothelial lipase |
WO2013049104A1 (en) | 2011-09-30 | 2013-04-04 | Bristol-Myers Squibb Company | Pyridinedione carboxamide inhibitors of endothelial lipase |
WO2013048928A1 (en) | 2011-09-27 | 2013-04-04 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
US20130123231A1 (en) | 2011-11-11 | 2013-05-16 | Nimbus Apollo, Inc. | Acc inhibitors and uses thereof |
WO2013119916A2 (en) | 2012-02-10 | 2013-08-15 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
WO2014066743A1 (en) | 2012-10-25 | 2014-05-01 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
WO2014139325A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
WO2014179144A1 (en) | 2013-04-29 | 2014-11-06 | E. I. Du Pont De Nemours And Company | Fungicidal heterocyclic compounds |
WO2014206343A1 (en) | 2013-06-28 | 2014-12-31 | Beigene, Ltd. | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors |
WO2015007453A1 (en) | 2013-07-15 | 2015-01-22 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives |
WO2015052226A1 (en) | 2013-10-11 | 2015-04-16 | F. Hoffmann-La Roche Ag | Thiazolopyrimidinones as modulators of nmda receptor activity |
WO2015064714A1 (ja) | 2013-10-31 | 2015-05-07 | 国立大学法人東京大学 | オートタキシン阻害活性を有する1-置換イミダゾピリミジノン誘導体 |
WO2015096611A1 (zh) | 2013-12-25 | 2015-07-02 | 重庆医药工业研究院有限责任公司 | 一种喹啉衍生物、其制备方法和应用 |
WO2016034703A1 (en) | 2014-09-05 | 2016-03-10 | AbbVie Deutschland GmbH & Co. KG | Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases |
WO2016081649A1 (en) | 2014-11-18 | 2016-05-26 | Emory University | Thieno[2,3-d]pyrimidin-4-one derivatives as nmdar modulators and uses related thereto |
WO2017066590A1 (en) | 2015-10-16 | 2017-04-20 | Northwestern University | Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder |
WO2017100599A1 (en) | 2015-12-09 | 2017-06-15 | Luc Therapeutics | Thienopyrimidinone nmda receptor modulators and uses thereof |
WO2017100591A1 (en) | 2015-12-09 | 2017-06-15 | Luc Therapeutics | Heteroaromatic nmda receptor modulators and uses thereof |
US20170305861A1 (en) | 2016-04-25 | 2017-10-26 | Immunomet Therapeutics, Inc | Heteroaryl compounds comprising nitrogen and use thereof |
WO2018026371A1 (en) | 2016-08-04 | 2018-02-08 | Sunovion Pharmaceuticals Inc. | Dual nav1.2/5ht2a inhibitors for treating cns disorders |
US9963434B2 (en) | 2013-09-26 | 2018-05-08 | Luc Therapeutics, Inc. | N-arylmethyl sulfonamide negative modulators of NR2A |
WO2018119374A1 (en) | 2016-12-22 | 2018-06-28 | Cadent Therapeutics | Nmda receptor modulators and uses thereof |
US10584131B2 (en) | 2018-08-03 | 2020-03-10 | Cadent Therapeutics, Inc. | Heteroaromatic NMDA receptor modulators and uses thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6339093B1 (en) | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
HU227197B1 (en) | 2000-10-24 | 2010-10-28 | Richter Gedeon Nyrt | Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them |
US7005432B2 (en) | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
CR20170462A (es) | 2015-04-15 | 2018-02-01 | Hoffmann La Roche | Piridopirimidinonas y utilización de las mismas como moduladores de receptores nmda |
GEP20227429B (en) | 2017-09-27 | 2022-10-25 | Incyte Corp | Salts of pyrrolotriazine derivatives useful as tam inhibitors |
US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
-
2017
- 2017-12-22 AU AU2017382339A patent/AU2017382339B2/en active Active
- 2017-12-22 JP JP2019534312A patent/JP7332472B2/ja active Active
- 2017-12-22 ES ES17882643T patent/ES2975336T3/es active Active
- 2017-12-22 EP EP17882643.4A patent/EP3558318B1/en active Active
- 2017-12-22 WO PCT/US2017/068135 patent/WO2018119374A1/en unknown
- 2017-12-22 US US16/471,880 patent/US11274107B2/en active Active
- 2017-12-22 CA CA3047403A patent/CA3047403A1/en active Pending
-
2022
- 2022-01-27 US US17/585,849 patent/US11807650B2/en active Active
Patent Citations (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1588166A (en) | 1976-07-22 | 1981-04-15 | Yamanouchi Pharma Co Ltd | Nitrogen-containing heterocyclic compounds |
JPS6051190A (ja) | 1983-07-25 | 1985-03-22 | サノフイ | トリアゾロ−ピリミジン誘導体、その製法ならびにそれを含有する強心剤 |
US4581358A (en) | 1983-07-25 | 1986-04-08 | Sanofi, S.A. | Triazolo-pyrimidine derivatives, a process for preparing them and their therapeutic use as cardiotonics |
US4921854A (en) | 1986-12-30 | 1990-05-01 | Egis Gyogyszergyar | Condensed thiazolopyrimidine, pyrimido-thiazine or thiazepine pyrimidine compounds |
US5298502A (en) | 1988-12-12 | 1994-03-29 | Fmc Corporation | Method and composition for photodynamic treatment and detection of tumors |
WO1994027975A1 (de) | 1993-05-21 | 1994-12-08 | Pentapharm Ag | 3-(mercaptoalkyl)- bzw. 3-(alkylthioalkyl)-pyrimidin-2,4 (1h, 3h)-dione |
WO1998000401A1 (en) | 1996-06-28 | 1998-01-08 | Merck & Co., Inc. | Fibrinogen receptor antagonist prodrugs |
WO2002000629A1 (en) | 2000-06-26 | 2002-01-03 | Merck & Co., Inc. | Iminopyrimidine nmda nr2b receptor antagonists |
US20020013329A1 (en) | 2000-06-26 | 2002-01-31 | Claremon David A. | Iminopyrimidine NMDA NR2B receptor antagonists |
JP2004501901A (ja) | 2000-06-26 | 2004-01-22 | メルク エンド カムパニー インコーポレーテッド | イミノピリミジン系nmdanr2b受容体拮抗薬 |
US20030114447A1 (en) | 2001-09-18 | 2003-06-19 | Ingrid Choong | Small molecule inhibitors of caspases |
US6852731B2 (en) | 2002-01-14 | 2005-02-08 | Pfizer | Antiviral compounds |
US20060014945A1 (en) | 2004-07-13 | 2006-01-19 | Guido Galley | Sulfonamides |
US20080214553A1 (en) | 2005-03-11 | 2008-09-04 | Jeffrey Letourneau | 2-(4-Oxo-4H-Quinazolin-3-Yl) Acetamides and Their Use as Vasopressin V3 Antagonists |
WO2006095014A1 (en) | 2005-03-11 | 2006-09-14 | N.V. Organon | 2- (4-0x0-4h-quinaz0lin-3-yl) acetamides and their use as vasopressin v3 antagonists |
US20070093509A1 (en) | 2005-10-26 | 2007-04-26 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists |
US20080064678A1 (en) | 2006-09-11 | 2008-03-13 | N.V. Organon | 2-(1-oxo-1h-isoquinolin-2-yl)acetamide derivatives |
WO2008033764A2 (en) | 2006-09-11 | 2008-03-20 | N.V. Organon | Quinazolinone and isoquinolinone acetamide derivatives |
WO2008033757A2 (en) | 2006-09-11 | 2008-03-20 | N.V. Organon | 2-(1-oxo-1h-isoquinolin-2-yl) acetamide derivatives |
US20080090802A1 (en) | 2006-09-11 | 2008-04-17 | N.V. Organon | Quinazolinone and isoquinolinone acetamide derivatives |
WO2008076883A2 (en) | 2006-12-15 | 2008-06-26 | Abraxis Bioscience, Inc. | Triazine derivatives and their therapeutical applications |
JP2010513463A (ja) | 2006-12-20 | 2010-04-30 | サノフイ−アベンテイス | 置換ヘテロアリールピリドピリミドン誘導体 |
WO2008078196A2 (en) | 2006-12-20 | 2008-07-03 | Sanofi-Aventis | Substituted heteroaryl pyridopyrimidone derivatives |
WO2008097538A1 (en) | 2007-02-08 | 2008-08-14 | Merck & Co., Inc. | Therapeutic agents |
WO2008128982A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thioxoquinazolinone derivatives as glutaminyl cyclase inhibitors |
WO2008138126A1 (en) | 2007-05-09 | 2008-11-20 | Neuromed Pharmaceuticals Ltd. | Bicyclic pyrimidine derivatives as calcium channel blockers |
US20080280900A1 (en) | 2007-05-09 | 2008-11-13 | Hassan Pajouhesh | Bicyclic pyrimidine derivatives as calcium channel blockers |
WO2009025784A1 (en) | 2007-08-21 | 2009-02-26 | Merck & Co., Inc. | Heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
WO2009062930A1 (en) | 2007-11-13 | 2009-05-22 | N.V. Organon | Heterocyclic derivatives |
WO2009134973A1 (en) | 2008-05-01 | 2009-11-05 | Sirtris Pharmaceuticals, Inc. | Quenolines and related analogs as sirtuin modulators |
WO2009146358A1 (en) | 2008-05-29 | 2009-12-03 | Sirtris Pharmaceuticals, Inc. | Imidazopyridine and related analogs as sirtuin modulators |
WO2009156864A2 (en) | 2008-06-26 | 2009-12-30 | Mitsubishi Tanabe Pharma Corporation | Substituted alkyl pyrimidin-4-one derivatives |
JP2011525908A (ja) | 2008-06-26 | 2011-09-29 | 田辺三菱製薬株式会社 | 置換アルキルピリミジン−4−オン誘導体 |
WO2010003048A1 (en) | 2008-07-03 | 2010-01-07 | Sirtris Pharmaceuticals, Inc. | Benzimidazoles and related analogs as sirtuin modulators |
JP2011528322A (ja) | 2008-07-18 | 2011-11-17 | 中国科学院広州生物医薬及健康研究院 | エストロゲン関連受容体モジュレーターとしての化合物、及びその使用 |
WO2010006496A1 (zh) | 2008-07-18 | 2010-01-21 | 中国科学院广州生物医药与健康研究院 | 用作雌激素相关受体调节剂的化合物及其应用 |
WO2010037129A1 (en) | 2008-09-29 | 2010-04-01 | Sirtris Pharmaceuticals Inc. | Quinazolinone, quinolone and related analogs as sirtuin modulators |
WO2010037127A1 (en) | 2008-09-29 | 2010-04-01 | Sirtris Pharmaceuticals, Inc. | Chromenone analogs as sirtuin modulators |
WO2010079443A1 (en) | 2009-01-12 | 2010-07-15 | Pfizer Limited | Sulfonamide derivatives |
WO2010111573A1 (en) | 2009-03-27 | 2010-09-30 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
US20100249087A1 (en) | 2009-03-27 | 2010-09-30 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
WO2010139483A1 (en) | 2009-06-04 | 2010-12-09 | Merz Pharma Gmbh & Co. Kgaa | Glycine b antagonists |
US20120178742A1 (en) | 2009-08-05 | 2012-07-12 | Merz Pharma Gmbh & Co. Kgaa | Metabotropic glutamate receptor modulators |
WO2011045258A1 (en) | 2009-10-13 | 2011-04-21 | N.V. Organon | Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor |
WO2011117381A1 (en) | 2010-03-26 | 2011-09-29 | Boehringer Ingelheim International Gmbh | B-raf kinase inhibitors |
WO2011117382A1 (en) | 2010-03-26 | 2011-09-29 | Boehringer Ingelheim International Gmbh | Pyridyltriazoles |
WO2012009688A1 (en) | 2010-07-16 | 2012-01-19 | Rockefeller University | Organic compounds |
WO2012052540A1 (en) | 2010-10-21 | 2012-04-26 | Universitaet Des Saarlandes | Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases |
US20120165330A1 (en) | 2010-12-22 | 2012-06-28 | Sirtris Pharmaceuticals, Inc. | Quinazolinone and related analogs as sirtuin modulators |
WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
WO2012154760A1 (en) | 2011-05-10 | 2012-11-15 | Gilead Sciences, Inc. | Fused heterocyclic compounds as sodium channel modulators |
WO2013048928A1 (en) | 2011-09-27 | 2013-04-04 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
WO2013048942A1 (en) | 2011-09-30 | 2013-04-04 | Bristol-Myers Squibb Company | Quinolinone carboxamide inhibitors of endothelial lipase |
WO2013049104A1 (en) | 2011-09-30 | 2013-04-04 | Bristol-Myers Squibb Company | Pyridinedione carboxamide inhibitors of endothelial lipase |
CN102336768A (zh) | 2011-10-24 | 2012-02-01 | 中国科学院上海有机化学研究所 | N’-芳亚甲基-2-(4-氧代噻吩[2,3-d]嘧啶-3-基)乙酰腙类化合物、制备方法和用途 |
US20130123231A1 (en) | 2011-11-11 | 2013-05-16 | Nimbus Apollo, Inc. | Acc inhibitors and uses thereof |
WO2013119916A2 (en) | 2012-02-10 | 2013-08-15 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
JP2015508075A (ja) | 2012-02-10 | 2015-03-16 | ピーティーシー セラピューティクス, インコーポレイテッド | 脊髄性筋萎縮症を治療するための化合物 |
WO2014066743A1 (en) | 2012-10-25 | 2014-05-01 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
WO2014139325A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
WO2014179144A1 (en) | 2013-04-29 | 2014-11-06 | E. I. Du Pont De Nemours And Company | Fungicidal heterocyclic compounds |
WO2014206343A1 (en) | 2013-06-28 | 2014-12-31 | Beigene, Ltd. | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors |
WO2015007453A1 (en) | 2013-07-15 | 2015-01-22 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives |
US9963434B2 (en) | 2013-09-26 | 2018-05-08 | Luc Therapeutics, Inc. | N-arylmethyl sulfonamide negative modulators of NR2A |
WO2015052226A1 (en) | 2013-10-11 | 2015-04-16 | F. Hoffmann-La Roche Ag | Thiazolopyrimidinones as modulators of nmda receptor activity |
US20160222033A1 (en) | 2013-10-11 | 2016-08-04 | Genentech, Inc. | Thiazolopyrimidinones and methods of use thereof |
JP2016532669A (ja) | 2013-10-11 | 2016-10-20 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Nmda受容体活性の調節因子としてのチアゾロピリミジノン |
WO2015064714A1 (ja) | 2013-10-31 | 2015-05-07 | 国立大学法人東京大学 | オートタキシン阻害活性を有する1-置換イミダゾピリミジノン誘導体 |
WO2015096611A1 (zh) | 2013-12-25 | 2015-07-02 | 重庆医药工业研究院有限责任公司 | 一种喹啉衍生物、其制备方法和应用 |
WO2016034703A1 (en) | 2014-09-05 | 2016-03-10 | AbbVie Deutschland GmbH & Co. KG | Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases |
US20170313719A1 (en) | 2014-11-18 | 2017-11-02 | Emory University | Thieno[2,3-D]pyrimidin-4-one Derivatives as NMDAR Modulators and Uses Related Thereto |
WO2016081649A1 (en) | 2014-11-18 | 2016-05-26 | Emory University | Thieno[2,3-d]pyrimidin-4-one derivatives as nmdar modulators and uses related thereto |
WO2017066590A1 (en) | 2015-10-16 | 2017-04-20 | Northwestern University | Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder |
US20180362541A1 (en) | 2015-12-09 | 2018-12-20 | Cadent Therapeutics Inc | Heteroaromatic nmda receptor modulators and uses thereof |
WO2017100591A1 (en) | 2015-12-09 | 2017-06-15 | Luc Therapeutics | Heteroaromatic nmda receptor modulators and uses thereof |
WO2017100593A1 (en) | 2015-12-09 | 2017-06-15 | Luc Therapeutics | Thienopyrimidinone nmda receptor modulators and uses thereof |
US20180360837A1 (en) | 2015-12-09 | 2018-12-20 | Cadent Therapeutics, Inc. | Thienopyrimidinone nmda receptor moduclators and uses thereof |
WO2017100599A1 (en) | 2015-12-09 | 2017-06-15 | Luc Therapeutics | Thienopyrimidinone nmda receptor modulators and uses thereof |
US20180369245A1 (en) | 2015-12-09 | 2018-12-27 | Cadent Therapeutics, Inc. | Thienopyrimidinone nmda receptor modulators and uses thereof |
US20210107916A1 (en) | 2015-12-09 | 2021-04-15 | Cadent Therapeutics, Inc. | Heteroaromatic nmda receptor modulators and uses thereof |
US20170305861A1 (en) | 2016-04-25 | 2017-10-26 | Immunomet Therapeutics, Inc | Heteroaryl compounds comprising nitrogen and use thereof |
WO2017188694A1 (ko) | 2016-04-25 | 2017-11-02 | 이뮤노메트테라퓨틱스 인코포레이티드 | 질소를 포함하는 헤테로아릴 화합물 및 이의 용도 |
WO2018026371A1 (en) | 2016-08-04 | 2018-02-08 | Sunovion Pharmaceuticals Inc. | Dual nav1.2/5ht2a inhibitors for treating cns disorders |
WO2018119374A1 (en) | 2016-12-22 | 2018-06-28 | Cadent Therapeutics | Nmda receptor modulators and uses thereof |
US10584131B2 (en) | 2018-08-03 | 2020-03-10 | Cadent Therapeutics, Inc. | Heteroaromatic NMDA receptor modulators and uses thereof |
US10752633B2 (en) | 2018-08-03 | 2020-08-25 | Cadent Therapeutics, Inc. | Heteroaromatic NMDA receptor modulators and uses thereof |
Non-Patent Citations (52)
Title |
---|
"Co-pending U.S. Appl. No. 16/530,274, filed Aug. 2, 2019." |
Almasi et al., Characterization of potential NMDA and cholecystokinin antagonists. II. Lipophilicity studies on 2-methyl-4-oxo-3H-quinazoline-3-alkyl-carboxylic acid derivatives. International Journal of Pharmaceuticals. Mar. 1, 1999;180(1):13-22. |
Beutler et al., Diastereoselective Dimerisation of Alkenylthiazolines: A Combined Synthetic and Computational Study. European Journal of Organic Chemistry. 2005;2005(17):3791-3800. |
Bonacorso et al., Beta-Alkoxyvinyl trichloromethyl ketones as N-heterocyclic acylating agent. A new access to 5H-thiazolo[3-2-alpha]pyrimidin-5-ones. Tetrahedron Letters. 2002;43:9315-9318. |
Broddefalk et al., Use of acid-labile protective groups for carbohydrate moieties in synthesis of glycopeptides Yelated to type II collagen. Tetrahedron. Sep. 24, 1998;54(39): 12047-12070. |
Ciapetti et al., Molecular Variations Based on Isosteric Replacements. The Practice of Medicinal Chemistry, Third Edition. Camille Georges Wermuth (Ed.), Academic Press, Amsterdam. Chapter 15, pp. 290-342, (2008). |
Copending U.S. Appl. No. 14/150,222, filed Jan. 15, 2021. |
Copending U.S. Appl. No. 16/779,517, filed Jan. 31, 2020. |
Copending U.S. Appl. No. 16/893,659, filed Jun. 5, 2020. |
Copending U.S. Appl. No. 16/919,136, filed Jul. 2, 2020. |
Copending U.S. Appl. No. 16/929,602, filed Apr. 15, 2020. |
Copending U.S. Appl. No. 17/174,826, filed Feb. 12, 2021. |
Copending U.S. Appl. No. 17/186,137, filed Feb. 26, 2021. |
Ding et al., Parallel synthesis of 5-cyano-6-aryl-2-thiouracil derivatives as inhibitors for hepatitis C viral NS5B RNA-dependent RNA polymerase. Bioorg Chem. 2006;34(1):26-38. |
Dotsenko et al., The Mannich reaction in the synthesis of N,S-containing heterocycles 5. Synthesis and structures of new pyrimido[2,1-b][1,3,5]thiadiazine derivatives. Russian Chemical Bulletin, International Edition. Jul. 2007;56(7):1437-1440. |
El-Sherief et al., Intramolecular Cyclization of Mannich Reaction for Synthesis of Pyrimido[2,1-b]-1,3,5-tiadiazines. J Heterocyclic Chem. 2010;47:1294-1302. |
Hamouda, Snythesis of novel pyrimidines thiazolopyrimidines, triazolopyrimidines and pyrimidotriazines as potent antimicrobial agent. Der Pharma Chemica. 2014;6(6):346-357. |
Haneheld et al., Iminium carbonic acid derivative salts. XI t. Synthesis of N,S-containing heterobicycles from N-protected 2-methylthio-1,3-thiazinium and 2-methylthiothiazouum salts. Part 3. Reaction of N-protected 2-methylthio-1,3-thiazinium and 2-methylthiothiazolium salts with 3-amino-2-cyano-3-arylacrylonitriles. Journal of Heterocyclic Chemistry. Nov. 1, 1996;33(6):1903-1907. |
International Search Report for Application No. PCT/US2016/065852, dated Feb. 14, 2017, 5 pages. |
International Search Report for Application No. PCT/US2016/065855, dated Feb. 21, 2017, 4 pages. |
International Search Report for Application No. PCT/US2016/065863, dated Feb. 22, 2017, 3 pages. |
Jeanneau-Nicolle et al., New thiazolo[3,2-alpha]pyrimidine derivatives, synthesis and structure-activity relationships. European Journal of Medicinal Chemistry. 1992;Mar. 27(2):115-120. |
Jia et al., Identification, design and bio-evaluation of novel Hsp90 inhibitors by ligand-based virtual screening. PLoS One. 2013;8(4):e59315, 15 pages. |
Kubo et al., Studies on the syntheses of 2(1H)-pyridone derivatives. IV. Synthesis of condensed heterocyclic 2(1H)-pyridones. Yakugaku Zasshi Sep. 1979;99(9):880-8. |
Lensen et al., Hexakis (pyridyl-functionalised porphyrinato)benzene as a building block for the construction of multi-chromophoric arrays. Tetrahedron Letters. Dec. 16, 2002;43(51)9351-9355. |
Mahran et al., Synthesis and biological evaluation of novel pyrimidines derived from 6-aryl-5-cyano-2-thiouracil. Zeitschrift fur Naturforschung 2016;71(5-6):133-140. |
Napier et al., Synthesis and SAR studies of novel 2-(6-aminomethylaryl-2-aryl-4-oxo-quinazolin-3(4H)-yl)acetamide vasopressin V1b receptor antagonists. Bioorg Med Chem Lett. Jun. 15, 2011;21(12):3813-7. |
Nerkar et al., In Silico Design, Synthesis and Pharmacological Screening of Novel Mono and Di-Bromo Quinazolinone Derivatives as NMDA Receptor Antagonists for Anticonvulsant Activity. International Journal of Pharmacy and Pharmaceutical Sciences. 2013;5(1):331-335. |
Noueiry et al., Identification of Novel Small-Molecule Inhibitors of West Nile Virus Infection. J Virol. Nov. 2007; 81(21):11992-12004. |
PUBCHEM-CID 10587973, Create Date: Oct. 25, 2006, 9 pages. |
PUBCHEM-CID 16957685, 8-(4-tert-butylphenyl)-6-oxo-3,4-dihydro-2H,6H-pyrimido[2,1-b][1,3]thiazine-7-carbonitrile. Create Date: Nov. 13, 2007, 7 pages. |
PUBCHEM-CID 6612590, 7-phenyl-8H-[1,2,4]triazolo[4,3-a] pyrimidin-5-one. Create Date: Jun. 5, 2006, 8 pages. |
Ram et al. Journal of Heterocyclic Chemistry, 1984, 21(5), 1307-1312. * |
Ram et al., 5-Cyano-2-thiouracils and their derivatives: a new class of leishmanicides. Bioorganic & Medicinal Chemistry Letters. Nov. 1994;4(22):2653-2656. |
Ram et al., Chemotherapeutical Agents, V. Syntheses and Activities of Novel Pyrimidines Derived from 5-Cyano-6-aryl-2-thiouracil. Liebigs Annalen der Chemie. Sep. 14, 1987;1987(9):797-801. |
Ram, Chemotherapeutic agents, XXI: Synthesis of Pi-deficient pyrimidines as leishmanicides. Arch Pharm (Weinheim). 1991;324(11):837-839. |
Registry (STN) online search of compounds available as of Nov. 23, 2007, 29 pages. |
Salem et al., Antioxidant Activity of Novel Fused Heterocyclic Compounds Derived from Tetrahydropyrimidine Derivative. Chem Pharm Bull (Tokyo). 2015;63(11):866-872. |
Salem et al., Pyrimidinthiones (Part I): Utility of 2-Thioxopyrimidin-6-(1H)ones as Ring Transformer in the Synthesis of Fused Bi- and Tri-Cyclic Heterocyclic Compounds and Their Potential Biological Activities. Phosphorus, Sulfur, and Silicon. 2008;183:2596-2614. |
Santangelo et al., Novel NMDA receptor modulators: an update. Expert Opin Ther Pat. Nov. 2012;22(11):1337-52. |
Singh et al. Journal of Indian Council of Chemists (2008), 25(1), 19-22. * |
STN Registry No. 309740-20-3, 5H-Thiazolo[3,2-a]pyrimidine-6-carbonitrile, 7-[4-1(1,1-dimethylethyl)phenyl]-2,3-dihydro-5-ox0. 1 page, Dec. 19, 2000. |
STN Registry No. 896665-59-1, 5H-Thiazolo[3,2-a]pyrimidine-6-carbonitrile, 7-(2,4-dimethoxyphenyl)-2,3-dihydro-5-oxo. 1 page, Jul. 28, 2006. |
STN Registry No. 903460-76-4, 5H-Thiazolo[3,2-a]pyrimidine-6-carbonitrile, 2,3-dihydro-7-[4-(methylthio)phenyl]-5-oxo. 1 page, Aug. 22, 2006. |
STN Registry No. 924249-59-2, Thieno[2,3-d]pyrimidin-4(3H)-one, 3-[3-(1-azetidinyl)-3-oxopropyl]-5-(4-methylphenyl)-, dated Mar. 2, 2007, 3 pages. |
STN Registry No. 927964-07-6, 2H, 6H-Pyrimido[2,1-b][1,3]thiazine-7-carbonitrile, 8-[4-(1,1-dimethylethyl)phenyl]-3,4-dihydro-6-oxo. 1 page, Mar. 23, 2007. |
Troisi et al., Synthesis and isomerization of N-alpha-aza-heteroaryl-beta-lactams. Tetrahedron. Dec. 18, 2006;62(51):12064-12070. |
U.S. Appl. No. 16/060,056, filed Jun. 7, 2018, U.S. Pat. No. 10,626,122, Issued. |
U.S. Appl. No. 16/060,294, filed Jun. 7, 2018, U.S. Pat. No. 10,500,205, Issued. |
U.S. Appl. No. 16/658,686, filed Oct. 21, 2019, Abandoned. |
U.S. Appl. No. 17/150,222, filed Jan. 15, 2021, Pending. |
Upadhyay et al., Synthesis of pyrimidine and azolopyrimidines as biodynamic agents. Indian Journal of Chemistry. Feb. 1999;38B:173-177. |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11807650B2 (en) | 2016-12-22 | 2023-11-07 | Novartis Ag | NMDA receptor modulators and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
AU2017382339A1 (en) | 2019-07-18 |
US20220153755A1 (en) | 2022-05-19 |
EP3558318B1 (en) | 2023-12-20 |
US20200087323A1 (en) | 2020-03-19 |
US11807650B2 (en) | 2023-11-07 |
CA3047403A1 (en) | 2018-06-28 |
WO2018119374A1 (en) | 2018-06-28 |
JP2020504743A (ja) | 2020-02-13 |
ES2975336T3 (es) | 2024-07-04 |
EP3558318A1 (en) | 2019-10-30 |
EP3558318A4 (en) | 2020-09-02 |
JP7332472B2 (ja) | 2023-08-23 |
AU2017382339B2 (en) | 2024-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11807650B2 (en) | NMDA receptor modulators and uses thereof | |
US20180044343A1 (en) | Bicyclic imidazolo derivative | |
US9216999B2 (en) | Substituted pyrrolo[2,3-h][1,6]naphthyridines and compositions thereof as JAK inhibitors | |
US8952037B2 (en) | Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors | |
US8569337B2 (en) | Tri-cyclic pyrazolopyridine kinase inhibitors | |
US20230265116A1 (en) | Degradation of (egfr) by conjugation of egfr inhibitors with e3 ligase ligand and methods of use | |
US20140357615A1 (en) | Substituted 1h-pyrazolo[3',4',4,5]thieno[2,3-b]pyridin-3-amine analogs as positive allosteric modulators of the muscarinic acetycholine receptor m4 | |
US11541057B2 (en) | Thienopyrimidinone NMDA receptor modulators and uses thereof | |
US9540371B2 (en) | Substituted quinazolin-4(3H)-ones, pyrido[3,4-d]pyrimidin-4(3H)-ones, pyrido[3,2-d]pyrimidin-4(3H)-ones and pyrido[2,3-d]pyrimidin-4(3H)-ones as positive allosteric modulators of muscarinic acetycholine receptor M1 | |
US20170022173A1 (en) | Substituted 4-benzyl-3,4-dihydro-2h-benzo[b][1,4]oxazine-2carboxamide analogs as positive allosteric modulators of muscarinic acetycholine receptor m1 | |
JP2018076285A (ja) | 二環性イミダゾロ誘導体を含む医薬 | |
US11426397B2 (en) | Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6 | |
US20230192659A1 (en) | N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as sstr4 agonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
AS | Assignment |
Owner name: CADENT THERAPEUTICS, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ANDERSON, DAVID R.;VOLKMANN, ROBERT A.;MENNITI, FRANK;AND OTHERS;SIGNING DATES FROM 20190613 TO 20190716;REEL/FRAME:049793/0935 |
|
AS | Assignment |
Owner name: CADENT THERAPEUTICS, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ANDERSON, DAVID R.;VOLKMANN, ROBERT A.;MENNITI, FRANK;AND OTHERS;SIGNING DATES FROM 20190613 TO 20190716;REEL/FRAME:051995/0496 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: AWAITING TC RESP., ISSUE FEE NOT PAID |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction | ||
AS | Assignment |
Owner name: NOVARTIS AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CADENT THERAPEUTICS, INC.;REEL/FRAME:063073/0358 Effective date: 20221201 |